

*03.05.2022*

<b>11:30 - 12:30</b>	<b>Type: Industry Satellite Symposium</b> <b>Title: Sanofi Genzyme - Tumor Board: How The Experts Approach Personalized Care Plans in ER-Positive Breast Cancer</b>	<b>Hamburg Hall</b>
11:30 - 11:35	<b>Welcome and Introductions</b>	
11:35 - 11:50	<b>Tumor Board 1: Current Management Options for HR+/HER2- Metastatic Breast Cancer</b>	
11:50 - 12:05	<b>Tumor Board 2: Novel Endocrine Agents and Other Investigational Strategies for HR+/HER2- Metastatic Breast Cancer</b>	
12:05 - 12:20	<b>Tumor Board 3: Evolving Management Paradigms for High-Risk Early-Stage HR+/HER2- Breast Cancer</b>	
12:20 - 12:25	<b>Q&amp;A</b>	
12:25 - 12:30	<b>Conclusions &amp; Post-Session Survey</b>	

<b>11:30 - 12:30</b>	<b>Type: Industry Satellite Symposium</b> <b>Title: Gilead - Triple-Negative Breast Cancer: See Beyond the Negatives</b> Chair(s): A.S., DE	<b>Munich Hall</b>
11:30 - 11:35	<b>Welcome and introduction</b> A. Schneeweiss, National Center for Tumor Diseases, University Hospital and German Cancer Research Center, Heidelberg, DE	
11:35 - 11:50	<b>Evolving treatment landscape in TNBC</b> J. Gligorov, Institut Universitaire de Cancérologie AP-HP. Sorbonne Université, Hôpital Tenon, Paris, FR	
11:50 - 12:15	<b>Sacituzumab govitecan: Setting the new standard of care for mTNBC</b> S. Tolaney, Dana Farber Cancer Institute, Boston, US	
12:15 - 12:30	<b>Live Q&amp;A</b>	
<b>11:30 - 12:30</b>	<b>Type: Young Oncologists session</b> <b>Title: YO "HowTo" Session: How to move genomic profiling to clinical practice by multidisciplinary collaboration?</b>	<b>Frankfurt Hall</b>
11:30 - 11:40	<b>Clinical case presentation from the molecular tumor board</b>	
11:40 - 12:25	<b>Panel discussion on the implementation of genomic profiling in clinical practice by multidisciplinary collaboration</b>	
12:25 - 12:30	<b>Closing remarks</b>	

<b>11:30 - 12:30</b>	<b>Type: Industry Satellite Symposium Title: AstraZeneca - Controversies in Breast Cancer</b>	<b>Cologne Hall</b>
11:30 - 11:45	<b>Jumping the Gun - Should we wait for OS data in eBC?</b>	
11:45 - 12:00	<b>What do we know About HER2-Low Breast Cancer?</b>	
12:00 - 12:15	<b>Treatment beyond CDK4/6 - what comes next?</b>	
12:15 - 12:30	<b>Q&amp;A / discussion</b>	
<b>13:00 - 13:10</b>	<b>Type: Opening session Title: Welcome to the ESMO Breast Cancer Congress 2022 Chair(s): G.C., IT; S.D., FR; S.-B.K., KR</b>	<b>Berlin Hall</b>
<b>13:10 - 13:40</b>	<b>Type: Keynote lecture Title: ESMO Breast Cancer 2022 Award lecture</b>	<b>Berlin Hall</b>
13:10 - 13:15	<b>Introduction by the Chair</b>	
13:15 - 13:40	<b>Award lecture TBC</b>	

<b>13:45 - 15:15</b>	<b>Type: Educational session</b> <b>Title: Neo-adjuvant and adjuvant triple negative breast cancer (TNBC)</b> Chair(s): P.S., GB	<b>Hamburg Hall</b>
13:45 - 14:05	<b>Chemotherapy strategies for early TNBC</b> <u>G. Curigliano</u> , IEO - Istituto Europeo di Oncologia, Milan, IT	
14:05 - 14:25	<b>Optimising loco-regional treatment in early TNBC</b> <u>S. Kuemmel</u> , Kliniken Essen Mitte Evang. Huysens-Stiftung, Essen, DE	
14:25 - 14:45	<b>Integrating novel agents into early TNBC strategies</b> <u>P. Schmid</u> , Barts Cancer Institute-Queen Mary University of London, London, GB	
14:45 - 15:05	<b>Can we de-escalate treatment options in selected patients?</b> <u>J. Cortés</u> , VHIO Valle de Hebrón Instituto de Oncología, Barcelona, ES	
15:05 - 15:15	<b>Q&amp;A</b>	

<b>13:45 - 15:15</b>	<b>Type: Proffered Paper session</b> <b>Title: Proffered Paper session 1</b>	<b>Munich Hall</b>
----------------------	---	--------------------

13:45 - 14:00	<b>One LBA TBC</b>	
14:00 - 14:15	<b>1620 - Primary analysis from DS8201-A-U105: A 2-part, open label, phase 1b trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer</b> <u>E. Hamilton</u> <sup>1</sup> , C.L. Shapiro <sup>2</sup> , V. Boni <sup>3</sup> , M. Martin Jimenez <sup>4</sup> , G. Del Conte <sup>5</sup> , J. Cortés <sup>6</sup> , L. Agrawal <sup>7</sup> , H.-T. Arkenau <sup>8</sup> , A. Tan <sup>9</sup> , P. Debruyne <sup>10</sup> , A. Minchom <sup>11</sup> , A. Rutten <sup>12</sup> , F. Valdes-Albini <sup>13</sup> , E. Yu <sup>14</sup> , F. Suto <sup>15</sup> , F.-C. Cheng <sup>15</sup> , B. Augustine <sup>15</sup> , B. Cheng <sup>16</sup> , D. Barrios <sup>15</sup> , S. Hurvitz <sup>17</sup> , <sup>1</sup> Sarah Cannon Research Institute/Tennessee Oncology, Nashville, US, <sup>2</sup> Icahn School of Medicine at Mount Sinai, New York, US, <sup>3</sup> START Madrid-CIOCC and NEXT Oncology, Quirónsalud University Hospital, Madrid, ES, <sup>4</sup> Hospital General Universitario Gregorio Marañón, Madrid, ES, <sup>5</sup> IRCCS Ospedale San Raffaele, Milan, IT, <sup>6</sup> International Breast Cancer Center (IBCC), Grupo Quiron, Madrid and Barcelona, ES, <sup>7</sup> Norton Cancer Institute, Louisville, US, <sup>8</sup> Sarah Cannon Research Institute UK, London, GB, <sup>9</sup> Levine Cancer Institute, Atrium Health, Charlotte, US, <sup>10</sup> AZ Groeninge, Kortrijk, Belgium, and School of Life Sciences, Anglia Ruskin University, Cambridge, GB, <sup>11</sup> Royal Marsden Hospital/Institute of Cancer Research, London, GB, <sup>12</sup> GZA Hospitals Sint-Augustinus, Wilrijk, BE, <sup>13</sup> University of Miami, Miami, US, <sup>14</sup> University of Washington and Fred Hutchinson Cancer Research Center, Seattle, US, <sup>15</sup> Daiichi Sankyo, Inc., Basking Ridge, US, <sup>16</sup> Daiichi Sankyo Inc., Basking Ridge, US, <sup>17</sup> UCLA, Jonsson Comprehensive Cancer Center, Los Angeles, US	
14:15 - 14:25		

**Invited Discussant one LBA TBC and 1620**

R. Dent, NCCS - National Cancer Centre Singapore, Singapore, SG

- 14:25 - 14:40 **1630 - Patient-reported outcomes (PROs) from DESTINY-Breast03, a randomized phase 3 study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC)**
- G. Curigliano<sup>1</sup>, K. Dunton<sup>2</sup>, M. Rosenlund<sup>2</sup>, M. Janek<sup>3</sup>, J. Cathcart<sup>4</sup>, Y. Liu<sup>4</sup>, P.A. Fasching<sup>5</sup>, H. Iwata<sup>6</sup>, <sup>1</sup>European Institute of Oncology IRCCS, University of Milan, Milan, IT, <sup>2</sup>Daiichi Sankyo Europe GmbH, Munich, DE, <sup>3</sup>Daiichi Sankyo, Braine-l'Alleud, BE, <sup>4</sup>Daiichi Sankyo, Inc., Basking Ridge, US, <sup>5</sup>University Hospital Erlangen and Comprehensive Cancer Centre, Erlangen, DE, <sup>6</sup>Aichi Cancer Center Hospital, Nagoya, JP
- 14:40 - 14:55 **1640 - Health-Related Quality of Life (HRQoL) With Pembrolizumab (pembro) + Chemotherapy (chemo) vs Placebo (pbo) + Chemo as 1L Treatment for Advanced Triple-Negative Breast Cancer (TNBC): Results From KEYNOTE-355**
- D. Cescon<sup>1</sup>, P. Schmid<sup>2</sup>, H. Rugo<sup>3</sup>, S.-A. Im<sup>4</sup>, M. Md Yusof<sup>5</sup>, C. Gallardo<sup>6</sup>, O. Lipatov<sup>7</sup>, C. Barrios<sup>8</sup>, J.M. Perez Garcia<sup>9</sup>, H. Iwata<sup>10</sup>, N. Masuda<sup>11</sup>, M.A. Torregroza Otero<sup>12</sup>, E. Gokmen<sup>13</sup>, S. Loi<sup>14</sup>, A. Haiderali<sup>15</sup>, X. Zhou<sup>16</sup>, Z. Guo<sup>15</sup>, A. Martin Nguyen<sup>15</sup>, J. Cortés<sup>9</sup>, <sup>1</sup>Princess Margaret Cancer Centre, Toronto, CA, <sup>2</sup>Barts Cancer Institute, San Francisco, US, <sup>3</sup>San Francisco Comprehensive Cancer Center, San Francisco, US, <sup>4</sup>Seoul National University College of Medicine, Seoul, KR, <sup>5</sup>Pantai Hospital Kuala Lumpur, Kuala Lumpur, MY, <sup>6</sup>Fundacion Arturo Lopez Perez, Providencia, CL, <sup>7</sup>Republican Clinical Oncology Dispensary, Republic of Bashkortostan, RU, <sup>8</sup>Hospital Sao Lucas da PUCRS, Porto Alegre, BR, <sup>9</sup>Quiron Group, Barcelona, ES, <sup>10</sup>Aichi Cancer Center Hospital, Nagoya, JP, <sup>11</sup>Nagoya University Graduate School of Medicine, Nagoya, JP, <sup>12</sup>Oncomedica S.A., Monteria, CO, <sup>13</sup>Ege University Medical School, Izmir, TR, <sup>14</sup>Peter MacCallum Cancer Centre, Melbourne, AU, <sup>15</sup>Merck & Co., Inc., Kenilworth, US, <sup>16</sup>Merck & Co., Inc., North Wales, US
- 14:55 - 15:05 **Invited Discussant 1630 and 1640**
- 15:05 - 15:15 **Q&A and discussion**

<b>13:45 - 15:15</b>	<b>Type: Special Symposium</b> <b>Title: Risk based prevention and screening in breast cancer</b> Chair(s): D.E., GB	<b>Frankfurt Hall</b>
13:45 - 14:05	<b>KARMA study</b> <u>P. Hall</u> , Karolinska University Hospital and Karolinska Institute - Huddinge, Stockholm, SE	
14:05 - 14:25	<b>PRISMA study</b> <u>M. Broeders</u> , Radboud University Medical Center, Nijmegen, NL	
14:25 - 14:45	<b>MyPeBS study</b> <u>S. Delaloge</u> , Institut Gustave Roussy, Villejuif, FR	
14:45 - 15:05	<b>Feasibility and acceptability of risk based screening including reduced screening in low risk women</b> <u>D. Evans</u> , The University of Manchester, Manchester, GB	
15:05 - 15:15	<b>Q&amp;A</b>	
<b>15:40 - 16:10</b>	<b>Type: Keynote lecture</b> <b>Title: Keynote lecture: Optimising adjuvant treatment in HR+/HER2 negative early breast cancer</b> Chair(s): G.C., IT; S.-B.K., KR	<b>Berlin Hall</b>
15:40 - 15:45	<b>Introduction by the Chairs</b>	
15:45 - 16:10	<b>Optimising adjuvant treatment in HR+/HER2 negative early breast cancer</b> <u>J. Sparano</u> , Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, US	



**16:15 - 17:45**    **Type: Educational session**    **Hamburg Hall**  
**Title: Immunotherapy of metastatic breast cancer: Where do we stand?**  
 Chair(s): Y.H.P., KR

16:15 - 16:35    **Biomarkers of immune checkpoint blockade focused on triple negative breast cancer**  
C. Denkert, Uniklinikum Giessen und Marburg, Marburg, DE

16:35 - 16:55    **Novel combinatorial strategies for enhancing the efficacy of immune checkpoint inhibitors in metastatic breast cancer**  
M. Kok, Netherlands Cancer Institute, Amsterdam, NL

16:55 - 17:15    **Insights into the mechanisms of toxicity associated with immune checkpoint blockade**  
M.F. Tolba, Ain Shams University, Cairo, EG

17:15 - 17:35    **ICI outcomes associated with tumour microenvironment in metastatic breast cancer**  
Y.H. Park, Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR

17:35 - 17:45    **Q&A**

**16:15 - 17:45**    **Type: Educational session**    **Munich Hall**  
**Title: How to collect and use PRO data in clinical settings**  
 Chair(s): L.F., GB

16:15 - 16:35    **Online symptom monitoring and implementation into the ER**  
G. Velikova, St. James's University Hospital Leeds, Leeds, GB

16:35 - 16:55    **Update on the CHES system**  
B. Holzner, Medical University of Innsbruck, Innsbruck, AT

16:55 - 17:15    **PROMIS in practice**  
D. Cella, Northwestern University, Chicago, US

17:15 - 17:35    **Biopsychosocial predictive model of resilience trajectories in breast cancer patients**  
K. Mazzocco, IEO - Istituto Europeo di Oncologia, Milan, IT

17:35 - 17:45    **Q&A**

**16:15 - 17:30**

**Type: Mini Oral session**
**Frankfurt Hall**
**Title: Mini Oral session 1**

- 16:15 - 16:22 **59MO - Adjuvant Abemaciclib Combined with Endocrine Therapy (ET): Efficacy Results in monarchE Cohort 1**
- M. Reinisch<sup>1</sup>, M. Toi<sup>2</sup>, F. Boyle<sup>3</sup>, Y.-H. Im<sup>4</sup>, D. Molthrop<sup>5</sup>, Z. Jiang<sup>6</sup>, R.J. Wei<sup>7</sup>, F. Sapunar<sup>7</sup>, B. Grimes<sup>7</sup>, S. Nabinger<sup>7</sup>, S. Johnston<sup>8</sup>, <sup>1</sup>Kliniken Essen Mitte Evang. Huysens-Stiftung, Essen, DE, <sup>2</sup>Kyoto University Hospital, Kyoto, JP, <sup>3</sup>Mater Hospital, North Sydney, North Sydney, AU, <sup>4</sup>Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, <sup>5</sup>Florida Cancer Specialists & Research Institute, Lake Mary, US, <sup>6</sup>307th Hospital of PLA (AMMS China), Beijing, CN, <sup>7</sup>Eli Lilly and Company - Global Headquarters, Indianapolis, US, <sup>8</sup>The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB
- 16:22 - 16:29 **60MO - Ovarian function in young patients (pts) treated with postneoadjuvant palbociclib (PAL) and endocrine therapy (ET) for hormone receptor (HR)-positive, HER2-negative early breast cancer (BC): explorative analysis in Penelope-B**
- J. Furlanetto<sup>1</sup>, F. Marmé<sup>2</sup>, C. Thode<sup>3</sup>, V. Nekljudova<sup>1</sup>, Y. Liu<sup>4</sup>, M. Martin Jimenez<sup>5</sup>, T. Reimer<sup>6</sup>, E. Knudsen<sup>7</sup>, C. Denkert<sup>8</sup>, M. Bassy<sup>3</sup>, L.-A. Martin<sup>9</sup>, T. Karn<sup>10</sup>, B. Sinn<sup>11</sup>, M. Filipitis<sup>12</sup>, M. Van Mackelenbergh<sup>13</sup>, P.A. Fasching<sup>14</sup>, V. Müller<sup>15</sup>, E. Stickeler<sup>16</sup>, C. Schem<sup>17</sup>, S. Loibl<sup>18</sup>, <sup>1</sup>German Breast Group, Neu-Isenburg, DE, <sup>2</sup>Heidelberg University, University Hospital Mannheim, Mannheim, DE, <sup>3</sup>Amedes-Group, Jever, DE, <sup>4</sup>Pfizer Inc - USA, San Diego, US, <sup>5</sup>Hospital General Universitario Gregorio Marañón, Madrid, ES, <sup>6</sup>University of Rostock, Rostock, DE, <sup>7</sup>Roswell Park Comprehensive Cancer Center, Buffalo, New York, US, <sup>8</sup>Philipps University Marburg and Marburg University Hospital (UKGM), Marburg, DE, <sup>9</sup>Breast Cancer Now Toby Robins Research Centre, London, GB, <sup>10</sup>UCT-Frankfurt-Marburg, Frankfurt, DE, <sup>11</sup>Charité - Universitätsmedizin Berlin, Berlin, DE, <sup>12</sup>medical university of Vienna, Vienna, AT, <sup>13</sup>Klinik für Gynäkologie und Geburtshilfe, Schleswig-Holstein, Kiel, DE, <sup>14</sup>University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, DE, <sup>15</sup>Universitätsklinikum Hamburg-Eppendorf, Hamburg, DE, <sup>16</sup>Uniklinik Aachen, Aachen, DE, <sup>17</sup>Mammazentrum Hamburg am Krankenhaus Jerusalem, Hamburg, DE, <sup>18</sup>German Breast Group/Centre for Haematology and Oncology Bethanien Frankfurt, Neu-Isenburg/Frankfurt, DE
- 16:29 - 16:36 **91MO - Randomized trial of neoadjuvant chemotherapy with or without concurrent aromatase inhibitor therapy to downstage ER+ve breast cancer: Breast Cancer Trials group ANZ 1401 ELIMINATE trial.**
- N. Murray<sup>1</sup>, P. Francis<sup>2</sup>, N. Zdenkowski<sup>3</sup>, N. Wilcken<sup>4</sup>, F. Boyle<sup>5</sup>, V. GebSKI<sup>6</sup>, S. Tiley<sup>7</sup>, L. Gilham<sup>8</sup>, S.-J. Dawson<sup>9</sup>, S. Loi<sup>9</sup>, A. Redfern<sup>10</sup>, J. Lombard<sup>11</sup>, A. Spillane<sup>6</sup>, C. Shadbolt<sup>9</sup>, H. Badger<sup>8</sup>, <sup>1</sup>Royal Adelaide Hospital RAH Cancer Centre, Adelaide, AU, <sup>2</sup>Peter MacCallum Cancer Center, Melbourne, AU, <sup>3</sup>The Breast & Endocrine Centre, Gateshead, AU, <sup>4</sup>Westmead Hospital, University of Sydney, Westmead, AU, <sup>5</sup>Mater Hospital, North Sydney, North Sydney, AU, <sup>6</sup>University of Sydney, Sydney, AU, <sup>7</sup>Gosford Hospital, Gosford, AU, <sup>8</sup>Breast Cancer Trials, Newcastle, AU, <sup>9</sup>Peter MacCallum Cancer Centre, Melbourne, AU, <sup>10</sup>University of Western Australia, Perth, AU, <sup>11</sup>Calvary Mater Hospital Newcastle, Newcastle, AU
- 16:36 - 16:43 **92MO - Neoadjuvant nivolumab (NIVO) + palbociclib (PALBO) + anastrozole (ANA) for estrogen receptor-positive (ER+)/human epidermal growth factor**



**receptor 2-negative (HER2-) primary breast cancer (BC): CheckMate 7A8**

S. Tolaney<sup>1</sup>, G. Jerusalem<sup>2</sup>, A. Prat<sup>3</sup>, R. Salgado<sup>4</sup>, M. Reinisch<sup>5</sup>, C. Saura<sup>6</sup>, M. Ruiz Borrego<sup>7</sup>, P. Nikolinakos<sup>8</sup>, J. Filian<sup>9</sup>, F. Ades<sup>10</sup>, N. Huang<sup>9</sup>, A. Mazzei-Abba<sup>11</sup>, <sup>1</sup>Dana Farber Cancer Institute, Boston, US, <sup>2</sup>Centre Hospitalier Universitaire Sart Tilman, Liège, BE, <sup>3</sup>Hospital Clinic of Barcelona, Barcelona, ES, <sup>4</sup>GZA Ziekenhuizen Campus Sint-Augustinus, Wilrijk, BE, <sup>5</sup>Kliniken Essen Mitte, Essen, DE, <sup>6</sup>Vall D'Hebron Institute of Oncology (VHIO), Barcelona, ES, <sup>7</sup>Hospital Universitario Virgen del Rocío, Seville, ES, <sup>8</sup>University Cancer & Blood Center, Athens, US, <sup>9</sup>Bristol Myers Squibb, Princeton, US, <sup>10</sup>Bristol Myers Squibb, Lawrenceville, US, <sup>11</sup>Bristol Myers Squibb, Boudry, CH

16:43 - 16:53

**Invited Discussant 59MO, 60MO, 91MO and 92MO**

J.W.-H. Tsang, HKBOG - Hong Kong Breast Oncology Group, Hong Kong, HK

16:53 - 17:00

**61MO - (Withdrawn)**

17:00 - 17:05

**Invited Discussant 61MO**

17:05 - 17:12

**93MO - Optimal 18F-FDG PET/CT (FDG-PET) cut-off for pathological complete response (pCR) prediction in HER2-positive [HER2+] early breast cancer (EBC) patients (pts) treated with neoadjuvant trastuzumab (T) and pertuzumab (P) in PHERGain trial**

G. Gebhart<sup>1</sup>, M. Keyaerts<sup>2</sup>, T. Guiot<sup>1</sup>, P. Flamen<sup>1</sup>, M. Ruiz Borrego<sup>3</sup>, A. Stradella<sup>4</sup>, B. Bermejo De Las Heras<sup>5</sup>, S. Escriva De Romani<sup>6</sup>, L. Calvo-Martinez<sup>7</sup>, N. Ribelles Entrena<sup>8</sup>, N. Martinez<sup>9</sup>, C.R. Albacar Miro<sup>10</sup>, M. Colleoni<sup>11</sup>, M. Atienza De Frutos<sup>12</sup>, M. Sampayo-Cordero<sup>13</sup>, J. Cortés<sup>14</sup>, J.M. Perez Garcia<sup>15</sup>, A. Llombart Cussac<sup>16</sup>, <sup>1</sup>Institute Jules Bordet, Brussels, BE, <sup>2</sup>UZ Brussel - Universitair Ziekenhuis Brussel, Jette, BE, <sup>3</sup>Hospital Virgen del Rocío de Sevilla, Seville, ES, <sup>4</sup>ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES, <sup>5</sup>Hospital Clinico Universitario de Valencia, Valencia, ES, <sup>6</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>7</sup>CHUAC - Complejo Hospitalario Universitario A Coruña, A Coruña, ES, <sup>8</sup>Hospital Universitario Virgen de la Victoria, Malaga, ES, <sup>9</sup>Hospital Universitario Ramon y Cajal, Madrid, ES, <sup>10</sup>Hospital Universitari Sant Joan de Reus, Reus, ES, <sup>11</sup>IEO - Istituto Europeo di Oncologia, Milan, IT, <sup>12</sup>Universidad Europea de Madrid, Villaviciosa de Odón, ES, <sup>13</sup>Medica Scientia Innovation Research (MEDSIR), Barcelona, ES, <sup>14</sup>International Breast Cancer Center (IBCC), Quiron Group, Madrid & Barcelona, ES, <sup>15</sup>International Breast Cancer Center (IBCC), Quiron Group, Barcelona, ES, <sup>16</sup>Hospital Arnau de Vilanova, Valencia, ES

17:12 - 17:17

**Invited Discussant 93MO**

17:17 - 17:30

**Q&A and discussion**

<b>18:00 - 19:00</b>	<b>Type: Industry Satellite Symposium</b> <b>Title: Roche - The opportunities and challenges of targeting pathways in HER2-positive BC beyond HER2</b>  Chair(s): J.C., ES	<b>Hamburg Hall</b>
18:00 - 18:03	<b>Welcome and introduction</b> J. Cortés, VHIO Valle de Hebrón Instituto de Oncología, Barcelona, ES	
18:03 - 18:16	<b>HER2-positive disease: Seeing opportunity amongst the complexity</b> J. Cortés, VHIO Valle de Hebrón Instituto de Oncología, Barcelona, ES	
18:16 - 18:30	<b>HER2+/HR+ disease: Our chance for improved patient outcomes</b> M. Piccart, Institute Jules Bordet, Brussels, BE	
18:30 - 18:44	<b>Cancer immunotherapy: exCITing prospects in HER2-positive breast cancer</b> G. Bianchini, IRCCS Ospedale San Raffaele, Milan, IT	
18:44 - 18:57	<b>Q&amp;A / discussion</b>	
18:57 - 19:00	<b>Meeting close</b> J. Cortés, VHIO Valle de Hebrón Instituto de Oncología, Barcelona, ES	

<b>18:00 - 19:30</b>	<b>Type: ESMO Colloquium</b> <b>Title: ESMO Colloquium supported by Lilly - Optimising risk prediction, management and compliance for patients with early HR+ HER2- breast cancer: The start of a journey</b> Chair(s): V.G., IT; T.B., FR	<b>Munich Hall</b>
18:00 - 18:10	<b>Introduction</b> V. Guarneri, University of Padua, Padova, IT	
18:10 - 18:25	<b>Risk prediction for patients with early HR+, HER2-, node-positive breast cancer: How to best integrate clinicopathologic and genomic tests?</b> C. Sotiriou, Institute Jules Bordet, Brussels, BE	
18:25 - 18:40	<b>An overview of the adjuvant trials evaluating CDK4/6 inhibitors in early HR+ HER2- breast cancer</b> F. Cardoso, Champalimaud Foundation - Champalimaud Clinical Center, Lisbon, PT	
18:40 - 18:55	<b>A clinical case of a patient with early HR+ HER2- breast cancer: How to optimise compliance to emerging adjuvant regimens - The utility of tumour boards</b> M. Martin Jimenez, Hospital General Universitario Gregorio Marañón, Madrid, ES	
18:55 - 19:10	<b>Shaping an emerging continuum of care for patients with HR+, HER2- breast cancer: Which patients to select, from localized to recurrent disease</b> T. Bachelot, Centre Léon Bérard, Lyon, FR	
19:10 - 19:25	<b>Q&amp;A and discussion</b>	
19:25 - 19:30	<b>Concluding remarks</b> T. Bachelot, Centre Léon Bérard, Lyon, FR	
<b>18:00 - 19:00</b>	<b>Type: Young Oncologists session</b> <b>Title: YO Vesalius talk: The road to a successful career in breast oncology research</b>	<b>Cologne Hall</b>
18:00 - 19:00	<b>Panelists</b>	

**04.05.2022**

**08:45 - 10:15**    **Type: Educational session**    **Frankfurt Hall**  
**Title: Genetic testing and implications in early breast cancer (eBC) patients**  
 Chair(s): A.T., GB

08:45 - 09:05    **Neo/adjuvant PARP inhibitors**  
A. Tutt, ICR - Institute of Cancer Research, London, GB

09:05 - 09:25    **Who and how to test for BRCA mutations**  
C. Singer, Medizinische Universitaet Wien (Medical University of Vienna), Vienna, AT

09:25 - 09:45    **Surgical options for BRCA mutated eBC patients**  
M. Joao Cardoso, Fundacao Champalimaud, Lisbon, PT

09:45 - 10:05    **Best additional systemic treatment options for eBC in the era of PARP inhibitors**  
S. Linn, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

10:05 - 10:15    **Q&A**

**08:45 - 10:15**    **Type: Special session**    **Cologne Hall**  
**Title: EONS - Taking care of disadvantaged people with breast cancer: What's the evidence?**  
 Chair(s): D.P., GR; C.F.C., GB

08:45 - 09:05    **Sexual and gender minority people**  
D. Protogiros, National Public Health Organisation, Athens, GR

09:05 - 09:25    **People with disabilities**

09:25 - 09:45    **Homeless people**  
C. Fernandes Cargaleiro, Guys and St Thomas NHS Trust, London, GB

09:45 - 10:05    **Immigrants and refugees**  
S. Terzoni, Ospedale San Paolo - ASST Santi Paolo e Carlo, Milan, IT

10:05 - 10:15    **Q&A and discussion**

**09:00 - 10:00**    **Type: Mini Oral session**    **Hamburg Hall**  
**Title: Mini Oral session 2**

09:00 - 09:07 **One LBA TBC**

09:07 - 09:14 **165MO - Trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients (pts) with active brain metastases: Primary outcome analysis from the TUXEDO-1 trial**

R. Bartsch<sup>1</sup>, A.S. Berghoff<sup>1</sup>, J. Furtner<sup>1</sup>, M. Marhold<sup>1</sup>, E. Bergen<sup>1</sup>, S. Roider-Schur<sup>2</sup>, A. Starzer<sup>1</sup>, H. Forstner<sup>1</sup>, B. Rottenmanner<sup>1</sup>, K. Dieckmann<sup>1</sup>, Z. Bago-Horvath<sup>1</sup>, G. Widhalm<sup>1</sup>, A. Ilhan-Mutlu<sup>1</sup>, C. Minichsdorfer<sup>1</sup>, T. Fuereder<sup>1</sup>, C. Singer<sup>1</sup>, A. Weltermann<sup>3</sup>, R. Puhr<sup>1</sup>, M. Preusser<sup>1</sup>, <sup>1</sup>Medical University of Vienna, Vienna, AT, <sup>2</sup>St. Joseph's Hospital, Vienna, AT, <sup>3</sup>Ordensklinikum Linz Elisabethinen, Linz, AT

09:14 - 09:21 **166MO - Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): initial results from BEGONIA, a phase 1b/2 study**

P. Schmid<sup>1</sup>, K. Jung<sup>2</sup>, P. Wysocki<sup>3</sup>, J. Jassem<sup>4</sup>, C. Ma<sup>5</sup>, R. Fernandes<sup>6</sup>, R. Huisden<sup>7</sup>, R. Stewart<sup>7</sup>, P. Vukovic<sup>7</sup>, A. Tablante Nunes<sup>8</sup>, Z. Nowecki<sup>9</sup>, <sup>1</sup>Barts Cancer Institute-Queen Mary University of London, London, GB, <sup>2</sup>Asan Medical Center - University of Ulsan, College of Medicine, Seoul, KR, <sup>3</sup>Jagiellonian University - Medical College, Krakow, PL, <sup>4</sup>Medical University of Gdańsk, Gdańsk, PL, <sup>5</sup>Washington University School of Medicine, St. Louis, US, <sup>6</sup>Schulich School of Medicine & Dentistry, Western University, London Health Sciences Centre, London, CA, <sup>7</sup>AstraZeneca, Cambridge, GB, <sup>8</sup>AstraZeneca, Gaithersburg, US, <sup>9</sup>Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, PL

09:21 - 09:28 **167MO - Association between ER, PR and HER2 levels and outcome under palbociclib (Pal) + aromatase inhibitors (AIs) as first-line therapy for ER+ HER2- metastatic breast cancer (MBC): An exploratory analysis of the PADA-1 trial**

T. De La Motte Rouge<sup>1</sup>, J.-S. Frenel<sup>2</sup>, A.-C. Hardy-Bessard<sup>3</sup>, T. Bachelot<sup>4</sup>, B. Pistilli<sup>5</sup>, S. Delalogue<sup>6</sup>, L. Deiana<sup>7</sup>, F. Del Piano<sup>8</sup>, D. Genet<sup>9</sup>, M. Gardner<sup>10</sup>, E. Legouffe<sup>11</sup>, C.B. Levache<sup>12</sup>, H. Orfeuvre<sup>13</sup>, C. Valmar<sup>14</sup>, L. Venat<sup>15</sup>, A. Zannetti<sup>16</sup>, R. Le Scodan<sup>17</sup>, F. Dalenc<sup>18</sup>, D. Berger<sup>19</sup>, F.C. Bidard<sup>20</sup>, <sup>1</sup>Centre Eugene - Marquis, Rennes, FR, <sup>2</sup>ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, <sup>3</sup>Hôpital Privé des Côtes d'Armor, Plérin, FR, <sup>4</sup>Centre Léon Bérard, Lyon, FR, <sup>5</sup>Institut Gustave Roussy, Villejuif, Cedex, FR, <sup>6</sup>Institut Gustave Roussy, Villejuif, FR, <sup>7</sup>CHRU Brest - Hopital Augustin Morvan, Brest, FR, <sup>8</sup>Centre Hospitalier de Thonon (du Lemman), Thonon-les-Bains, FR, <sup>9</sup>Polyclinique de Limoges - Le Site Francois Chénieux, Limoges, FR, <sup>10</sup>Hôpital clinique Claude-Bernard, Metz-Tessy, FR, <sup>11</sup>Institut de cancérologie du Gard, Nimes, FR, <sup>12</sup>Clinique Francheville, Périgueux, FR, <sup>13</sup>Ch Fleyriat, Bourg En Bresse, FR, <sup>14</sup>Centre Hospitalier Du Mans, Le Mans, FR, <sup>15</sup>CHU Limoges - Hopital Dupuytren, Limoges, FR, <sup>16</sup>CH Cholet, Cholet, FR, <sup>17</sup>CHP Saint-Grégoire, St. Grégoire, FR, <sup>18</sup>Institut Claudius Regaud-IUCT-Oncopole, Toulouse, FR, <sup>19</sup>Hopital René Huguenin - Institut Curie, Saint-Cloud, FR, <sup>20</sup>Institut Curie, Paris, FR

09:28 - 09:38 **Invited Discussant one LBA TBC, 165MO, 166MO and 167MO**

M. Oliveira, Vall d'Hebron University Hospital, Barcelona, ES



09:38 - 09:50 **Q&A and discussion**

**09:00 - 10:00** **Type: Controversy session** **Munich Hall**  
**Title: Can we decrease chemotherapy in LN+ premenopausal women based on genomic tests?**  
 Chair(s): D.C., GB

09:00 - 09:10 **Introduction and first vote**  
D. Cameron, Edinburgh Cancer Centre Western General Hospital, Edinburgh, GB

09:10 - 09:30 **Yes**  
J.W.-H. Tsang, HKBOG - Hong Kong Breast Oncology Group, Hong Kong, HK

09:30 - 09:50 **No**  
N. Harbeck, Ludwig Maximilians University - Grosshadern, Munich, DE

09:50 - 10:00 **Second vote and conclusions**  
D. Cameron, Edinburgh Cancer Centre Western General Hospital, Edinburgh, GB

**10:45 - 12:15** **Type: Multidisciplinary Tumour Board** **Hamburg Hall**  
**Title: Oligometastatic diseases (OMD)**  
 Chair(s): P.P., BE

10:45 - 11:05 **Surgery in OMD, metastases-directed, of the primary or both?**  
M.J. Vrancken Peeters, Netherlands Cancer Institute, Amsterdam, NL

11:05 - 11:25 **Ablative radiation therapy for extracranial OMD**  
A. Kirby, The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB

11:25 - 11:45 **Ablative radiation therapy for brain OMD**  
O. Kaidar-Person, Chaim Sheba Medical Center, Ramat Gan, IL

11:45 - 12:05 **Systemic treatments for OMD**  
B. Linderholm, Sahlgrenska University Hospital - Jubileumskliniken, Göteborg, SE

12:05 - 12:15 **Q&A**



**10:45 - 12:15**    **Type: Educational session**    **Munich Hall**  
**Title: Treatment strategies for HER2+ metastatic breast cancer (mBC)**  
 Chair(s): M.O., ES

10:45 - 11:05    **How can we improve the first-line treatment of HER2+ mBC?**  
S. Hurvitz, UCLA Hematology/Oncology Santa Monica, Santa Monica, US

11:05 - 11:25    **Special topics in HER2+ mBC: Oligometastatic disease and exceptional responders**  
I. Krop, Dana Farber Cancer Institute, Boston, US

11:25 - 11:45    **Treatment strategies in triple positive tumours**  
M.V. Dieci, University of Padua, Padova, IT

11:45 - 12:05    **Brain mets**  
J. Watanabe, Juntendo University, Bunkyo-ku, JP

12:05 - 12:15    **Q&A**

**10:45 - 12:15**    **Type: Special Symposium**    **Frankfurt Hall**  
**Title: Major advances for breast cancer survivorship**  
 Chair(s): I.L., FR

10:45 - 11:05    **Comprehensive biobehavioral approach to tackle toxicities and quality of life (QoL) deterioration after breast cancer**  
A. Di Meglio, Institut Gustave Roussy - INSERM UMR 981, Villejuif, FR

11:05 - 11:25    **Can we personalise health promotion?**  
J. Ligibel, Dana Farber Cancer Institute, Boston, US

11:25 - 11:45    **Reproductive and sexual health among young breast cancer survivors**  
Y. Peng, Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN

11:45 - 12:05    **Integrating eHealth in the process of psycho-social rehabilitation**  
G. Pravettoni, IEO - Istituto Europeo di Oncologia, Milan, IT

12:05 - 12:15    **Conclusions and clinical perspectives**  
I. Luis, Institut Gustave Roussy, Villejuif, Cedex, FR

<b>10:45 - 11:30</b>	<b>Type: ESMO Guidelines session</b> <b>Title: Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</b> Chair(s): G.C., IT; S.L., DE	<b>Cologne Hall</b>
10:45 - 11:05	<b>Presentation</b> <u>L. Carey</u> , UNC - The University of North Carolina at Chapel Hill - School of Medicine, Chapel Hill, US	
11:05 - 11:30	<b>Discussion led by the Chairs</b> <u>G. Curigliano</u> <sup>1</sup> , <u>S. Loibl</u> <sup>2</sup> , <sup>1</sup> IEO - Istituto Europeo di Oncologia, Milan, IT, <sup>2</sup> German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE	
<b>12:15 - 13:00</b>	<b>Type: Poster Display session</b> <b>Title: Poster Display session</b>	<b>Exhibition area</b>
12:15 - 12:35	<b>Biomarkers and translational research and precision medicine</b>	
12:35 - 12:55	<b>4P - Longitudinal proteogenomic profiling reveals therapeutic vulnerabilities of immunometabolism in breast cancer</b> <u>K. Wang</u> <sup>1</sup> , I. Zerdes <sup>1</sup> , E. Sifakis <sup>1</sup> , H. Johansson <sup>1</sup> , A. Mezheyeuski <sup>2</sup> , J. Lehtiö <sup>1</sup> , J. Bergh <sup>1</sup> , T. Hatschek <sup>1</sup> , A. Matikas <sup>1</sup> , T. Foukakis <sup>1</sup> , <sup>1</sup> Karolinska Institute, Stockholm, SE, <sup>2</sup> Uppsala University - Rudbecklaboratoriet, Uppsala, SE	
12:55 - 13:15	<b>5P - Exploratory biomarker analysis from neoadjuvant atezolizumab, pertuzumab, trastuzumab plus docetaxel (NEO-PATH) in HER2+ early breast cancer</b> <u>H. Ahn</u> <sup>1</sup> , K. Park <sup>2</sup> , S.H. Sim <sup>3</sup> , K.J. Suh <sup>4</sup> , M.H. Kim <sup>5</sup> , W.-Y. Park <sup>2</sup> , Y.-L. Choi <sup>6</sup> , S.-A. Im <sup>7</sup> , K. Jung <sup>8</sup> , Y.H. Park <sup>6</sup> , <sup>1</sup> Gachon University Gil Medical Center, Incheon, KR, <sup>2</sup> Samsung Medical Center, Seoul, KR, <sup>3</sup> National Cancer Center, Goyang, KR, <sup>4</sup> Seoul National University Bundang Hospital, Seongnam, KR, <sup>5</sup> Yonsei University, Seoul, KR, <sup>6</sup> Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR, <sup>7</sup> Seoul National University College of Medicine, Seoul, KR, <sup>8</sup> Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR	
13:15 - 13:35	<b>6P - The oncolytic virus pelareorep primes the tumor microenvironment for checkpoint blockade therapy in early breast cancer patients -results from AWARE-1 study</b> <u>J. Gavila Gregori</u> <sup>1</sup> , H. Loghmani <sup>2</sup> , L. Manso Sanchez <sup>3</sup> , A. Gonzalez <sup>4</sup> , L. Pare Brunet <sup>5</sup> , F. Salvador <sup>5</sup> , T. Pascual <sup>6</sup> , B. Gonzalez-Farre <sup>7</sup> , M. Juan <sup>4</sup> , A. Prat <sup>8</sup> , T. Heineman <sup>9</sup> , <sup>1</sup> Instituto Valenciano de Oncología (IVO), Valencia, ES, <sup>2</sup> Oncolytics Biotech Inc, Calgary, CA, <sup>3</sup> Hospital Universitario 12 de Octubre, Madrid, ES, <sup>4</sup> Hospital Clinic de Barcelona/IDIBAPS, Barcelona, ES, <sup>5</sup> SOLTI Cancer Research Group, Barcelona, ES, <sup>6</sup> SOLTI Cancer Research Group/Hospital Clinic de Barcelona, Barcelona, ES, <sup>7</sup> Hospital Clinic of Barcelona, Barcelona, ES, <sup>8</sup> Hospital Clinic de Barcelona/SOLTI/IDIBAPS, Barcelona, ES, <sup>9</sup> Oncolytics Biotech, Inc, La Jolla, US	

- 13:35 - 13:55 **7P - Development and Validation of a Deep Learning RNA Modification Model Predict Disease-free Survival in Patients with Breast Cancer**  
Y. Yu<sup>1</sup>, Q. Ou<sup>1</sup>, C. Yu<sup>2</sup>, L. Wang<sup>2</sup>, R. Zhang<sup>2</sup>, R. Zhao<sup>2</sup>, B. Qu<sup>2</sup>, Z. Wang<sup>2</sup>, R. Lin<sup>2</sup>, H. Yao<sup>3</sup>,  
<sup>1</sup>Beijing Normal University-Hong Kong Baptist University United International College, Hong Kong Baptist University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangdong, CN, <sup>2</sup>Beijing Normal University-Hong Kong Baptist University United International College, Hong Kong Baptist University, Guangdong, CN, <sup>3</sup>Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangdong, CN
- 13:55 - 14:15 **8P - An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy.**  
C. Blaye<sup>1</sup>, E. Darbo<sup>2</sup>, M. Debled<sup>3</sup>, V. Brouste<sup>3</sup>, V. Vélasco<sup>3</sup>, C. Pinard<sup>4</sup>, I. Pellegrin<sup>2</sup>, A. Tarricone<sup>2</sup>, M. Arnedos<sup>5</sup>, J. Commeny<sup>3</sup>, H. Bonnefoi<sup>3</sup>, C. Larmonier<sup>3</sup>, G. Macgrogan<sup>3</sup>,  
<sup>1</sup>Bergonié Institute, BORDEAUX, FR, <sup>2</sup>Université de Bordeaux - Campus de Carreire / Victoire, Bordeaux, CEDEX, FR, <sup>3</sup>Institute Bergonié - Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, FR, <sup>4</sup>CHU - Centre Hospitalier Universitaire de Martinique, Fort-de-France, Cedex, MQ, <sup>5</sup>Institute Bergonié, Bordeaux, FR
- 14:15 - 14:35 **9P - Long term recurrence risk predictions by CanAssist Breast in a sub-cohort of TEAM trial**  
M. Bakre<sup>1</sup>, A. Gunda<sup>1</sup>, E. Meershoek-Klein Kranenbarg<sup>2</sup>, B.A. Savitha<sup>1</sup>, C. Prakash<sup>1</sup>, P. Shrivastava<sup>1</sup>, T. Kaur<sup>1</sup>, C. Seynaeve<sup>3</sup>, G.-J. Liefers<sup>2</sup>, M. Siraganahalli Eshwaraiah<sup>1</sup>, C. Van De Velde<sup>2</sup>, P. Kuppen<sup>2</sup>, <sup>1</sup>OncoStem Diagnostics Pvt Ltd, Bangalore, IN, <sup>2</sup>Leiden University Medical Center, Leiden, NL, <sup>3</sup>Erasmus Medical Center, Rotterdam, NL
- 14:35 - 14:55 **10P - Survival according to early ctDNA dynamics in advanced breast cancer (ABC) treated with endocrine therapy (ET) and a CDK4/6 inhibitor (CDK4/6i)**  
O. Martinez Saez<sup>1</sup>, E. Felip Falgas<sup>2</sup>, M. Cappelletti<sup>3</sup>, P. Tolosa<sup>4</sup>, F. Brasó-Maristany<sup>5</sup>, E. Sanfeliu Torres<sup>1</sup>, T. Pascual<sup>1</sup>, N. Chic<sup>1</sup>, M. Vidal<sup>1</sup>, B. Adamo<sup>1</sup>, M. Munoz<sup>1</sup>, I. Faull<sup>6</sup>, J. Odegaard<sup>7</sup>, G. Patel<sup>8</sup>, R. Mcewen<sup>9</sup>, D. Carroll<sup>9</sup>, E. Ciruelos<sup>4</sup>, D. Generali<sup>3</sup>, M. Margeli Vila<sup>2</sup>, A. Prat<sup>1</sup>, <sup>1</sup>Hospital Clinic of Barcelona, Barcelona, ES, <sup>2</sup>ICO - Institut Català d'Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, ES, <sup>3</sup>ASST Cremona - Azienda Socio-Sanitaria Territoriale, Cremona, IT, <sup>4</sup>Hospital Universitario 12 de Octubre, Madrid, ES, <sup>5</sup>IDIBAPS - Institut D'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, ES, <sup>6</sup>Guardant Health, Barcelona, ES, <sup>7</sup>Guardant Health, Redwood City, US, <sup>8</sup>AstraZeneca, Macclesfield, GB, <sup>9</sup>AstraZeneca - Oncology R&D, Cambridge, GB
- 14:55 - 15:15 **11P - Real-world analysis of Oncotype DX Recurrence Score (ODX RS) indications and impact on adjuvant chemotherapy (CT) decisions: experience from the French LISE cohort**  
C. Charles<sup>1</sup>, B. Cutuli<sup>2</sup>, <sup>1</sup>Scilink, BIARRITZ, FR, <sup>2</sup>Institut du Cancer Courlancy, Reims, FR
- 15:15 - 15:35 **12P - Prevalence of functional and genomic homologous recombination deficiency (HRD) in germline RAD51C/D patients**  
A. Llop-Guevara<sup>1</sup>, S. Torres-Esquius<sup>1</sup>, M. Romey<sup>2</sup>, S. Gutierrez-Enriquez<sup>1</sup>, P. Nuciforo<sup>1</sup>, O. Diez<sup>1</sup>, G. Llort Pursals<sup>3</sup>, A. Teule<sup>4</sup>, A. Vallmajó<sup>5</sup>, I. Diaz De Corcuera<sup>6</sup>, I. Chirivella

Gonzalez<sup>7</sup>, S. Gonzalez Santiago<sup>8</sup>, P. Sanchez Henarejos<sup>9</sup>, J. Sanz Buxo<sup>10</sup>, C. Guillen Ponce<sup>11</sup>, A.B. Sanchez<sup>12</sup>, J.M. Brunet Vidal<sup>13</sup>, C. Denkert<sup>2</sup>, V. Serra Elizalde<sup>1</sup>, J. Balmaña<sup>1</sup>, <sup>1</sup>Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, <sup>2</sup>Philipps-University Marburg and University Hospital Marburg (UKGM)-Universitätsklinikum Marburg, Marburg, DE, <sup>3</sup>Parc Tauli Hospital Universitari, Sabadell, ES, <sup>4</sup>Institut Català d'Oncologia Hospitalet, Barcelona, ES, <sup>5</sup>Hospital Universitario Arnau de Vilanova, Lleida, ES, <sup>6</sup>Hospital Galdakao - Usansolo, Galdakao, ES, <sup>7</sup>Hospital Clinico Universitario de Valencia, Valencia, ES, <sup>8</sup>Hospital San Pedro De Alcantara, Caceres, ES, <sup>9</sup>Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, ES, <sup>10</sup>Althaia, Xarxa Assistencial Universitària de Manresa and Institut Català d'Oncologia, Manresa, ES, <sup>11</sup>Hospital Universitario Ramon y Cajal, Madrid, ES, <sup>12</sup>Hospital General Universitario de Elche, Elche, ES, <sup>13</sup>ICO Girona - Institut Català d'Oncologia Girona, Girona, ES

15:35 - 15:55

**13P - Clinicopathological and Prognostic Significance of Tertiary Lymphoid Structures in Breast Cancer: A Systemic Review and Meta-Analysis**

B. Wang, Y. Jiang, West China School of Medicine/West China Hospital of Sichuan University, Chengdu, CN

15:55 - 16:15

**14P - Gut and oral microbiota profiling in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC) receiving pembrolizumab (P) plus eribulin (E): CALADRIO**

N. Teng<sup>1</sup>, M. Dalby<sup>1</sup>, R. Kiu<sup>1</sup>, T. Robinson<sup>2</sup>, M. Gion Cortes<sup>3</sup>, B. Bermejo De Las Heras<sup>4</sup>, J.M. Perez Garcia<sup>5</sup>, L. Calvo-Martinez<sup>6</sup>, A. Prat<sup>7</sup>, R. Marquez Vazquez<sup>8</sup>, M. Ruiz Borrego<sup>9</sup>, S. De La Cruz<sup>10</sup>, A. Llombart Cussac<sup>11</sup>, G. Curigliano<sup>12</sup>, P. Schmid<sup>13</sup>, M. Mancino<sup>14</sup>, L. Hall<sup>1</sup>, S. Robinson<sup>1</sup>, J. Cortés<sup>15</sup>, A. Malfettone<sup>16</sup>, <sup>1</sup>Quadram Institute Bioscience, Norwich, GB, <sup>2</sup>Bristol Haematology and Oncology Centre - NHS Foundation Trust, Bristol, GB, <sup>3</sup>Hospital Universitario Ramon y Cajal, Madrid, ES, <sup>4</sup>Hospital Clinico Universitario de Valencia, Valencia, ES, <sup>5</sup>Centro Medico Teknon, Barcelona, ES, <sup>6</sup>CHUAC - Complejo Hospitalario Universitario A Coruña, A Coruña, ES, <sup>7</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>8</sup>MD Anderson Cancer Center Madrid, Madrid, ES, <sup>9</sup>Hospital Universitario Virgen del Rocio, Seville, ES, <sup>10</sup>Complejo Hospitalario de Navarra - Royal Navarre Hospital, Pamplona, ES, <sup>11</sup>Hospital Arnau de Vilanova, Valencia, ES, <sup>12</sup>IEO - Istituto Europeo di Oncologia, Milan, IT, <sup>13</sup>Barts Cancer Institute-Queen Mary University of London, London, GB, <sup>14</sup>MedSIR - Medica Scientia Innovation Research, S.L., Valencia, ES, <sup>15</sup>VHIO Valle de Hebrón Instituto de Oncología, Barcelona, ES, <sup>16</sup>MedSIR - Medica Scientia Innovation Research, Barcelona, ES

16:15 - 16:35

**15P - Integration of whole genome data with machine learning technology in breast cancer subtyping**

W. Majer-Burman<sup>1</sup>, K. Pacewicz<sup>2</sup>, M. Meler<sup>1</sup>, M. Gniot<sup>1</sup>, D. Sielski<sup>1</sup>, M. Piernik<sup>3</sup>, P. Sztromwasser<sup>1</sup>, A. Wozna<sup>4</sup>, P. Zawadzki<sup>4</sup>, <sup>1</sup>MNM Diagnostics Sp. z o.o., Poznań, PL, <sup>2</sup>MNM Diagnostics Sp. z o.o., Poznan, PL, <sup>3</sup>Poznan University of Technology, Poznań, PL, <sup>4</sup>Adam Mickiewicz University - Faculty of Physics, Poznan, PL

16:35 - 16:55

**16P - Assessing early changes in plasma HER2 levels is useful for predicting therapeutic response in advanced breast cancer: A multicenter, prospective, noninterventional clinical study**

Y.-K. Kang, P. Yuan, Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN



- 16:55 - 17:15 **17P - Clinicopathological and transcriptomic characterization of luminal HER2-enriched breast cancer**  
L. Hohmann, D. Oliveira, K. Sigurjónsdóttir, A. Bosch, Å. Borg, J. Vallon-Christersson, J. Staaf, Lund University, Lund, SE
- 17:15 - 17:35 **18P - Comparative genomic profiling of primary and locally recurrent luminal breast cancers (BC)**  
E. Rassy<sup>1</sup>, I. Garberis<sup>2</sup>, A. Tran Dien<sup>1</sup>, V. Scott<sup>1</sup>, I. Bouakka<sup>2</sup>, J. Bassil<sup>1</sup>, M. Lacroix-Triki<sup>2</sup>, F. Zanconati<sup>3</sup>, F. Giudici<sup>2</sup>, D. Generali<sup>4</sup>, E. Rouleau<sup>2</sup>, L. Lacroix<sup>2</sup>, F. André<sup>5</sup>, B. Pistilli<sup>5</sup>,  
<sup>1</sup>Institut Gustave Roussy, Villejuif, Cedex, FR, <sup>2</sup>Institut Gustave Roussy, Villejuif, FR, <sup>3</sup>University of Trieste-Ospedale di Cattinara, Trieste, IT, <sup>4</sup>Università di Trieste, Trieste, IT, <sup>5</sup>Gustave Roussy - Cancer Campus, Villejuif, FR
- 17:35 - 17:55 **19P - Usefulness of Hounsfield Unit on computed tomography, serum neutrophil to lymphocyte ratio, and their combination as prognostic factor in patients with breast cancer.**  
A. Han, K. Kim, H. Choi, H. Noh, I.-J. Cho, S. Lim, J.I. Lee, Yonsei University Wonju Severance Christian Hospital, Wonju-si, KR
- 17:55 - 18:15 **20P - The importance of ARG2 expression in the immune-depleted microenvironment of primary breast cancer and brain metastasis**  
A. Giannoudis<sup>1</sup>, D. Vareslija<sup>2</sup>, V. Sharma<sup>3</sup>, R. Zakaria<sup>4</sup>, A. Platt-Higgins<sup>1</sup>, P. Rudland<sup>1</sup>, M. Jenkinson<sup>4</sup>, L. Young<sup>2</sup>, C. Palmieri<sup>1</sup>, <sup>1</sup>Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, GB, <sup>2</sup>Endocrine Oncology Research Group, RCSI University of Medicine and Health Sciences, Dublin, IE, <sup>3</sup>The Royal Liverpool University Hospital - Liverpool University Hospitals NHS Foundation Trust, Liverpool, GB, <sup>4</sup>The Walton Centre NHSFT and University of Liverpool, Liverpool, GB
- 18:15 - 18:35 **21P - Metabolomic profiling and response to neoadjuvant therapy in operable breast cancer**  
A. Gennari<sup>1</sup>, V. Martini<sup>2</sup>, R. Boldorini<sup>1</sup>, C. Saggia<sup>2</sup>, V. Rossi<sup>2</sup>, F. D'Avanzo<sup>2</sup>, I. Dodaro<sup>2</sup>, E. Gallarotti<sup>2</sup>, A. Rua<sup>1</sup>, C. Branni<sup>2</sup>, A. Stella<sup>1</sup>, A. Tassone<sup>1</sup>, E. Gioffi<sup>1</sup>, P. Maggiora<sup>1</sup>, A. Gambaro<sup>2</sup>, A. Rampi<sup>2</sup>, A. Sica<sup>3</sup>, S. Khoso<sup>1</sup>, E. Barberis<sup>1</sup>, M. Manfredi<sup>1</sup>, <sup>1</sup>Università Degli Studi Del Piemonte Orientale - Scuola di Medicina, Novara, IT, <sup>2</sup>AOU Maggiore della Carità di Novara, Novara, IT, <sup>3</sup>Università degli Studi del Piemonte Orientale - Amedeo Avogadro, Novara, IT
- 18:35 - 18:55 **22P - Biobanking in Breast Cancer: 10 years of practice at the European Institute of Oncology**  
G. Viale<sup>1</sup>, G. Bonizzi<sup>1</sup>, M. Capra<sup>1</sup>, L. Zattoni<sup>1</sup>, C. Cassi<sup>1</sup>, G. Taliento<sup>1</sup>, E. Sajjadi<sup>1</sup>, E. Guerini-Rocco<sup>1</sup>, M. Colleoni<sup>2</sup>, V. Galimberti<sup>2</sup>, P. Veronesi<sup>2</sup>, G. Curigliano<sup>2</sup>, R. Orecchia<sup>3</sup>, N. Fusco<sup>1</sup>, <sup>1</sup>IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT, <sup>2</sup>IEO - Istituto Europeo di Oncologia, Milan, IT, <sup>3</sup>Istituto Europeo di Oncologia, Milan, IT
- 18:55 - 19:15 **23P - In Vivo Multi-Dimensional CRISPR Screens Identify Lgals2 as an Immunotherapy Target in Triple-Negative Breast Cancer**  
P. Ji, Y. Gong, M. Jin, X. Hu, G. Di, Z. Shao, Fudan University Shanghai Cancer Center,

Shanghai, CN

19:15 - 19:35

**24P - Intermediate biopsies during neoadjuvant chemotherapy for breast cancer to predict patient outcome**

B. Sinn<sup>1</sup>, M. Untch<sup>2</sup>, T. Karn<sup>3</sup>, M. Van Mackelenbergh<sup>4</sup>, J. Huober<sup>5</sup>, K. Sychra<sup>1</sup>, W. Schmitt<sup>1</sup>, F. Marmé<sup>6</sup>, C. Schem<sup>7</sup>, C. Solbach<sup>8</sup>, E. Stickeler<sup>9</sup>, H. Tesch<sup>10</sup>, P.A. Fasching<sup>11</sup>, A. Schneeweiss<sup>12</sup>, V. Müller<sup>13</sup>, V. Nekljudova<sup>14</sup>, S. Loibl<sup>14</sup>, C. Denkert<sup>15</sup>, <sup>1</sup>Charité - Universitätsmedizin Berlin, Berlin, DE, <sup>2</sup>Helios Klinikum Berlin-Buch, Berlin, DE, <sup>3</sup>UCT-Frankfurt-Marburg, Frankfurt am Main, DE, <sup>4</sup>Klinik für Gynäkologie und Geburtshilfe, Schleswig-Holstein, Kiel, DE, <sup>5</sup>Kantonsspital St.Gallen, Brustzentrum, St.Gallen, CH, <sup>6</sup>Heidelberg University, University Hospital Mannheim, Mannheim, DE, <sup>7</sup>Mammazentrum Hamburg, Hamburg, DE, <sup>8</sup>Universitätsklinikum Frankfurt, Frankfurt am Main, DE, <sup>9</sup>Uniklinik Aachen, Aachen, DE, <sup>10</sup>Onkologie Bethanien, Frankfurt am Main, DE, <sup>11</sup>Universitätsklinikum Erlangen, Erlangen, DE, <sup>12</sup>Universitätsklinikum und Deutsches Krebsforschungszentrum, Heidelberg, Heidelberg, DE, <sup>13</sup>Universitätsklinikum Hamburg-Eppendorf, Hamburg, DE, <sup>14</sup>German Breast Group (GBG), Neu-Isenburg, DE, <sup>15</sup>Philipps University Marburg and Marburg University Hospital (UKGM), Marburg, DE

19:35 - 19:55

**25P - Research-based HER2DX in patients with early-stage HER2-positive (HER2+) breast cancer treated in the N9831 phase III clinical trial**

F. Brasó-Maristany<sup>1</sup>, O. Martinez Saez<sup>2</sup>, L. Pare Brunet<sup>3</sup>, M. Marín-Aguilera<sup>3</sup>, P.F. Conte<sup>4</sup>, P. Jares<sup>2</sup>, V. Guarneri<sup>5</sup>, T. Pascual<sup>6</sup>, J. Puig-Butille<sup>6</sup>, A. Vivancos<sup>7</sup>, J. Parker<sup>8</sup>, P. Villagrasa Gonzalez<sup>3</sup>, S. Tolaney<sup>9</sup>, L. Carey<sup>10</sup>, C. Perou<sup>11</sup>, A. Prat<sup>6</sup>, <sup>1</sup>IDIBAPS - Institut D'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, ES, <sup>2</sup>Hospital Clinic of Barcelona, Barcelona, ES, <sup>3</sup>Reveal Genomics, Barcelona, ES, <sup>4</sup>IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>5</sup>University of Padua, Padova, IT, <sup>6</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>7</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>8</sup>UNC - Lineberger Comprehensive Cancer Center, Chapel Hill, US, <sup>9</sup>Dana Farber Cancer Institute, Boston, US, <sup>10</sup>UNC - The University of North Carolina at Chapel Hill - School of Medicine, Chapel Hill, US, <sup>11</sup>UNC, Chapel Hill, US

19:55 - 20:15

**26P - Evaluation of tumor-infiltrating lymphocytes on matched baseline and residual disease samples of triple-negative breast cancer patients treated with anthracycline-taxane based neoadjuvant chemotherapy with or without carboplatin**

F. Miglietta<sup>1</sup>, G. Zarrilli<sup>2</sup>, D. Massa<sup>1</sup>, G. Griguolo<sup>1</sup>, M. Fassan<sup>2</sup>, M. Bottosso<sup>1</sup>, C.A. Giorgi<sup>3</sup>, T. Giarratano<sup>1</sup>, G. Vernaci<sup>4</sup>, M. Cesarotto<sup>5</sup>, M.C. Guarascio<sup>1</sup>, V. Guarneri<sup>1</sup>, M.V. Dieci<sup>1</sup>, <sup>1</sup>IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>2</sup>Azienda Universitaria Ospedaliera di Padova, Padova, IT, <sup>3</sup>Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>4</sup>University of Padua - School of Medicine, Padua, IT, <sup>5</sup>Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padua, 35128 Padova, Italy, Padova, IT

20:15 - 20:35

**27P - Association between CD8+ tumor infiltrating lymphocytes and the clinical outcome of patients with operable breast cancer treated with adjuvant dose-dense chemotherapy. A 10 - year follow up report of a Hellenic Cooperative Oncology Group observational study**

N. Spathas, A. Goussia, G.A. Koliou, H. Gogas, F. Zagouri, M. Bobos, D. Pectasides, E. Galani, A. Koutras, G. Zarkavelis, E. Saloustros, D. Bafaloukos, C. Karanikiotis, G. Aravantinos, A. Psyrri, E. Razis, A. Koumarianou, E. Res, H. Linardou, G. Fountzilias,



Hellenic Cooperative Oncology Group (HeCOG), Athens, GR

- 20:35 - 20:55 **28P - ACLY mediated breast tumorigenesis is driven by immune escape via PD-L1 signaling**  
M. Hegde, A. Kunnumakkara, IITG - Indian Institute of Technology Guwahati, Guwahati, IN
- 20:55 - 21:15 **29P - The molecular landscape of breast mucoepidermoid carcinoma**  
N. Fusco<sup>1</sup>, K. Venetis<sup>1</sup>, E. Sajjadi<sup>1</sup>, M. Ivanova<sup>1</sup>, S. Andaloro<sup>1</sup>, S. Pessina<sup>1</sup>, C. Zanetti<sup>1</sup>, G. Citelli<sup>1</sup>, C. Rossi<sup>2</sup>, M. Lucioni<sup>3</sup>, U. Malapelle<sup>4</sup>, F. Pagni<sup>5</sup>, M. Barberis<sup>1</sup>, E. Guerini-Rocco<sup>1</sup>, G. Viale<sup>1</sup>, <sup>1</sup>IEO - Istituto Europeo di Oncologia IRCCS, Milan, IT, <sup>2</sup>Universita Degli Studi di Pavia - Polo Scientifico, Pavia, IT, <sup>3</sup>Fondazione IRCCS Policlinico San Matteo, Pavia, IT, <sup>4</sup>Università degli Studi di Napoli Federico II, Napoli, IT, <sup>5</sup>Università degli Studi di Milano-Bicocca, Milano, IT
- 21:15 - 21:35 **30P - Circulating 27-hydroxycholesterol, 25-hydroxycholesterol, and breast cancer prognosis**  
N. Decker<sup>1</sup>, T. Johnson<sup>1</sup>, S. Behrens<sup>1</sup>, N. Obi<sup>2</sup>, R. Kaaks<sup>1</sup>, J. Chang-Claude<sup>1</sup>, R. Turzanski Fortner<sup>1</sup>, <sup>1</sup>DKFZ - German Cancer Research Center, Heidelberg, DE, <sup>2</sup>UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE
- 21:35 - 21:55 **31P - Prognostic significance of the Hounsfield unit when assessing tumors in patients with breast cancer**  
K. Kim<sup>1</sup>, I.-J. Cho<sup>1</sup>, H. Noh<sup>1</sup>, H. Choi<sup>1</sup>, S. Hahn<sup>2</sup>, S. Lim<sup>1</sup>, J.I. Lee<sup>1</sup>, A. Han<sup>1</sup>, <sup>1</sup>Yonsei University Wonju Severance Christian Hospital, Wonju-si, KR, <sup>2</sup>Haeundae Paik hospital, Pusan, KR
- 21:55 - 22:15 **32P - Neutrophil Lymphocyte Ratio (NLR) as a surrogate clinical marker for Ki-67 in Breast Cancer**  
R. Arora, F. Alam, A. Zaka- Ur-Rab, V. Maheshwari, K. Alam, Jawaharlal Nehru Medical College - Aligarh Muslim University, Aligarh, IN
- 22:15 - 22:35 **33P - The multi-switching activity of circulatory neutrophils in patients with Early Breast Cancer**  
A. Ramessur<sup>1</sup>, I. Malanchi<sup>2</sup>, R.C. Coombes<sup>3</sup>, <sup>1</sup>Imperial College London, AZ, GB, <sup>2</sup>Francis Crick Institute, London, GB, <sup>3</sup>Hammersmith Hospital - Imperial College Healthcare NHS Trust, London, GB
- 22:35 - 22:55 **34P - Quadruple negative breast cancer (PD-L1 negative triple negative breast cancer, TNBC): Poorer response to chemotherapy and poorer survival compared to other TNBCs: A systematic review and meta-analysis**  
L. Kassem<sup>1</sup>, K. Shohdy<sup>2</sup>, H. Elghazawy<sup>3</sup>, M. Salib<sup>4</sup>, D. Almeldin<sup>4</sup>, H. Azim<sup>5</sup>, <sup>1</sup>Kasr Alainy Medical School - Cairo University, Cairo, EG, <sup>2</sup>Cairo University - Faculty of Medicine (Kasr Alainy School), Cairo, EG, <sup>3</sup>Ain Shams University - Faculty of Medicine, Cairo, EG, <sup>4</sup>Cairo University - Faculty Of Medicine, Cairo, EG, <sup>5</sup>Kasr Alainy Medical School - Cairo University, Giza, EG
- 22:55 - 23:15 **35P - European consensus on the utility of breast cancer multigene signatures in**

**routine clinical practice - PROCURE Project final results**

G. Curigliano<sup>1</sup>, F. Cardoso<sup>2</sup>, M. Gnant<sup>3</sup>, N. Harbeck<sup>4</sup>, J. King<sup>5</sup>, A.-V. Laenkholm<sup>6</sup>, F. Penault-Llorca<sup>7</sup>, A. Prat<sup>8</sup>, <sup>1</sup>European Institute of Oncology, IRCCS and University of Milano, Milan, Italy, Milano, IT, <sup>2</sup>Champalimaud Foundation - Champalimaud Clinical Center, Lisbon, PT, <sup>3</sup>Universitätskliniken der MedUni Wien - AKH Wien, Vienna, AT, <sup>4</sup>LMU University Hospital Munich, Munich, DE, <sup>5</sup>UCLH - University College London Hospitals NHS Foundation Trust, London, GB, <sup>6</sup>Zealand University Hospital, Roskilde, DK, <sup>7</sup>Jean Perrin Center, Clermont-Ferrand, FR, <sup>8</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES

23:15 - 23:35

**36P - Young breast cancer biology explored by NanoString BC360 panel in a formalin-fixed paraffin-embedded cohort**

L.M. Ingebriksen, A.A. Svanøe, A.K.M. Sæle, K. Toska, M.B. Kalvenes, B. Davidsen, A. Heie, G. Knutsvik, I.M. Stefansson, L.A. Akslen, E. Wik, University of Bergen, Bergen, NO

23:35 - 23:55

**37P - SLC22A17 as a Novel Therapeutic Target for Triple-Negative Breast Cancer**

A. Kunnumakara, K. Thakur, Indian Institute of Technology, Guwahati, Assam, India, Guwahati, IN

23:55 - 00:15

**38P - Tumour infiltrating lymphocytes and correlation with prognostic signature scores in early-stage hormone-positive, HER2-negative (ER+/HER2-) breast cancer.**

M. Lucas<sup>1</sup>, Z. Kinsella<sup>1</sup>, C. Gonzalez<sup>2</sup>, C. Hurley<sup>1</sup>, A. Blümel<sup>1</sup>, T. O'Grady<sup>1</sup>, V. Murphy<sup>3</sup>, C. Jahangir<sup>2</sup>, C. Burke<sup>2</sup>, A. Rahman<sup>2</sup>, C. Kelly<sup>4</sup>, W. Gallagher<sup>2</sup>, D. O'Connor<sup>1</sup>, <sup>1</sup>RCSI - Royal College of Surgeons in Ireland, Dublin, IE, <sup>2</sup>University College Dublin, Dublin, IE, <sup>3</sup>Cancertrials Irelan, Dublin, IE, <sup>4</sup>The Mater Misericordiae University Hospital, Dublin, IE

00:15 - 00:35

**39P - Understanding the crosstalk between micro-RNA and Wnt signaling cascade associated with the expression level of HOXB13 and SRC genes in female breast cancer.**

A. Khan<sup>1</sup>, M. Faisal<sup>1</sup>, B. Aslam<sup>2</sup>, H. Anwar<sup>3</sup>, H. Muzaffar<sup>1</sup>, A. Roobi<sup>1</sup>, N. Aslam<sup>2</sup>, L. Majeed<sup>1</sup>, S. Ali<sup>1</sup>, J. Aslam<sup>2</sup>, M. Mehmood<sup>1</sup>, Q. Tanveer<sup>1</sup>, A. Mahmood<sup>4</sup>, <sup>1</sup>University of Agriculture, Faisalabad, Faisalabad, PK, <sup>2</sup>University of Agriculture Faisalabad, Faisalabad, PK, <sup>3</sup>GCUF - Government College University Faisalabad, Faisalabad, PK, <sup>4</sup>Islamia University of Bahawalpur, Bahawalpur, PK

00:35 - 00:55

**40P - Connexin43 as double therapeutic target in triple negative breast cancer: role in tumour progression and antitumour immune response**

M. Rodriguez-Candela Mateos<sup>1</sup>, J. Röder<sup>2</sup>, P. Oberoi<sup>2</sup>, W. Wels<sup>2</sup>, P. Santiago-Freijanes<sup>3</sup>, J. Mosquera<sup>3</sup>, B. Acea-Nebril<sup>3</sup>, M.D. Mayan<sup>1</sup>, <sup>1</sup>Institute of Biomedical Research of A Coruña (INIBIC), A Coruña, ES, <sup>2</sup>Georg-Speyer Haus, Frankfurt am Main, DE, <sup>3</sup>Breast Unit, Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruña, ES

00:55 - 01:15

**41P - The impact of tumour infiltrating lymphocyte subpopulations on pathological complete response in HER2+ breast cancer**

C. Hurley<sup>1</sup>, L. Lacroix<sup>2</sup>, M. Lucas<sup>1</sup>, R. Buckley<sup>1</sup>, A. Blümel<sup>1</sup>, K. Sheehan<sup>3</sup>, S. Toomey<sup>4</sup>, B. Hennessy<sup>4</sup>, J. Crown<sup>5</sup>, C. Sautes-Fridman<sup>2</sup>, D. O'Connor<sup>1</sup>, <sup>1</sup>RCSI - Royal College of

Surgeons in Ireland, Dublin, IE, <sup>2</sup>Centre de Recherche des Cordeliers, Paris, FR, <sup>3</sup>RCSI Education & Research Centre, Beaumont Hospital, Dublin, IE, <sup>4</sup>Royal College of Surgeons in Ireland, Dublin, IE, <sup>5</sup>St. Vincent's University Hospital, Dublin, IE

- 01:15 - 01:35 **42P - Endothelin-1 genetic polymorphism (SNP rs5370-TT) fails to predict resistance to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial**  
 S.P. Gampenrieder<sup>1</sup>, M. Steiner<sup>1</sup>, C. Hufnagl<sup>1</sup>, H. Hackl<sup>2</sup>, G. Rinnerthaler<sup>1</sup>, T. Westphal<sup>1</sup>, F. Huemer<sup>1</sup>, C. Monzo-Fuentes<sup>1</sup>, P. Morre<sup>1</sup>, C. Hauser-Kronberger<sup>1</sup>, R. Greil<sup>1</sup>,  
<sup>1</sup>Paracelsus Medical University Salzburg, Salzburg, AT, <sup>2</sup>Medical University of Innsbruck, Innsbruck, AT
- 01:35 - 01:55 **43P - Dynamic alterations of immunosenescence-related genes in older women with breast cancer receiving chemotherapy**  
 Q. Wu<sup>1</sup>, B. Brouwers<sup>2</sup>, B. Dalmasso<sup>3</sup>, C. Kenis<sup>1</sup>, L. Dal Lago<sup>4</sup>, P. Neven<sup>5</sup>, P. Vuylsteke<sup>6</sup>, G. Debrock<sup>7</sup>, H. Van Den Bulck<sup>8</sup>, A. Smeets<sup>5</sup>, A. Laenen<sup>1</sup>, H. Wildiers<sup>9</sup>, S. Hatse<sup>1</sup>, <sup>1</sup>KU Leuven, Leuven, BE, <sup>2</sup>AZ Sint-Jan Brugge-Oostende AV, Brugge, BE, <sup>3</sup>IRCCS Ospedale Policlinico San Martino, Genova, IT, <sup>4</sup>Institute Jules Bordet, Brussels, BE, <sup>5</sup>University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, <sup>6</sup>Clinique Sainte-Elisabeth, Namur, BE, <sup>7</sup>Ziekenhuis Oost-Limburg - Campus Sint-Jan, Genk, BE, <sup>8</sup>Imeldaziekenhuis, Bonheiden, BE, <sup>9</sup>Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven, BE
- 01:55 - 02:15 **44P - Breast cancer subtypes in Georgia: Higher frequency of triple-negative breast cancer compared to resource-rich areas**  
 I. Kiladze<sup>1</sup>, L. Katselashvili<sup>1</sup>, D. Dizon<sup>2</sup>, <sup>1</sup>CMC - Caucasus Medical Centre, Tbilisi, GE, <sup>2</sup>Women & Infants Hospital - Warren Alpert Medical School of Brown Univ, Providence, US
- 02:15 - 02:35 **45P - Spatially-resolved single-cell HER2 tumor heterogeneity captured by biophysical modeling**  
 D. Cook, N. Hobbs, D. Lopez-Ramos, J. Cole, S. Patel, SimBioSys, Inc., Chicago, US
- 02:35 - 02:55 **46P - Co-expression of GR with PR isoforms is associated with differential prognosis in estrogen receptor positive breast cancer**  
 V. Nimbalkar<sup>1</sup>, V. Snijesh<sup>1</sup>, S. Rajarajan<sup>1</sup>, S. Patil<sup>1</sup>, C. Anupama<sup>1</sup>, R. Ramesh<sup>2</sup>, B. Srinath<sup>3</sup>, J. Prabhu<sup>1</sup>, <sup>1</sup>SJRI - St. John's Research Institute, Bangalore, IN, <sup>2</sup>St. John's Medical College Hospital, Bangalore, IN, <sup>3</sup>Sri Shankara Cancer Hospital and Research Centre - SSCF, Bangalore, IN
- 02:55 - 03:15 **47P - Immune tumor microenvironment and markers of apoptosis in breast cancer in carriers of hereditary mutations in the BRCA1 gene**  
 A. Stukan, Krasnodar Regional Oncological Centre, Krasnodar, RU
- 03:15 - 03:35 **48P - T-helper cell driven immune response as an effect for seroma formation (SF) after mastectomy (ME) in breast cancer (BC) (SerMa pilot EUBREAST 5)**  
 N. Ditsch<sup>1</sup>, M. Schneider<sup>1</sup>, N. Pochert<sup>1</sup>, N. Ansorge<sup>1</sup>, A. Strieder<sup>1</sup>, J. Sagasser<sup>2</sup>, T. Kühn<sup>3</sup>,

A. Neumann<sup>1</sup>, M. Reiger<sup>1</sup>, C. Traidl-Hoffmann<sup>1</sup>, U. Jeschke<sup>1</sup>, C. Dannecker<sup>1</sup>,  
<sup>1</sup>Universitätsklinikum Augsburg, Augsburg, DE, <sup>2</sup>University Hospital Augsburg,  
 Augsburg, DE, <sup>3</sup>Klinikum Esslingen, Esslingen am Neckar, DE

- 03:35 - 03:55 **49P - Analysis of HER2-low carcinomas and PAM50 signature in an early-stage breast cancer cohort**  
 R. Sanchez Bayona, P. Tolosa, M. Alba Bianchi, A. Madariaga Urrutia, S. Teran, M. Rey Cardenas, L. Lema Roso, Y. Ruano, L. Manso, E. Ciruelos, Hospital Universitario 12 de Octubre, Madrid, ES
- 03:55 - 04:15 **50P - Brain 18-FDG-PET patterns in early breast cancer subtypes: relationship with headache**  
 R. De Sanctis<sup>1</sup>, L. Antunovic<sup>2</sup>, C. Benvenuti<sup>3</sup>, F. Jacobs<sup>3</sup>, M. Gaudio<sup>3</sup>, M. Ilieva<sup>1</sup>, A. Viganò<sup>4</sup>, A. Chiti<sup>1</sup>, A. Santoro<sup>1</sup>, <sup>1</sup>Humanitas University, Milan, IT, <sup>2</sup>IRCCS Humanitas Research Hospital, Rozzano, IT, <sup>3</sup>Istituto Clinico Humanitas, Rozzano, IT, <sup>4</sup>Fondazione Don Gnocchi, Milan, IT
- 04:15 - 04:35 **51P - Novel platform combines pathology and transcriptomics for a multi-scale analysis and visualization of the breast tumor heterogeneity**  
 J. Peterson, M. Shin, M. Hallock, S. Patel, SimBioSys, Inc., Chicago, US
- 04:35 - 04:55 **52P - RNA Sequencing-Based Single Sample Predictors of Molecular Subtype and Risk of Recurrence for Clinical Assessment of Early-Stage Breast Cancer**  
 J. Vallon-Christersson<sup>1</sup>, J. Staaf<sup>1</sup>, J. Häkkinen<sup>1</sup>, C. Hegardt<sup>1</sup>, L. Saal<sup>1</sup>, A. Ehinger<sup>1</sup>, C. Larsson<sup>1</sup>, N. Loman<sup>1</sup>, L. Rydén<sup>1</sup>, M. Malmberg<sup>2</sup>, Å. Borg<sup>1</sup>, <sup>1</sup>Lund University, Lund, SE, <sup>2</sup>Skåne University Hospital, Lund, SE
- 04:55 - 05:15 **53P - 'HER2-LOW' Breast Cancer Brain Metastases: An opportunity for targeted systemic therapies in a high-need patient population**  
 R. Chehade<sup>1</sup>, M. Freeman<sup>2</sup>, K. Jerzak<sup>2</sup>, <sup>1</sup>University of Toronto, Toronto, CA, <sup>2</sup>Sunnybrook Health Sciences Centre - Odette Cancer Centre, Toronto, CA
- 05:15 - 05:35 **54P - Development of a Prognostic Test for Breast Cancer Recurrence Using a Highly Efficient Molecular Profiling Platform**  
 P. Capewell<sup>1</sup>, J. Loane<sup>2</sup>, J. Robson<sup>1</sup>, H. Vansteenhout<sup>1</sup>, D. Andersen<sup>1</sup>, <sup>1</sup>BioClavis Ltd., Glasgow, GB, <sup>2</sup>Glasgow Royal Infirmary - NHS Greater Glasgow and Clyde, Glasgow, GB
- 05:35 - 05:55 **55P - Morphological changes and regulation of hormone receptor-related proteins in breast cancer patients with higher levels of progesterone receptor A than B treated with mifepristone**  
 L. Saldain<sup>1</sup>, S. Vanzulli<sup>2</sup>, E. Spengler<sup>3</sup>, A. Elia<sup>1</sup>, M. Abascal<sup>1</sup>, P. Martínez Vazquez<sup>3</sup>, J. Burruchaga<sup>3</sup>, I. Caillet Bois<sup>3</sup>, M. Liguori<sup>3</sup>, H. Gass<sup>3</sup>, C. Lanari<sup>1</sup>, P. Rojas<sup>1</sup>, <sup>1</sup>Institute of Biology and Experimental Medicine (IBYME-CONICET), Buenos Aires, AR, <sup>2</sup>National Academy of Medicine, Buenos Aires, AR, <sup>3</sup>Magdalena V de Martínez Hospital, General Pacheco, General Pacheco, AR
- 05:55 - 06:15 **56P - Lymph node germinal centres and B cell responses in triple negative breast cancer**



E. Alberts<sup>1</sup>, V. Boulat<sup>1</sup>, F. Liu<sup>1</sup>, T. Hardiman<sup>1</sup>, M. Li<sup>1</sup>, J. Quist<sup>1</sup>, C. Gillett<sup>1</sup>, S. Pinder<sup>2</sup>, D.P. Calado<sup>3</sup>, A. Grigoriadis<sup>1</sup>, <sup>1</sup>King's College London - Guy's Campus, London, GB, <sup>2</sup>Guy's and St. Thomas' Hospital NHS Trust, London, GB, <sup>3</sup>The Francis Crick Institute, London, GB

06:15 - 06:35 **57TiP - SOLTI-1910: Predicting olaparib sensitivity in patients with unresectable locally advanced/metastatic HER2-negative breast cancer with BRCA1/2, PALB2, RAD51C/D mutations or HRD by the RAD51 test: RADIOLA TRIAL**

J. Balmana<sup>1</sup>, T. Pascual<sup>2</sup>, A. Llop-Guevara<sup>3</sup>, P. Tolosa<sup>4</sup>, I. Blancas López-Barajas<sup>5</sup>, M.E. Perez Lopez<sup>6</sup>, B. Adamo<sup>7</sup>, I. Teruel-Garcia<sup>8</sup>, J. Ponce<sup>9</sup>, M. González-Cordero<sup>10</sup>, G. Viñas Villaro<sup>11</sup>, L. Lema Roso<sup>12</sup>, F.J. Salvador Bofill<sup>13</sup>, M.T. Martinez<sup>14</sup>, A.N. Guerrero<sup>15</sup>, A. Prat<sup>7</sup>, V. Serra Elizalde<sup>16</sup>, <sup>1</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>2</sup>SOLTI Cancer Research Group/Hospital Clinic de Barcelona, Barcelona, ES, <sup>3</sup>Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, <sup>4</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>5</sup>Hospital Clinico San Cecilio, Granada, ES, <sup>6</sup>CHUAC - Complejo Hospitalario Universitario A Coruña, A Coruña, ES, <sup>7</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>8</sup>ICO - Institut Català d' Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, ES, <sup>9</sup>Hospital General Universitario de Alicante, Alicante, ES, <sup>10</sup>Hospital Universitario Badajoz (Hospital Infanta Cristina), Badajoz, ES, <sup>11</sup>Catalan Institute of Oncology (ICO)-Hospital Universitari Josep Trueta, Girona, ES, <sup>12</sup>Hospital Universitario 12 de Octubre, Madrid, ES, <sup>13</sup>Hospital Universitario Virgen de Valme, Seville, ES, <sup>14</sup>Hospital Clinico Universitario de Valencia, Valencia, ES, <sup>15</sup>SOLTI Cancer Research Group, Barcelona, ES, <sup>16</sup>Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES

06:35 - 06:55 **Early breast cancer: Adjuvant therapy**

06:55 - 07:15 **62P - Outcomes of high-risk breast cancer (BC) patients from El Álamo IV registry and GEICAM adjuvant clinical trials**

M. Martin Jimenez<sup>1</sup>, A. Rodríguez-Lescure<sup>2</sup>, R. Andres Conejero<sup>3</sup>, S. Servitja Tormo<sup>4</sup>, A. Anton Torres<sup>5</sup>, M. Ruiz Borrego<sup>6</sup>, B. Bermejo De Las Heras<sup>7</sup>, A. Guerrero<sup>8</sup>, M. Ramos Vazquez<sup>9</sup>, A. Santaballa Bertran<sup>10</sup>, M. Munoz<sup>11</sup>, J.N. Batista<sup>12</sup>, S. Lopez-Tarruella Cobo<sup>13</sup>, J.I. Chacon Lopez-Muniz<sup>14</sup>, I. Alvarez Lopez<sup>15</sup>, M. Martinez Del Prado<sup>16</sup>, J.J. Miralles<sup>17</sup>, O. Polonio<sup>18</sup>, C. Jara Sanchez<sup>19</sup>, M. Mori De Santiago<sup>20</sup>, <sup>1</sup>Hospital General Universitario Gregorio Marañón. CIBERONC-ISCI. 2. GEICAM Spanish Breast Cancer Group, Madrid, ES, <sup>2</sup>Hospital General Universitario de Elche. 2. GEICAM, Spanish Breast Cancer Group, Elche, ES, <sup>3</sup>Hospital Clínico Universitario Lozano Blesa. GEICAM , Spanish Breast Cancer Group, Zaragoza, ES, <sup>4</sup>Hospital del Mar - Parc de Salut Mar. GEICAM Spanish Breast Cancer Group, Barcelona, ES, <sup>5</sup>Hospital Universitario Miguel Servet. GEICAM Spanish Breast Cancer Group, Zaragoza, ES, <sup>6</sup>Hospital Universitario Virgen del Rocío. Spanish Breast Cancer Group, Seville, ES, <sup>7</sup>Hospital Clinico Universitario de Valencia. GEICAM Spanish Breast Cancer Group, Valencia, ES, <sup>8</sup>Instituto Valenciano de Oncología. GEICAM Spanish Breast Cancer Group, Valencia, ES, <sup>9</sup>Centro Oncológico de Galicia. GEICAM Spanish Breast Cancer Group, A Coruña, ES, <sup>10</sup>Hospital Universitario y Politécnico La Fe. GEICAM Spanish Breast Cancer Group, Valencia, ES, <sup>11</sup>Hospital Clinic de Barcelona. GEICAM Spanish Breast Cancer Group, Barcelona, ES, <sup>12</sup>Hospital Universitario de Canarias. GEICAM Spanish Breast Cancer Group, San Cristobal de la Laguna, ES, <sup>13</sup>Hospital General Universitario Gregorio Marañón.

CIBERONC-ISCIH. GEICAM Spanish Breast Cancer Group, Madrid, ES, <sup>14</sup>Hospital General Universitario de Toledo. GEICAM Spanish Breast Cancer Group, Toledo, ES, <sup>15</sup>Hospital Universitario de Donostia. GEICAM Spanish Breast Cancer Group, San Sebastian (Donostia), ES, <sup>16</sup>Hospital Universitario de Basurto. GEICAM Spanish Breast Cancer Group, Bilbao, ES, <sup>17</sup>GEICAM - Spanish Breast Cancer Research Group, San Sebastian de los Reyes, ES, <sup>18</sup>GEICAM-Spanish Breast Cancer Research Group, San Sebastian de los Reyes, ES, <sup>19</sup>Hospital Universitario Fundación Alcorcón. GEICAM Spanish Breast Cancer Group, Alcorcon, ES, <sup>20</sup>Hospital Universitario de Gran Canaria Doctor Negrin. GEICAM Spanish Breast Cancer Group, Las Palmas de Gran Canaria, ES

07:15 - 07:35

**63P - Efficacy and safety results by menopausal status in monarchE: Adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2- high-risk early breast cancer**

S. Paluch-Shimon<sup>1</sup>, P. Neven<sup>2</sup>, J. Huober<sup>3</sup>, I. Cicin<sup>4</sup>, Z. Jiang<sup>5</sup>, M. Goetz<sup>6</sup>, C. Shimizu<sup>7</sup>, C. Huang<sup>8</sup>, R.J. Wei<sup>9</sup>, S. Nabinger<sup>9</sup>, T. Forrester<sup>9</sup>, N. Harbeck<sup>10</sup>, <sup>1</sup>Hadassah University Hospital - Ein Kerem, Jerusalem, IL, <sup>2</sup>University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, <sup>3</sup>University of Ulm, Ulm, DE, <sup>4</sup>Trakya University Rektörlüğü, Edirne, TR, <sup>5</sup>307th Hospital of PLA (AMMS China), Beijing, CN, <sup>6</sup>Mayo Clinic, Rochester, US, <sup>7</sup>NCGM - National Center for Global Health and Medicine, Shinjuku-ku, JP, <sup>8</sup>NTUH - National Taiwan University Hospital, Taipei City, TW, <sup>9</sup>Eli Lilly and Company - Global Headquarters, Indianapolis, US, <sup>10</sup>LMU University Hospital Munich, Munich, DE

07:35 - 07:55

**64P - Concomitant discontinuation of cardiovascular therapy and adjuvant hormone therapy in breast cancer patients**

E. Zeng<sup>1</sup>, W. He<sup>2</sup>, A. Sjölander<sup>1</sup>, K. Czene<sup>1</sup>, <sup>1</sup>Karolinska Institutet, Stockholm, SE, <sup>2</sup>Zhejiang University, Hangzhou, CN

07:55 - 08:15

**65P - Evaluation of survival outcome of adjuvant chemoradiotherapy compared to other treatment modalities stratified by tumor size in T1N0M0 triple negative breast cancer**

A. Ellaithy, Suez Canal University, Ismailia, EG

08:15 - 08:35

**66P - Impact of MAF selection of patients for adjuvant bisphosphonate therapy and comparison with current clinical guidance.**

R. Coleman<sup>1</sup>, A. Paterson<sup>2</sup>, R. Gomis<sup>3</sup>, <sup>1</sup>Weston Park Hospital - Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, GB, <sup>2</sup>Tom Baker Cancer Centre, Calgary, CA, <sup>3</sup>Institute for Research in Biomedicine (IRB Barcelona), Barcelona, ES

08:35 - 08:55

**67P - Clinicopathologic features of breast cancer patients eligible for adjuvant abemaciclib**

P. Tarantino<sup>1</sup>, Q. Jin<sup>1</sup>, E. Mittendorf<sup>2</sup>, T. King<sup>2</sup>, G. Curigliano<sup>3</sup>, S. Tolaney<sup>1</sup>, <sup>1</sup>Dana-Farber Cancer Institute, Boston, US, <sup>2</sup>Brigham and Women's Hospital, Boston, US, <sup>3</sup>IEO - Istituto Europeo di Oncologia, Milan, IT

08:55 - 09:15

**68P - 20-year tamoxifen benefit in ER-positive/HER2-negative breast cancer patients in randomized clinical trials**

H. Dar<sup>1</sup>, A. Johansson<sup>2</sup>, A. Nordenskjöld<sup>3</sup>, C. Yau<sup>4</sup>, C. Benz<sup>5</sup>, L. Esserman<sup>6</sup>, K. Rodriguez-Wallberg<sup>7</sup>, B. Nordenskjöld<sup>3</sup>, G. Perez-Tenorio<sup>3</sup>, O. Stal<sup>8</sup>, T. Fornander<sup>2</sup>, L. Lindström<sup>9</sup>,



<sup>1</sup>Karolinska Institute, Stockholm, SE, <sup>2</sup>Karolinska Institutet, Huddinge, SE, <sup>3</sup>LiU - Linköping University, Linköping, SE, <sup>4</sup>UCSF - University of California San Francisco, San Francisco, US, <sup>5</sup>Buck Institute for Age Research, Novato, US, <sup>6</sup>UCSF Diabetes Teaching Center, San Francisco, US, <sup>7</sup>Karolinska Universitetssjukhuset Huddinge - Reproduktionsmedicin, Huddinge, SE, <sup>8</sup>Linköping University Hospital, Linköping, SE, <sup>9</sup>Karolinska Institutet, Stockholm, SE

09:15 - 09:35

**69P - Impact of statin use on survival outcomes of patients with HER2-positive early breast cancer in the APHINITY trial**

C. Maurer<sup>1</sup>, E. Agostinetto<sup>2</sup>, L. Ameye<sup>2</sup>, M. Lambertini<sup>3</sup>, S. Martel<sup>4</sup>, N. Ponde<sup>5</sup>, M. Brandão<sup>2</sup>, F. Poggio<sup>6</sup>, A. Ferreira<sup>7</sup>, R. Schiff<sup>8</sup>, C. De Angelis<sup>9</sup>, R. Gelber<sup>10</sup>, S. Dent<sup>11</sup>, C. Thomssen<sup>12</sup>, M. Piccart<sup>2</sup>, E. De Azambuja<sup>2</sup>, <sup>1</sup>University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, DE, <sup>2</sup>Institut Jules Bordet and l'Université Libre de Bruxelles (U.L.B.), Brussels, BE, <sup>3</sup>University of Genova, Genova, IT, <sup>4</sup>CISSS Montérégie-Centre/Hôpital Charles-Le Moyne and Université of Sherbrooke, Greenfield Park, CA, <sup>5</sup>IQVIA Biotech, Morrisville, US, <sup>6</sup>IRCCS Ospedale Policlinico San Martino, Genova, IT, <sup>7</sup>Champalimaud Clinical Center, Champalimaud Foundation and Universidade Católica Portuguesa, Lisbon, PT, <sup>8</sup>Baylor College of Medicine, Houston, US, <sup>9</sup>University of Naples "Federico II", Naples, IT, <sup>10</sup>Harvard Medical School, Harvard TH Chan School of Public Health, Boston, US, <sup>11</sup>Duke University, Durham, US, <sup>12</sup>Martin-Luther-University Halle-Wittenberg, Halle (Saale), DE

09:35 - 09:55

**70P - Factors influencing patient treatment decisions in early breast cancer (eBC): discrete choice experiment (DCE) findings**

A. Gennari<sup>1</sup>, C. Jackisch<sup>2</sup>, S. Mccutcheon<sup>3</sup>, E. Flood<sup>4</sup>, B. Murali<sup>5</sup>, X. Guillaume<sup>6</sup>, O. Will<sup>7</sup>, C. Shimizu<sup>8</sup>, S. Mokiou<sup>3</sup>, <sup>1</sup>Università Degli Studi Del Piemonte Orientale - Scuola di Medicina, Novara, IT, <sup>2</sup>Sana Klinikum Offenbach GmbH, Offenbach am Main, DE, <sup>3</sup>AstraZeneca, Cambridge, GB, <sup>4</sup>AstraZeneca, Gaithersburg, US, <sup>5</sup>Cerner Enviza, New York, US, <sup>6</sup>Cerner Enviza, Paris, FR, <sup>7</sup>Cerner Enviza, Malverne, US, <sup>8</sup>Comprehensive Cancer Center, National Center for Global Health and Medicine, Tokyo, JP

09:55 - 10:15

**71P - Aromatase inhibitors and fracture prevention- is our current approach correct?**

A. Mirza, Z.W. Naing, P. Khonsari, H. Khan, P. Rezai, A.K. Abbas, M. Nisar, Luton and Dunstable Hospital NHS Foundation Trust, Luton, GB

10:15 - 10:35

**72P - Prognostic value of HER2/CEP17 ratio in HER2-positive early breast cancer by FISH testing**

F. Zheng<sup>1</sup>, F. Du<sup>2</sup>, P. Yuan<sup>1</sup>, <sup>1</sup>Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN, <sup>2</sup>Peking University Cancer Hospital and Institute, Beijing, CN

10:35 - 10:55

**73P - Effect of diarrheal prophylaxis or dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer: Final findings from the CONTROL trial**

A. Chan<sup>1</sup>, M. Ruiz Borrego<sup>2</sup>, G. Marx<sup>3</sup>, A. Brufsky<sup>4</sup>, A.J. Chien<sup>5</sup>, M. Thirlwell<sup>6</sup>, M. Trudeau<sup>7</sup>, R. Bose<sup>8</sup>, J.Á. García Saenz<sup>9</sup>, D. Egle<sup>10</sup>, B. Pistilli<sup>11</sup>, J. Wassermann<sup>12</sup>, K. Cheong<sup>13</sup>, D. Semsek<sup>14</sup>, C. Singer<sup>15</sup>, D. Diprimeo<sup>16</sup>, N. Foruzan<sup>16</sup>, L. Mcculloch<sup>16</sup>, C. Barcenás<sup>17</sup>, <sup>1</sup>Breast Cancer Research Centre BCRC - WA, Nedlands, AU, <sup>2</sup>Hospital

Universitario Virgen del Rocio, Seville, ES, <sup>3</sup>University of Sydney, Sydney, AU, <sup>4</sup>Magee-Womens Hospital, University of Pittsburgh Medical Center, Pittsburgh, US, <sup>5</sup>UCSF - University of California San Francisco, San Francisco, US, <sup>6</sup>McGill University Health Centre - Glen Site - Royal Victoria Hospital, Montreal, CA, <sup>7</sup>Sunnybrook Health Sciences Centre - Odette Cancer Centre, Toronto, CA, <sup>8</sup>Washington University School of Medicine, St. Louis, US, <sup>9</sup>Hospital Clinico Universitario San Carlos, Madrid, ES, <sup>10</sup>University Frauenklinik Innsbruck, Innsbruck, AT, <sup>11</sup>Gustave Roussy Cancer Center, Villejuif, Cedex, FR, <sup>12</sup>Hôpital Pitié-Salpêtrière, Paris, FR, <sup>13</sup>Adelaide Cancer Centre, Adelaide, AU, <sup>14</sup>Praxis am Diakonie Krankenhaus Onkologische Schwerpunktpraxis, Freiburg im Breisgau, DE, <sup>15</sup>Medical University of Vienna, Vienna, AT, <sup>16</sup>Puma Biotechnology Inc., South San Francisco, US, <sup>17</sup>The University of Texas MD Anderson Cancer Center - Main Building, Houston, US

10:55 - 11:15

**74P - Management of early-stage hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer in a real-world setting in Germany: a patient perspective**

C. Jackisch<sup>1</sup>, M. Banys-Paluchowski<sup>2</sup>, A. Korfel<sup>3</sup>, C. Stoffregen<sup>4</sup>, T. Otto<sup>4</sup>, J. Brown<sup>5</sup>, I. Sanderson<sup>6</sup>, A. Rider<sup>7</sup>, D. Lüftner<sup>8</sup>, <sup>1</sup>Sana Klinikum Offenbach GmbH, Offenbach am Main, DE, <sup>2</sup>UKSH - Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Lübeck, DE, <sup>3</sup>Lilly Deutschland GmbH, Bad Homburg, DE, <sup>4</sup>Lilly Deutschland GmbH, Bad Homburg vor der Höhe, DE, <sup>5</sup>Eli Lilly Research & Development, Windlesham, GB, <sup>6</sup>Adelphi Real World - Adelphi Group, Bollington, GB, <sup>7</sup>Adelphi Communications - Adelphi Group, Bollington, GB, <sup>8</sup>Charite, Campus Benjamin Franklin Medizinische Klinik III, Berlin, DE

11:15 - 11:35

**75P - Interim analysis (n=150) of the multi-national, prospective, non-interventional ELEANOR study observing real-life extended adjuvant treatment with neratinib in patients with HER2+ / HR+ early breast cancer (eBC)**

N. Harbeck<sup>1</sup>, D. Wrobel<sup>2</sup>, M. Zaiss<sup>3</sup>, D. Guth<sup>4</sup>, A. Distelrath<sup>5</sup>, J. Terhaag<sup>6</sup>, A. Lorenz<sup>7</sup>, R. Bartsch<sup>8</sup>, U. Breitenstein<sup>9</sup>, M. Schwitter<sup>10</sup>, M. Balic<sup>11</sup>, C. Jackisch<sup>12</sup>, V. Müller<sup>13</sup>, G. Rinnerthaler<sup>14</sup>, M. Schmidt<sup>15</sup>, K. Zaman<sup>16</sup>, T. Schinköthe<sup>17</sup>, D. Lüftner<sup>18</sup>, <sup>1</sup>LMU University Hospital, Munich, DE, <sup>2</sup>Klinikum Bamberg, Bamberg, DE, <sup>3</sup>Interdisziplinäre Onkologie, Freiburg im Breisgau, DE, <sup>4</sup>Dr. med. Dagmar Guth, Plauen, DE, <sup>5</sup>Onkologie und Urologie, Plauen, DE, <sup>6</sup>Rottal/Inn Clinic, Eggenfelden, DE, <sup>7</sup>Dr. med. Lorenz, Hildburghausen, DE, <sup>8</sup>Medical University of Vienna, Vienna, AT, <sup>9</sup>Brust-Zentrum Zürich, Zurich, CH, <sup>10</sup>Kantonsspital Graubünden, Chur, CH, <sup>11</sup>Medical University of Graz, Graz, AT, <sup>12</sup>Sana Klinikum Offenbach GmbH, Offenbach am Main, DE, <sup>13</sup>UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, <sup>14</sup>Paracelsus Medical University Salzburg, Salzburg, AT, <sup>15</sup>University Hospital Mainz, Mainz, DE, <sup>16</sup>Lausanne University Hospital CHUV, Lausanne, CH, <sup>17</sup>Service GmbH, Kirchheim, DE, <sup>18</sup>University Hospital Charité, Berlin, DE

11:35 - 11:55

**76P - How explain current reluctance against therapeutic de-escalation: results of the exploratory qualitative phase of the Mixed Method Research program CARTE herapy in older women with early breast cancer in France.**

M. Bendiane<sup>1</sup>, D. Rey<sup>1</sup>, A. Richard Tallet<sup>2</sup>, J. Mancini<sup>1</sup>, <sup>1</sup>Aix Marseille Univ, INSERM, IRD, ISSPAM, SESSTIM, Cancer, Biomedicine & Society group, Ligue 2019 labelled team, Marseille, FR, <sup>2</sup>IPC - Institut Paoli-Calmettes, Marseille, FR

- 11:55 - 12:15 **77P - A Real-World Population Study in Early Breast Cancer to Identify Patient Characteristics, Treatment and Outcomes in Scotland**  
P. Hall<sup>1</sup>, G. Tramonti<sup>1</sup>, M. Rañopa<sup>2</sup>, M. Vallet<sup>1</sup>, R. Jarvis<sup>2</sup>, W. Badreldin<sup>2</sup>, <sup>1</sup>University of Edinburgh, Edinburgh, GB, <sup>2</sup>Eli Lilly and Company Limited, Basingstoke, GB
- 12:15 - 12:35 **78P - Breast cancer hypofractionated radiotherapy and it's implications**  
S. Acharya, Assam Cancer Care Foundation, Guwahati, IN
- 12:35 - 12:55 **79P - The impact of Trastuzumab administration patterns on the clinical outcomes of patients with early breast cancer in resource-limited settings**  
E. Amer, Kasr alainy department of oncology, Cairo, EG
- 12:55 - 13:15 **81P - Clinical experience with endopredict test : building a clinicopathological model predictive of genomic test result.**  
S. Di Lascio<sup>1</sup>, M. Frattini<sup>2</sup>, U. Perriard<sup>2</sup>, V. Torri<sup>3</sup>, <sup>1</sup>EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH, <sup>2</sup>EOC - Ente Ospedaliero Cantonale, Bellinzona, CH, <sup>3</sup>Istituto Di Ricerche Farmacologiche Mario Negri, Milan, IT
- 13:15 - 13:35 **82P - Clinical application of a genomic tool for decision support in breast cancer patients in Scotland**  
A. Peters<sup>1</sup>, B. Elseberger<sup>2</sup>, P. Hall<sup>3</sup>, L. Jordan<sup>4</sup>, F. Soh<sup>5</sup>, G. Urquhart<sup>2</sup>, L. Hannington<sup>6</sup>, D. Cartwright<sup>7</sup>, S. Makaranka<sup>2</sup>, M. Vallet<sup>3</sup>, H. Marashi<sup>1</sup>, <sup>1</sup>BWSCC - Beatson West of Scotland Cancer Centre - NHS Greater Glasgow and Clyde, Glasgow, GB, <sup>2</sup>Aberdeen Royal Infirmary - NHS Grampian, Aberdeen, GB, <sup>3</sup>Cancer Research UK Edinburgh Centre, Edinburgh, GB, <sup>4</sup>Ninewells Hospital & Medical School, Dundee, GB, <sup>5</sup>Raigmore Hospital - NHS Highland, Inverness, GB, <sup>6</sup>BWSCC - Beatson West of Scotland Cancer Centre, Glasgow, GB, <sup>7</sup>CRUK - Cancer Research UK Beatson Institute, Glasgow, GB
- 13:35 - 13:55 **83P - The educational impact of a curriculum for oncologists on the latest developments in the use of CDK4/6 inhibitors in HR+/HER2- early and metastatic breast cancer**  
N. Dorkhom<sup>1</sup>, D. Ragoonath-Cameron<sup>2</sup>, S. Bahra<sup>3</sup>, U. Patel<sup>4</sup>, V. Phoenix<sup>4</sup>, <sup>1</sup>Medscape, Naarden, NL, <sup>2</sup>Medscape, Miami, US, <sup>3</sup>Medscape, London, GB, <sup>4</sup>Medscape, New York, US
- 13:55 - 14:15 **84P - Serum 25-hydroxyvitamin D and cancer-related fatigue: associations and effects on health-related quality of life in breast cancer survivors during adjuvant endocrine therapy**  
B.M. Santos<sup>1</sup>, Í.D. Custódio<sup>1</sup>, F. Nunes<sup>1</sup>, M. Lima<sup>1</sup>, K. Carvalho<sup>1</sup>, D. Santana<sup>1</sup>, J. Chiaretto<sup>1</sup>, P. Canto<sup>2</sup>, B. Laird<sup>3</sup>, C. Paiva<sup>4</sup>, Y.C. Maia<sup>1</sup>, <sup>1</sup>UFU - Universidade Federal de Uberlandia - Faculdade de Medicina (FAMED), Uberlandia, BR, <sup>2</sup>Grupo Oncoclinicas, Sao Paulo, BR, <sup>3</sup>University of Edinburgh, Edinburgh, GB, <sup>4</sup>Hospital de Amor (Hospital De Cancer De Barretos) - Fundacao Pio XII, Barretos, BR
- 14:15 - 14:35 **85P - Correlation between Prosigna® and three IHC-based surrogate intrinsic breast cancer subtype classifiers: a real world-study**



M. Martin Jimenez<sup>1</sup>, M. Del Monte<sup>2</sup>, Y. Jerez<sup>2</sup>, I. Echavarria Diaz-Guardamino<sup>3</sup>, B. Herrero Lopez<sup>3</sup>, S. Gamez Casado<sup>3</sup>, M. Roche-Molina<sup>3</sup>, I. Marquez-Rodas<sup>2</sup>, M. Cebollero<sup>3</sup>, E. Alvarez<sup>3</sup>, T. Massarrah<sup>2</sup>, I. Ocaña<sup>3</sup>, A. Arias<sup>3</sup>, J.Á. García Saenz<sup>4</sup>, F. Moreno Anton<sup>4</sup>, C. Olier Garate<sup>5</sup>, D. Moreno Muñoz<sup>5</sup>, D. Marrupe Gonzalez<sup>6</sup>, T. Merina<sup>7</sup>, S. Lopez-Tarruella Cobo<sup>1</sup>, <sup>1</sup>Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Universidad Complutense, CyberOnc, GEICAM, Madrid, ES, <sup>2</sup>Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), CyberOnc, Madrid, ES, <sup>3</sup>Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, ES, <sup>4</sup>Hospital Clínico Universitario San Carlos. Instituto de Investigación Sanitaria Hospital Clinico San Carlos (IdISSC), Madrid, ES, <sup>5</sup>Hospital Universitario Fundación Alcorcón, Alcorcon, ES, <sup>6</sup>Hospital Universitario de Móstoles, Mostoles, ES, <sup>7</sup>Oncogenomics SL, Madrid, ES

14:35 - 14:55 **86P - Change in dietary habits does not affect body composition in early breast cancer patients treated with aromatase inhibitor**

L. Laini<sup>1</sup>, A. Bonalumi<sup>1</sup>, S. Bosio<sup>1</sup>, N. Villa<sup>1</sup>, V. Amoroso<sup>1</sup>, L. Lorini<sup>1</sup>, B. Zanini<sup>2</sup>, G. Schivardi<sup>1</sup>, P. Di Mauro<sup>1</sup>, D. Cosentini<sup>1</sup>, L. Vassalli<sup>1</sup>, A. Alberti<sup>1</sup>, A. Esposito<sup>1</sup>, V. Cremaschi<sup>1</sup>, E. Simoncini<sup>1</sup>, A. Berruti<sup>1</sup>, R. Pedersini<sup>1</sup>, <sup>1</sup>ASST Spedali Civili of Brescia, Brescia, IT, <sup>2</sup>University of Brescia, Brescia, IT

14:55 - 15:15 **87P - EPclin vs OncotypeDx in invasive lobular cancer (ILC)**

I. Leao<sup>1</sup>, E. Zamora<sup>2</sup>, P. Gomez Pardo<sup>2</sup>, M. Arumi De Dios<sup>2</sup>, I. Pimentel<sup>2</sup>, S. Escriva De Romani<sup>2</sup>, C. Ortiz Velez<sup>2</sup>, M. Cruellas Lapena<sup>2</sup>, L. Sanz<sup>2</sup>, M. Borrell<sup>2</sup>, K. Vega Cano<sup>3</sup>, D. Gómez-Puerto<sup>3</sup>, J. De La Torre<sup>4</sup>, M. Espinosa-Bravo<sup>4</sup>, M. Oliveira<sup>2</sup>, R. Fasani<sup>5</sup>, P. Nuciforo<sup>5</sup>, C. Saura<sup>2</sup>, V. Peg<sup>6</sup>, M. Bellet<sup>2</sup>, <sup>1</sup>Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova de Gaia, PT, <sup>2</sup>Vall d'Hebron University Hospital / Institute of Oncology (VHIO), Barcelona, ES, <sup>3</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>4</sup>Breast Cancer Center Vall d'Hebron University Hospital, Barcelona, ES, <sup>5</sup>Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, <sup>6</sup>Vall d'Hebron University Hospital, Barcelona, ES

15:15 - 15:35 **88P - Genetic platforms in hormone receptor (HR) + early breast cancer (eBC). Could logistic regression models be used instead?**

A. Lopez Paradis, A. Pous, L. Notario Rincon, G. Cerdà Sebastià, M. Sant Albors, M. Bergamino, A. Ferrando Diez, I. Teruel-Garcia, M. Romeo Marin, V. Quiroga Garcia, B. Cirauqui Cirauqui, M. Margeli Vila, E. Felip Falgas, ICO - Institut Català d'Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, ES

15:35 - 15:55 **89TiP - (Trial in progress) Perceptions, attitudes, and behaviors towards the risk of disease recurrence among women with early-stage HER2+ breast cancer in Europe: The ASKHER2 survey**

S. Matos, A. Zkik, O. Dialla, I. Dagen, Pierre Fabre Médicament, Boulogne, FR

15:55 - 16:15 **90TiP - Adjuvant Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer (EBC), Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity (AMEERA-6)**

G. Rossi<sup>1</sup>, E. Brain<sup>2</sup>, A. Dueck<sup>3</sup>, H. De Swert<sup>1</sup>, S. Marreaud<sup>4</sup>, A. Partridge<sup>3</sup>, C. Herold<sup>5</sup>, H. Vachon<sup>4</sup>, T. Spanic<sup>6</sup>, A. Arahmani<sup>7</sup>, T. Verbiest<sup>4</sup>, L. Wang<sup>8</sup>, T. Goulioti<sup>1</sup>, B. Malanda<sup>4</sup>, L.

Carey<sup>9</sup>, S. Anneheim<sup>10</sup>, G. Paux<sup>11</sup>, C. Poncet<sup>4</sup>, O. Metzger<sup>3</sup>, D. Cameron<sup>12</sup>, <sup>1</sup>Breast International Group (BIG) - AISBL, Brussels, BE, <sup>2</sup>Hôpital René Huguenin, Saint-Cloud, FR, <sup>3</sup>Alliance Foundation Trials (AFT), Boston, US, <sup>4</sup>European Organisation for Research and Treatment of Cancer (EORTC), Brussels, BE, <sup>5</sup>Sanofi Genzyme, Cambridge, US, <sup>6</sup>Europa Donna – the European Breast Cancer Coalition, Milan, IT, <sup>7</sup>Breast International Group (BIG)-aisbl, Brussels, BE, <sup>8</sup>Sanofi, Boston, US, <sup>9</sup>North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA, Boston, US, <sup>10</sup>Sanofi-Aventis Recherche et Développement, Vitry-sur-Seine, FR, <sup>11</sup>Sanofi-Aventis U.S. LLC, Bridgewater, US, <sup>12</sup>University of Edinburgh Cancer Research Centre, Institute of Genetics and Cancer, Western General Hospital, Edinburgh, United Kingdom, Edinburgh, GB

16:15 - 16:35 **Early breast cancer: Neoadjuvant therapy**

16:35 - 16:55 **94P - Patient quality of life (QoL) from the GeparX trial on the addition of denosumab (Dmab) added to two different nab-paclitaxel (nP) regimens as neoadjuvant chemotherapy (NACT) in primary breast cancer (BC)**

M. Reinisch<sup>1</sup>, J.-U. Blohmer<sup>2</sup>, T. Link<sup>3</sup>, M. Just<sup>4</sup>, M. Untch<sup>5</sup>, O. Stötzer<sup>6</sup>, P.A. Fasching<sup>7</sup>, A. Schneeweiss<sup>8</sup>, P. Wimberger<sup>3</sup>, S. Seiler<sup>9</sup>, J. Huober<sup>10</sup>, M. Thill<sup>11</sup>, C. Jackisch<sup>12</sup>, K. Rhiem<sup>13</sup>, C. Solbach<sup>14</sup>, C. Hanusch<sup>15</sup>, C. Denkert<sup>16</sup>, K. Engels<sup>17</sup>, V. Nekljudova<sup>9</sup>, S. Loibl<sup>9</sup>, <sup>1</sup>Kliniken Essen Mitte, Essen, DE, <sup>2</sup>Charité Universitätsmedizin Berlin, Berlin, DE, <sup>3</sup>Technische Universität Dresden, Dresden, DE, <sup>4</sup>Schwerpunktpraxis Bielefeld, Bielefeld, DE, <sup>5</sup>Helios Klinikum Berlin-Buch, Berlin, DE, <sup>6</sup>Gemeinschaftspraxis, München, München, DE, <sup>7</sup>University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, DE, <sup>8</sup>Universitätsklinikum und Deutsches Krebsforschungszentrum, Heidelberg, Heidelberg, DE, <sup>9</sup>German Breast Group (GBG), Neu-Isenburg, DE, <sup>10</sup>Kantonsspital St.Gallen, Brustzentrum, St.Gallen, CH, <sup>11</sup>Agaplesion Markus Krankenhaus, Frankfurt am Main, DE, <sup>12</sup>Sana Klinikum Offenbach, Offenbach am Main, DE, <sup>13</sup>Universität Köln, Cologne, DE, <sup>14</sup>Universitätsklinikum Frankfurt, Frankfurt am Main, DE, <sup>15</sup>Breast Center, Red Cross Hospital München, München, DE, <sup>16</sup>Philipps Universität Marburg and Universitätsklinikum Marburg (UKGM), Marburg, DE, <sup>17</sup>Zentrum für Pathologie, Zytologie und Molekularpathologie Neuss, Neuss, DE

16:55 - 17:15 **95P - PAM50 HER2-enriched phenotype as a predictor of early response to neoadjuvant lapatinib plus trastuzumab HER2-positive breast cancer: Survival results of the SOLTI-PAMELA study**

T. Pascual<sup>1</sup>, B. Bermejo De Las Heras<sup>2</sup>, N. Martinez<sup>3</sup>, M. Oliveira<sup>4</sup>, S. Pernas Simon<sup>5</sup>, R. Lopez Lopez<sup>6</sup>, I. Ruiz Cabrero<sup>7</sup>, J. Alarcon<sup>8</sup>, E. Martinez De Dueñas<sup>9</sup>, D. Malon Gimenez<sup>10</sup>, M. Gonzalez Cao<sup>11</sup>, L. Manso Sanchez<sup>12</sup>, S. Morales Murillo<sup>13</sup>, H. Lopez De Ceballos<sup>14</sup>, J. Cortés<sup>15</sup>, A. Llombart Cussac<sup>16</sup>, A. Prat<sup>17</sup>, <sup>1</sup>SOLTI Cancer Research Group/Hospital Clinic de Barcelona, Barcelona, ES, <sup>2</sup>Hospital Clinico Universitario de Valencia, Valencia, ES, <sup>3</sup>Hospital Universitario Ramon y Cajal, Madrid, ES, <sup>4</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>5</sup>ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES, <sup>6</sup>CHUS - Complejo Hospitalario Universitario de Santiago de Compostela SERGAS, Santiago de Compostela, ES, <sup>7</sup>Hospitals Santa Tecla, Tarragona, ES, <sup>8</sup>Hospital Universitario Son Espases, Palma de Mallorca, ES, <sup>9</sup>Hospital Provincial Castellon, Castellon de la Plana, ES, <sup>10</sup>Hospital



Universitario de Fuenlabrada, Fuenlabrada, ES, <sup>11</sup>Hospital Universitari Dexeus, Barcelona, ES, <sup>12</sup>Hospital Universitario 12 de Octubre, Madrid, ES, <sup>13</sup>Hospital Arnau de Vilanova - Lleida, Alpicat, ES, <sup>14</sup>Hospital San Pedro De Alcantara, Caceres, ES, <sup>15</sup>VHIO Valle de Hebrón Instituto de Oncología, Barcelona, ES, <sup>16</sup>Hospital Arnau de Vilanova, Valencia, ES, <sup>17</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES

17:15 - 17:35

**96P - PAM50-based ROR indexes as a tool to individualize the use of neoadjuvant endocrine therapy in ER+/HER2- breast cancer**

J. Lopez Velazco<sup>1</sup>, S. Manzano<sup>1</sup>, K. Elorriaga<sup>2</sup>, A. Lahuerta Martinez<sup>3</sup>, L. Álvarez<sup>4</sup>, I. Etxabe Azkue<sup>4</sup>, M. Huarte Martinez<sup>4</sup>, E. Buch<sup>5</sup>, J. Giménez Climent<sup>6</sup>, V. Quiroga Garcia<sup>7</sup>, S. Aragón<sup>8</sup>, L. Paré<sup>9</sup>, A. Prat<sup>10</sup>, I. Alvarez Lopez<sup>11</sup>, M. Muñoz Caffarel<sup>12</sup>, A. Urruticoechea<sup>11</sup>, <sup>1</sup>Biodonostia Health Research Institute, San Sebastian (Donostia), ES, <sup>2</sup>Gipuzkoa Pathology Unit, OSIDonostialdea-Onkologikoa, San Sebastian (Donostia), ES, <sup>3</sup>Gipuzkoa Cancer Unit/OSI Donostialdea - Onkologikoa, San Sebastian (Donostia), ES, <sup>4</sup>Gynecology and General Surgery Departments - Breast Unit, Onkologikoa, San Sebastian (Donostia), ES, <sup>5</sup>Hospital Sagunto - Hospital Clinic University, Valencia, ES, <sup>6</sup>Valencia Oncology Institute (IVO), Valencia, ES, <sup>7</sup>ICO - Institut Català d' Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, ES, <sup>8</sup>Hospital 12 de octubre, Madrid, ES, <sup>9</sup>Hospital Clinic of Barcelona, Barcelona, ES, <sup>10</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>11</sup>Biodonostia Health Research Institute and Gipuzkoa Cancer Unit/OSI Donostialdea - Onkologikoa, San Sebastian (Donostia), ES, <sup>12</sup>Biodonostia Health Research Institute and IKERBASQUE, Basque Foundation for Science, Bilbao, ES

17:35 - 17:55

**97P - Genomic bases of endocrine sensitivity in triple-positive early breast cancer: a translational analysis of the PerELISA trial**

G. Griguolo<sup>1</sup>, M.V. Dieci<sup>1</sup>, G. Bisagni<sup>2</sup>, A. Frassoldati<sup>3</sup>, G. Bianchi<sup>4</sup>, L. Urso<sup>1</sup>, T. Pascual<sup>5</sup>, L. Pare Brunet<sup>6</sup>, P. Galván<sup>7</sup>, C.A. Giorgi<sup>8</sup>, M. Bottosso<sup>1</sup>, G. Vernaci<sup>8</sup>, F. Miglietta<sup>1</sup>, S. Indraccolo<sup>1</sup>, P.F. Conte<sup>1</sup>, A. Prat<sup>9</sup>, V. Guarneri<sup>1</sup>, <sup>1</sup>University of Padua, Padova, IT, <sup>2</sup>Azienda Ospedaliera - Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, IT, <sup>3</sup>Azienda Ospedaliero Universitaria di Ferrara-Arcispedale Sant'Anna, Ferrara, IT, <sup>4</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>5</sup>SOLTI Cancer Research Group/Hospital Clinic de Barcelona, Barcelona, ES, <sup>6</sup>Reveal Genomics, Barcelona, ES, <sup>7</sup>IDIBAPS - August Pi i Sunyer Biomedical Research Institute, Barcelona, ES, <sup>8</sup>Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>9</sup>Hospital Clinic de Barcelona/SOLTI/IDIBAPS, Barcelona, ES

17:55 - 18:15

**98P - Neo-CheckRay, radiation therapy and adenosine pathway blockade to potentiate benefit of immuno-chemotherapy in early stage luminal B breast cancer: results of the safety run-in phase.**

A. De Caluwe<sup>1</sup>, E. Romano<sup>2</sup>, P. Poortmans<sup>3</sup>, A. Gombos<sup>1</sup>, A. Laragione<sup>1</sup>, E. Agostinetto<sup>1</sup>, G. Nader Marta<sup>1</sup>, S. Picchia<sup>1</sup>, C. Vandekerckhove<sup>1</sup>, L. Ameye<sup>1</sup>, L. Craciun<sup>1</sup>, I. Veys<sup>1</sup>, D. Van Gestel<sup>1</sup>, D. Larsimont<sup>1</sup>, C. Sotiriou<sup>1</sup>, M. Piccart<sup>1</sup>, M. Ignatiadis<sup>1</sup>, L. Buisseret<sup>1</sup>, <sup>1</sup>Institute Jules Bordet, Brussels, BE, <sup>2</sup>Institut Curie, Paris, FR, <sup>3</sup>AZ Sint-Augustinus - Oncologisch Centrum GZA - Iridium Kankernetwerk, Antwerpen, BE

18:15 - 18:35

**99P - Cost Effectiveness of pembrolizumab in combination with chemotherapy as neoadjuvant therapy and continued as a single agent as adjuvant therapy for high-risk early-stage TNBC in the United States**

P.A. Fasching<sup>1</sup>, M. Huang<sup>2</sup>, A. Haiderali<sup>3</sup>, W. Xue<sup>4</sup>, W. Pan<sup>5</sup>, Z.-Y. Zhou<sup>4</sup>, P. Hu<sup>2</sup>, M. Chaudhuri<sup>6</sup>, C. Le Bailly De Tillegem<sup>7</sup>, N. Cappoen<sup>7</sup>, J. O'Shaughnessy<sup>8</sup>, <sup>1</sup>University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, DE, <sup>2</sup>Merck & Co. Inc - MRL Labs - Upper Gwynedd Campus, North Wales, US, <sup>3</sup>Merck & Co., Inc. - Corporate Headquarters, Kenilworth, US, <sup>4</sup>Analysis Group Ltd., London, GB, <sup>5</sup>Merck & Co, Rahway, US, <sup>6</sup>CHEORS - Complete Health Economics Outcomes and Research Solutions, North Wales, US, <sup>7</sup>MSD, Brussels, BE, <sup>8</sup>Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, US

18:35 - 18:55 **100P - Outcomes of Non-Metastatic Triple Negative Breast Cancers: Real-World Data from a Large Indian Cohort**

J. Bajpai<sup>1</sup>, L. Kashyap<sup>1</sup>, D. Vallathol<sup>2</sup>, R. Pathak<sup>1</sup>, S. Rath<sup>1</sup>, A. Sekar<sup>1</sup>, S. Mohanta<sup>1</sup>, A. Reddy<sup>1</sup>, S. Joshi<sup>1</sup>, T. Wadasadawala<sup>1</sup>, N. Nair<sup>1</sup>, V. Parmar<sup>1</sup>, S. Desai<sup>1</sup>, T. Shet<sup>1</sup>, M. Thakur<sup>1</sup>, R. Sarin<sup>1</sup>, S. Gupta<sup>1</sup>, R. Badwe<sup>1</sup>, A. Das<sup>1</sup>, M. Singh<sup>3</sup>, <sup>1</sup>Tata Memorial Hospital - Tata Memorial Centre, Mumbai, IN, <sup>2</sup>MVR Cancer Centre & Research Institute, Kozhikode, IN, <sup>3</sup>Tata Memorial Hospital - Parel, Mumbai, IN

18:55 - 19:15 **101P - Proteome and RNA-Seq changes in breast cancer patients with higher levels of progesterone receptor A than B after mifepristone treatment**

A. Elia<sup>1</sup>, J. Sanchez<sup>2</sup>, P. Rojas<sup>1</sup>, L. Saldain<sup>1</sup>, P. Martínez Vazquez<sup>3</sup>, J. Burruchaga<sup>3</sup>, E. Spengler<sup>3</sup>, I. Caillet Bois<sup>3</sup>, M. Liguori<sup>4</sup>, H. Gass<sup>3</sup>, M. Abba<sup>5</sup>, J. Muñoz<sup>2</sup>, L. Helguero<sup>6</sup>, C. Lanari<sup>1</sup>, <sup>1</sup>IBYME - Instituto de Biología y Medicina Experimental, Buenos Aires, AR, <sup>2</sup>CNIO - Centro Nacional de Investigaciones Oncológicas, Madrid, ES, <sup>3</sup>Hospital Magdalena V de Martínez, General Pacheco, AR, <sup>4</sup>Hospital Magdalena V de Martinez, Pacheco, AR, <sup>5</sup>CINIBA - CENTRO DE INVESTIGACIONES INMUNOLOGICAS BASICAS Y APLICADAS, Buenos Aires, AR, <sup>6</sup>IBIMED, Aveiro, PT

19:15 - 19:35 **102P - Long-term prediction of clinical outcomes by the 21-gene test in HR+ HER2- breast cancer patients with residual disease after neoadjuvant chemotherapy.**

V. Peg<sup>1</sup>, N. De Los Ángeles<sup>2</sup>, B. Vieites<sup>3</sup>, M. Bellet<sup>4</sup>, C. Castilla<sup>5</sup>, P. Gomez Pardo<sup>6</sup>, A. Pérez - Luque<sup>5</sup>, M.A. Lopez<sup>7</sup>, F.J. Salvador Bofill<sup>5</sup>, L. Alfaro<sup>5</sup>, J.M. Perez Garcia<sup>8</sup>, M. Espinosa-Bravo<sup>1</sup>, <sup>1</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>2</sup>Hospital del Mar - Parc de Salut Mar, Barcelona, ES, <sup>3</sup>IBIS - Instituto de Biomedicina de Sevilla - Campus Hospital Universitario Virgen del Rocío, Seville, ES, <sup>4</sup>Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, <sup>5</sup>Hospital Universitario Virgen del Rocio, Seville, ES, <sup>6</sup>Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, <sup>7</sup>Hospital Universitario Virgen del Rocio, seville, ES, <sup>8</sup>Centro Medico Teknon, Barcelona, ES

19:35 - 19:55 **103P - Prediction of Response to Neoadjuvant Therapy in Early-Stage Breast Cancer using a Biophysical Simulation Platform**

J. Cole, E. Braun, P. Carrigan, A. Antony, J. Pfeiffer, J. Peterson, T.S. Team, SimBioSys, Inc., Chicago, US

19:55 - 20:15 **104P - HELENA : Study of HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer**

F. Cherifi<sup>1</sup>, A. Da Silva<sup>1</sup>, A. Johnson<sup>1</sup>, C. Blanc Fournier<sup>1</sup>, A. Broyelle<sup>2</sup>, O. Abramovici<sup>2</sup>, A.

Morel<sup>1</sup>, M. Bertho<sup>1</sup>, I. Hrab<sup>1</sup>, D. Allouache<sup>1</sup>, C. Segura Djezzer<sup>1</sup>, C. Levy<sup>1</sup>, C. Boscher<sup>1</sup>, M. Villemin<sup>1</sup>, P. Rottier<sup>1</sup>, J. Lequesne<sup>1</sup>, G. Emile<sup>1</sup>, <sup>1</sup>Centre Francois Baclesse, Caen, FR, <sup>2</sup>Centre Oscar Lambret, Lille, FR

- 20:15 - 20:35 **105P - CDK4/6 inhibitors in hormone receptor-positive, HER2 negative, locally advanced breast cancer (LABC): biological and clinical activity, and post-surgical approaches**
- S. Parola<sup>1</sup>, V. Di Lauro<sup>2</sup>, P. De Placido<sup>1</sup>, V. Forestieri<sup>1</sup>, G. Buono<sup>2</sup>, C. Von Arx<sup>2</sup>, E. Pietroluongo<sup>1</sup>, M. Pagliuca<sup>1</sup>, D. Cianniello<sup>2</sup>, R. Lauria<sup>1</sup>, R. Caputo<sup>2</sup>, G. Arpino<sup>1</sup>, S. De Placido<sup>1</sup>, M. Giuliano<sup>1</sup>, M. De Laurentiis<sup>2</sup>, C. De Angelis<sup>1</sup>, <sup>1</sup>Azienda Ospedaliera Universitaria Federico II, Napoli, IT, <sup>2</sup>Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT
- 20:35 - 20:55 **106P - Subsets of circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy**
- E. Grigoryeva, O. Savelieva, L. Tashireva, V. Alifanov, M. Zavyalova, N. Tarabanovskaya, N. Cherdyntseva, V. Perelmuter, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, RU
- 20:55 - 21:15 **107P - Impact of COVID-19 pandemic on breast cancer neoadjuvant therapy - a retrospective institutional analysis**
- M. Baptista Freitas<sup>1</sup>, C. Lopes De Almeida<sup>2</sup>, A.C. Valente<sup>2</sup>, M. Costa<sup>3</sup>, I. Nogueira Costa<sup>4</sup>, J. Reis<sup>2</sup>, N. Tavares<sup>3</sup>, I. Dionísio De Sousa<sup>3</sup>, D. Almeida<sup>2</sup>, C. Caeiro<sup>5</sup>, I. Augusto<sup>2</sup>, L. Nunes Aguas<sup>1</sup>, M. Barbosa<sup>1</sup>, <sup>1</sup>Centro Hospitalar Sao Joao E.P.E - Polo Porto, Porto, PT, <sup>2</sup>Centro Hospitalar Universitario de Sao Joao EPE - SNS, Porto, PT, <sup>3</sup>CHUSJ - Centro Hospitalar Sao Joao E.P.E - SNS - Polo Porto, Porto, PT, <sup>4</sup>CHUSJ - Centro Hospitalar Sao Joao E.P.E - Polo Porto, Porto, PT, <sup>5</sup>HSJ - Hospital de Sao Joao Centro Hospitalar Universitario, EPE - SNS, Porto, PT
- 21:15 - 21:35 **108P - Pathologic nodal positivity in patients cT1-2 cN0 HER2+ breast cancer treated with upfront surgery or neoadjuvant anti-HER2-based therapy**
- O. Martinez Saez<sup>1</sup>, C. Hernando Melia<sup>2</sup>, M. Rey<sup>1</sup>, N. Chic<sup>1</sup>, M.T. Martinez<sup>2</sup>, I. Cebreco<sup>3</sup>, B. Bermejo De Las Heras<sup>2</sup>, X. Bargalló<sup>3</sup>, O. Burgués<sup>2</sup>, S. Ganau<sup>3</sup>, B. Úbeda<sup>3</sup>, M. Mollá<sup>3</sup>, S. Vidal-Siscart<sup>3</sup>, E. Sanfeliu Torres<sup>1</sup>, B. Gonzalez-Farre<sup>1</sup>, M. Vidal<sup>1</sup>, B. Adamo<sup>1</sup>, M. Munoz<sup>1</sup>, A. Prat<sup>1</sup>, J.M. Cejalvo Andujar<sup>2</sup>, <sup>1</sup>Hospital Clinic of Barcelona, Barcelona, ES, <sup>2</sup>Hospital Clinico Universitario de Valencia, Valencia, ES, <sup>3</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES
- 21:35 - 21:55 **Early breast cancer: Surgery and radiotherapy**
- 21:55 - 22:15 **109P - Routine Collection of Patient-Reported Outcomes: Impact of Breast Cancer Therapies on Body Image**
- M. Afshar-Bakshloo, S. Albers, O. Berninger, C. Richter, R. Röhle, A. Hage, M. Karsten, Charité - Universitätsmedizin Berlin, Berlin, DE
- 22:15 - 22:35 **110P - An in-depth analysis of pathology results of surgical specimen and biopsies performed after NST in an attempt to identify patients with pCR: time**

**to reconsider the omission of surgery?**

A. Van Hemert<sup>1</sup>, F.H. Van Duijnhoven<sup>1</sup>, A.A. Van Loevezijn<sup>1</sup>, C.E. Loo<sup>1</sup>, T. Wiersma<sup>1</sup>, G. Sonke<sup>1</sup>, E. Groen<sup>2</sup>, M.J. Vrancken Peeters<sup>1</sup>, <sup>1</sup>NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, <sup>2</sup>Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

22:35 - 22:55 **111P - Sentinel Lymph Node Biopsy in Post NeoAdjuvant Chemotherapy Breast Cancer Patients Using Combination of Fluorescein and Blue Dye Versus Blue Dye Alone - An Interim Analysis of a Randomized Controlled Trial (SONAR-FB)**

B. Rajendar<sup>1</sup>, J.R. Vishnoi<sup>2</sup>, S. Misra<sup>1</sup>, <sup>1</sup>AIIMS - All India Institute of Medical Sciences, Jodhpur, JODHPUR, IN, <sup>2</sup>AIIMS - All India Institute of Medical Sciences, Jodhpur, Jodhpur, IN

22:55 - 23:15 **112P - Patients' knowledge about ductal carcinoma in situ**

E. Engelhardt<sup>1</sup>, R. Schmitz<sup>1</sup>, M. Gerritsma<sup>1</sup>, C. Sondermeijer<sup>1</sup>, E. Verschuur-Van Der Voort<sup>2</sup>, M. Van Oirsouw<sup>2</sup>, V. Retel<sup>1</sup>, F.H. Van Duijnhoven<sup>1</sup>, J. Wesseling<sup>1</sup>, E. Bleiker<sup>1</sup>, <sup>1</sup>Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, <sup>2</sup>Dutch Breast Cancer Coalition, Utrecht, NL

23:15 - 23:35 **113P - Axillary lymph node management in early breast cancer patients with positive sentinel lymph node: a systematic review and meta-analysis of randomized trials.**

T. Ruelle<sup>1</sup>, M. Perachino<sup>1</sup>, E. Blondeaux<sup>1</sup>, M. Bruzzone<sup>1</sup>, A. Fozza<sup>1</sup>, A. Garlaschi<sup>1</sup>, L. Belgioia<sup>1</sup>, F. Pitto<sup>1</sup>, A. Levaggi<sup>1</sup>, M. Sparavigna<sup>1</sup>, L. Del Mastro<sup>2</sup>, M. Lambertini<sup>2</sup>, P. Fregatti<sup>1</sup>, <sup>1</sup>IRCCS Ospedale Policlinico San Martino, Genova, IT, <sup>2</sup>IRCCS Ospedale Policlinico San Martino Hospital - University of Genova, Genova, IT

23:35 - 23:55 **114P - Axillary management in elderly women (≥70 years) with breast cancer: 10-years follow-up**

A. Girardi<sup>1</sup>, G. Corso<sup>2</sup>, A.M. De Scalzi<sup>1</sup>, E. Mazzotta<sup>1</sup>, E.M.C. Rossi<sup>1</sup>, F. Magnoni<sup>1</sup>, P. Veronesi<sup>2</sup>, <sup>1</sup>IEO - European Institute of Oncology, Milan, IT, <sup>2</sup>Milan University, Milan, IT

23:55 - 00:15 **115P - Geriatric breast cancer- Does age matter?**

T. Surya, S.V.S. Deo, D.N. Sharma, A. Gogiya, S. Bhorawal, A. Mishra, AIIMS - All India Institute of Medical Sciences, New Delhi, IN

00:15 - 00:35 **116P - Robustness evaluation of VMAT by robust optimization and manual flash approach for breast cancer radiotherapy**

H.M. Hung<sup>1</sup>, W.S. Leung<sup>2</sup>, <sup>1</sup>Pamela Youde Nethersole Eastern Hospital, Hong Kong, HK, <sup>2</sup>The Hong Kong Polytechnic University, Hong Kong, HK

00:35 - 00:55 **117P - Oncological outcomes of chest wall perforator flap reconstruction in breast cancer**

M. Gowda<sup>1</sup>, S. Jafferbhoy<sup>1</sup>, S. Marla<sup>2</sup>, S. Narayanan<sup>1</sup>, S. Soumian<sup>1</sup>, <sup>1</sup>UHNM, STOKE ON TRENT, GB, <sup>2</sup>UHNM, Stoke on trent, GB

00:55 - 01:15 **118P - CD146 interaction with integrin β1 activates LATS1-YAP signaling and**



**provokes the radiation-resistance in breast cancer cells**

L. Yuanke<sup>1</sup>, D. Zeng<sup>2</sup>, H. Lin<sup>1</sup>, <sup>1</sup>The First Affiliated Hospital of Shantou University Medical College, Shantou, CN, <sup>2</sup>Cancer Hospital of Shantou University, Shantou, CN

- 01:15 - 01:35 **119P - Impact of magnetic resonance imaging in the surgical treatment of early breast cancer in two private cancer care centers in Lima, Peru**  
S. Aldecoa-Falcon<sup>1</sup>, F. Aldecoa Bedoya<sup>2</sup>, S. Falcon<sup>3</sup>, <sup>1</sup>Universidad Peruana de Ciencias Aplicadas (UPC), Lima, PE, <sup>2</sup>CLINICA INTERNACIONAL, Lima, PE, <sup>3</sup>Aliada - Centro Oncologico, Lima, PE
- 01:35 - 01:55 **120P - AXSANA (AXillary Surgery After NeoAdjuvant Treatment) EUBREAST-3: an international prospective multicenter cohort study to evaluate different surgical methods of axillary staging in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy (NCT04373655)**  
F. Ruf<sup>1</sup>, T. Kühn<sup>2</sup>, S. Hartmann<sup>3</sup>, J. De Boniface<sup>4</sup>, O. Gentilini<sup>5</sup>, E. Stickeler<sup>6</sup>, G. Cakmak<sup>7</sup>, I. Rubio<sup>8</sup>, L. Niinikoski<sup>9</sup>, M. Kontos<sup>10</sup>, D. Murawa<sup>11</sup>, E.-A. Bonci<sup>12</sup>, M. Hauptmann<sup>13</sup>, M. Thill<sup>14</sup>, H. Markus<sup>15</sup>, M.P. Lux<sup>16</sup>, M. Appelgren<sup>4</sup>, J.-U. Blohmer<sup>17</sup>, M. Untch<sup>18</sup>, M. Banys-Paluchowski<sup>19</sup>, <sup>1</sup>University Hospital of Schleswig Holstein, Campus Lübeck, Lübeck, DE, <sup>2</sup>Klinikum Esslingen, Esslingen am Neckar, DE, <sup>3</sup>Klinikum Südstadt Rostock, Rostock, DE, <sup>4</sup>Karolinska Institutet, Huddinge, SE, <sup>5</sup>IRCCS Ospedale San Raffaele, Milan, IT, <sup>6</sup>Universitaetsklinikum Aachen (UKA), Aachen, DE, <sup>7</sup>Bulent Ecevit University Medical School, Zonguldak, TR, <sup>8</sup>Clinica Universidad de Navarra, Madrid, ES, <sup>9</sup>Helsinki University Hospital - Surgical Hospital, Helsinki, FI, <sup>10</sup>National and Kapodistrian University of Athens - School of Medicine, Athens, GR, <sup>11</sup>University of Zielona Gora, Zielona Gora, PL, <sup>12</sup>IOCN - The Oncology Institute Prof. Dr. Ion Chiricuta, Cluj-Napoca, RO, <sup>13</sup>MHB - Brandenburg Medical School Theodor Fontane - Institute of Social Medicine and Epidemiology, Brandenburg an der Havel, DE, <sup>14</sup>Agaplesion Markus Krankenhaus, Frankfurt am Main, DE, <sup>15</sup>Universitätsfrauenklinik Tübingen, Tuebingen, DE, <sup>16</sup>Frauenklinik St. Louise, Paderborn; St. Josefs-Krankenhaus, Salzkotten; Frauen- und Kinderklinik St. Louise, Paderborn, DE, <sup>17</sup>Charité Universitätsmedizin Berlin, Berlin, DE, <sup>18</sup>Helios Klinikum Berlin-Buch, Berlin, DE, <sup>19</sup>UKSH - Universitätsklinikum Schleswig-Holstein - Campus Lübeck, Lübeck, DE
- 01:55 - 02:15 **121P - Acute skin toxicity after conservative surgery for breast cancer: impact of radiotherapy fractionation**  
R. Trigui, N. Fourati, F. Dhouib, W. Siala, W. Mnejja, J. Daoud, University of Sfax - Hoptal Habib Bourguiba, Sfax, TN
- 02:15 - 02:35 **122P - Dual plane intraoperative digital radiography in breast-conserving surgery.**  
N. Maksimov, E. Shivilov, G. Kvetenadze, K. Arslanov, GBUZ Moscow Clinical Scientific Center named after A. S. Loginov DHM, Moscow, RU
- 02:35 - 02:55 **123P - Paget's disease of the breast: our 20 years experience**  
L. Scardina, S. Magno, A. Franco, E. Biondi, M. Sanchez, A. Di Leone, S. D'Archi, B. Carnassale, R. Masetti, G. Franceschini, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT

- 02:55 - 03:15 **124P - Impact of regional lymph node hypofractionated radiotherapy on acute skin toxicity in patients with node positive breast cancer**  
R. Ben Amor, M. Bohli, Z. Naimi, J. Yahiaoui, L. Kochbati, Hopital Abderrahmen Mami de Pneumo-Phisiologie, Ariana, TN
- 03:15 - 03:35 **125P - De-escalation of breast cancer surgery after neoadjuvant systemic therapy in cCR/pCR patients confirmed by vacuum-assisted biopsy (VAB) and SLNB. A first report of the prospective non-randomized trial results.**  
P. Krivorotko, S. Yerechshenko, A. Emelyanov, E. Busko, T. Tabagua, S. Novikov, A. Artemyeva, P. Krzhivitskiy, E. Zhiltsova, A. Komyahov, K. Nikolaev, L. Gigolaeva, R. Pesotsky, V. Mortada, Z. Bryantseva, V. Smirnova, V. Kushnarev, T. Semiglazova, A. Belyaev, V. Semiglazov, N.N. Petrov National Medical Research Center of Oncology, Saint-Petersburg, RU
- 03:35 - 03:55 **126P - Usefulness of Perforator Flaps in Breast Cancer - A single-centre clinical audit from India**  
C. Koppiker<sup>1</sup>, S. Joshi<sup>1</sup>, R. Mishra<sup>1</sup>, D. Kelkar<sup>1</sup>, A. Joshi<sup>1</sup>, J. John<sup>1</sup>, S. Kadu<sup>1</sup>, N. Gupta<sup>2</sup>, N. Gangurde<sup>1</sup>, G. Sharan<sup>3</sup>, U. Dhar<sup>4</sup>, H. Allampati<sup>5</sup>, L. Busheri<sup>1</sup>, S. Nare<sup>1</sup>, A. Dewle<sup>1</sup>, D. Thakkar<sup>1</sup>, C. Guduru<sup>1</sup>, <sup>1</sup>Prashanti Cancer Care Mission Centre for Translational Cancer Research, Pune, IN, <sup>2</sup>International School for Oncoplastic Surgery, Prashanti Cancer Care Mission, Pune, IN, <sup>3</sup>M N Budhrani Cancer Institute, Pune, IN, <sup>4</sup>Jehangir Hospital, Pune, IN, <sup>5</sup>Ruby Hall Cancer Center Ruby Hall Clinic, Pune, IN
- 03:55 - 04:15 **127P - Sentinel lymph node biopsy in older patients with breast cancer: which subset can be omitted?**  
M. Grand<sup>1</sup>, F. Rapisarda<sup>2</sup>, M. Giacchino<sup>2</sup>, L. Farmer<sup>2</sup>, L. Cook<sup>2</sup>, O. Odofin<sup>3</sup>, W. Sotheran<sup>3</sup>, M. Ostrowski<sup>2</sup>, R. Bonomi<sup>2</sup>, D. Betal<sup>2</sup>, <sup>1</sup>Brighton and Sussex Medical School - University of Sussex, Brighton, GB, <sup>2</sup>University Hospitals Sussex NHS Foundation Trust, Worthing, GB, <sup>3</sup>University Hospitals Sussex NHS Foundation Trust, Chichester, GB
- 04:15 - 04:35 **128P - The role of volumetric modulated arc therapy in left breast cancer**  
E.Y.W. Cheung, TWC - Tung Wah College - King's Park Campus, Kowloon, HK
- 04:35 - 04:55 **129P - Effect of Intra-Operative and Post operative topical tranexamic acid on the duration and the volume of the intra-operative drain in patients undergoing axillary lymph node dissection for breast cancer - A Randomized controlled trial.**  
R.N.N. Irrinki, A. Pachimatla, S. Khare, I. Laroia, G. Singh, PGIMER - Postgraduate Institute of Medical Education and Research, Chandigarh, Chandigarh, IN
- 04:55 - 05:15 **130P - Dosimetric evaluation of Continuous positive airway pressure with deep inspiratory breath hold for left sided breast cancer.**  
P. Singh, AIIMS - All India Institute of Medical Sciences - Patna, Patna, IN
- 05:15 - 05:35 **131P - Immediate breast reconstruction in patients with BRCA mutation and breast cancer - our approach**  
T. Ventruba<sup>1</sup>, L. Minář<sup>1</sup>, D. Brancikova<sup>2</sup>, M. Protivankova<sup>3</sup>, P. Ventruba<sup>3</sup>, <sup>1</sup>Masaryk University Faculty of Medicine, Brno, CZ, <sup>2</sup>University Hospital Brno, Brno, CZ, <sup>3</sup>Masaryk University Hospital Brno FN Brno Bohunice, Brno, CZ

- 05:35 - 05:55 **132TiP - HCB-ONC001 ELPIS TRIAL: Omission of surgery and sentinel lymph node dissection in clinically low-risk HER2 positive breast cancer with high HER2 addiction and a complete response following standard anti-HER2-based neoadjuvant therapy**
- T. Pascual<sup>1</sup>, N. Chic<sup>2</sup>, O. Martinez Saez<sup>3</sup>, E. Sanfeliu Torres<sup>3</sup>, B. Adamo<sup>2</sup>, I. Cebrecos<sup>2</sup>, E. Mension<sup>2</sup>, X. Bargalló<sup>2</sup>, X. Caparros<sup>2</sup>, S. Ganau<sup>2</sup>, B. Gonzalez-Farre<sup>3</sup>, M. Mollá<sup>2</sup>, G. Osés<sup>2</sup>, A.B. Rodriguez<sup>2</sup>, B. Úbeda<sup>2</sup>, M.J. Vidal Losada<sup>3</sup>, S. Vidal-Siscart<sup>2</sup>, M. Munoz<sup>3</sup>, A. Prat<sup>2</sup>, <sup>1</sup>Medical Oncology Dept., Hospital Clinic de Barcelona, Barcelona, ES, <sup>2</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>3</sup>Hospital Clinic of Barcelona, Barcelona, ES
- 05:55 - 06:15 **Early detection, hereditary breast cancer and prevention**
- 06:15 - 06:35 **133P - Using breast cancer risk factors of women to estimate incidence of breast cancer in their sisters**
- X. Mao<sup>1</sup>, W. He<sup>2</sup>, M. Eriksson<sup>1</sup>, L. Lindström<sup>1</sup>, N. Holowko<sup>1</sup>, S. Lagercrantz<sup>3</sup>, K. Humphreys<sup>1</sup>, D. Easton<sup>4</sup>, P. Hall<sup>1</sup>, K. Czene<sup>1</sup>, <sup>1</sup>Karolinska Institutet, Stockholm, SE, <sup>2</sup>Zhejiang University, Hangzhou, CN, <sup>3</sup>Karolinska Institutet, Solna, SE, <sup>4</sup>University of Cambridge, Cambridge, GB
- 06:35 - 06:55 **135P - Real time genotyping-based breast cancer risk assessment in MyPeBS, an International randomized trial in the general population comparing risk-stratified to standard breast cancer screening (BCS)**
- S. Delaloge<sup>1</sup>, P. Giorgi Rossi<sup>2</sup>, C. Balleyguier<sup>3</sup>, M. Guindy<sup>4</sup>, F. Gilbert<sup>5</sup>, J.-B. Burrion<sup>6</sup>, M. Roman<sup>7</sup>, S. De Montgolfier<sup>8</sup>, L. Giordano<sup>9</sup>, D. Drubay<sup>3</sup>, D. Evans<sup>10</sup>, D. Keatley<sup>11</sup>, E. Gauthier<sup>12</sup>, A. Du Bois D'Aische<sup>13</sup>, C. Baron<sup>14</sup>, A. Boland<sup>15</sup>, H. Blanché<sup>16</sup>, D. Couch<sup>17</sup>, J.-F. Deleuze<sup>18</sup>, S. Michiels<sup>3</sup>, <sup>1</sup>Institut Gustave Roussy, Villejuif, FR, <sup>2</sup>IRCCS- AUSL Reggio Emilia, Guastalla, IT, <sup>3</sup>Institut Gustave Roussy, Villejuif, Cedex, FR, <sup>4</sup>Assuta Hospital, Tel Aviv, IL, <sup>5</sup>University of Cambridge, Cambridge, GB, <sup>6</sup>Institute Jules Bordet, Brussels, BE, <sup>7</sup>Hospital del Mar - Parc de Salut Mar, Barcelona, ES, <sup>8</sup>Université Paris 13, Aubervilliers, FR, <sup>9</sup>CPO Centro Prevenzione Oncologica, Torino, IT, <sup>10</sup>The University of Manchester, Manchester, GB, <sup>11</sup>Northern Ireland Cancer Centre - Belfast Health & Social Care Trust, London, GB, <sup>12</sup>Predilife, Villejuif, Cedex, FR, <sup>13</sup>Eonix, Mons, BE, <sup>14</sup>UNICANCER, Paris, FR, <sup>15</sup>CEA-Commissariat à l'Énergie Atomique et aux Energies Alternatives, Evry, FR, <sup>16</sup>Fondation Jean Dausset - CEPH, Paris, FR, <sup>17</sup>Unicancer, Paris, FR, <sup>18</sup>CEA-Commissariat à l'Énergie Atomique et aux Energies Alternatives, Evry, FR
- 06:55 - 07:15 **136P - Development of breast cancer risk prediction models using the UK Biobank dataset**
- K. Alajmi<sup>1</sup>, A. Lophatananon<sup>2</sup>, K. Muir<sup>2</sup>, <sup>1</sup>University of technology and applied sciences, Shinas, OM, <sup>2</sup>University of Manchester, Manchester, GB
- 07:15 - 07:35 **137P - Impact of Staffing a Breast Cancer Screening Clinic with Clinical Officers at a Public Referral Center in Western Kenya**
- S. Jepkirui<sup>1</sup>, M. Bhatia<sup>2</sup>, L. Nanjala<sup>1</sup>, S. Kiptoo<sup>1</sup>, S. Kibiwot<sup>1</sup>, D. Awuor<sup>1</sup>, N. Kisilu<sup>3</sup>, I.

Kiplimo<sup>1</sup>, T. Vic<sup>4</sup>, J. Hunter-Squires<sup>3</sup>, N. Busakhala<sup>5</sup>, <sup>1</sup>Academic Model Providing Access To Healthcare, Eldoret, KE, <sup>2</sup>Indiana University, Indianapolis, US, <sup>3</sup>MU - Moi University - School of Medicine, Eldoret, KE, <sup>4</sup>Indiana University Simon Cancer Center, Indianapolis, US, <sup>5</sup>Moi Teaching and Referral Hospital, Eldoret, KE

- 07:35 - 07:55 **138P - Bone mineral density and risk of breast cancer: a cohort study and Mendelian randomization analysis**  
 Y. Zhang<sup>1</sup>, X. Mao<sup>2</sup>, X. Yu<sup>1</sup>, X. Huang<sup>3</sup>, W. He<sup>4</sup>, H. Yang<sup>1</sup>, <sup>1</sup>Fujian Medical University, Fuzhou, CN, <sup>2</sup>Karolinska Institutet, Stockholm, SE, <sup>3</sup>Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, CN, <sup>4</sup>Zhejiang University, Hangzhou, CN
- 07:55 - 08:15 **139P - Breast cancer risk estimation (CanRisk tool) and perception in unaffected women with family history of breast cancer**  
 T. Ramon Y Cajal<sup>1</sup>, À. Lopez-Fernandez<sup>2</sup>, M. Pardo<sup>2</sup>, E. Darder<sup>3</sup>, E. Perez<sup>2</sup>, A. Costal<sup>4</sup>, A. Teule<sup>5</sup>, A. Perez<sup>6</sup>, M. Torres<sup>2</sup>, R. Alfonso<sup>1</sup>, A. Vallmajó<sup>7</sup>, N. Tuset Der-Abraín<sup>7</sup>, M. Cruellas Lapena<sup>2</sup>, M. Espinosa-Bravo<sup>2</sup>, O. Diez<sup>2</sup>, C. Lázaro<sup>4</sup>, L. Feliubadaló<sup>4</sup>, G. Llorc Pursals<sup>6</sup>, J.M. Brunet Vidal<sup>3</sup>, J. Balmaña<sup>8</sup>, <sup>1</sup>Hospital de la Santa Creu i Sant Pau, Barcelona, ES, <sup>2</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>3</sup>ICO Girona - Institut Català d'Oncologia Girona, Girona, ES, <sup>4</sup>ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES, <sup>5</sup>Institut Català d'Oncologia Hospitalet, Barcelona, ES, <sup>6</sup>Parc Tauli Hospital Universitari, Sabadell, ES, <sup>7</sup>Hospital Universitario Arnau de Vilanova, Lleida, ES, <sup>8</sup>Hospital General Vall d'Hebron, Barcelona, ES
- 08:15 - 08:35 **140P - A Study On Assessment Of Barriers To Genetic Counselling and Testing Among Breast and Ovarian Cancer Patients In A Tertiary Referral Hospital In India.**  
 I. Siripurapu<sup>1</sup>, V. Maka<sup>1</sup>, S. Majumdar<sup>2</sup>, R. Palassery<sup>1</sup>, N. Elackatt<sup>1</sup>, A. Mandade<sup>3</sup>, T. Adadadara<sup>1</sup>, S. Pathak<sup>1</sup>, C. Agrawal<sup>1</sup>, P. Jayaprakash<sup>1</sup>, P. Manmatha<sup>1</sup>, S. Kumar<sup>1</sup>, <sup>1</sup>MS Ramaiah Memorial Hospital, Bangalore, IN, <sup>2</sup>Tata Memorial Hospital - Tata Memorial Centre, Mumbai, IN, <sup>3</sup>M. S. Ramaiah University of Applied Sciences, Bangalore, IN
- 08:35 - 08:55 **141P - Molecular landscape of hereditary breast cancer in Ukrainian women**  
 D. Kozakov<sup>1</sup>, S. Livshun<sup>1</sup>, V. Guryanov<sup>2</sup>, D. Ryspayeva<sup>3</sup>, A. Matveieva<sup>4</sup>, O. Zahoruiko<sup>4</sup>, R. Shabalkov<sup>1</sup>, O. Sulaieva<sup>4</sup>, <sup>1</sup>CSD Medical Laboratory, Kyiv, UA, <sup>2</sup>NMU - National Medical University named after O.O. Bogomolets, Kiev, UA, <sup>3</sup>LISOD Israeli Oncology Hospital, Plyuty Village, UA, <sup>4</sup>CSD Medical Laboratory, Kiev, UA
- 08:55 - 09:15 **142P - Multidimensional impact of breast cancer screening: results from a real-world French cohort**  
 B. Cutuli<sup>1</sup>, C. Charles<sup>2</sup>, <sup>1</sup>Institut du Cancer Courlancy, Reims, FR, <sup>2</sup>Scilink, BIARRITZ, FR
- 09:15 - 09:35 **143P - Demographics of Breast Cancer and Non Malignant breast lesions in Western India: A study of 8000 breast pathologies**  
 N. Agarwal<sup>1</sup>, S. Singh<sup>1</sup>, P. Patel<sup>1</sup>, K. Lakhera<sup>1</sup>, A. Hussain<sup>1</sup>, R. Sharma<sup>2</sup>, <sup>1</sup>Surgical oncology, SMS (Sawai Man Singh) Medical College & Attached Hospital, Jaipur, IN,



<sup>2</sup>Mahatma Gandhi Medical College, Jaipur, IN

- 09:35 - 09:55 **144P - The differences in fatty acid profiles and stearoyl-CoA desaturase (SCD1) mRNA level in adipose tissue surrounding breast tumor of Iranian women with breast cancer and benign breast disease**  
R. Sefidabi<sup>1</sup>, A. Moini<sup>1</sup>, A. Alizadeh<sup>2</sup>, S. Alipour<sup>1</sup>, R. Omranipoor<sup>1</sup>, M. Hafezi<sup>2</sup>, M. Shahhoseini<sup>2</sup>, A. Izadi<sup>2</sup>, S. Vesali<sup>2</sup>, <sup>1</sup>Cancer Institute, Tehran University of Medical Sciences, Tehran, IR, <sup>2</sup>Royan Institute for Reproductive Biomedicine, ACECR, Tehran, IR
- 09:55 - 10:15 **145P - Trajectory of physical activity and breast cancer risk: Findings from a population-based cohort study in South Korea**  
T. Tran<sup>1</sup>, N.M. Luu<sup>1</sup>, T.T. Bui<sup>1</sup>, M. Han<sup>2</sup>, M.K. Lim<sup>3</sup>, J.-K. Oh<sup>2</sup>, <sup>1</sup>National Cancer Center Graduate School of Cancer Science and Policy, Goyang-si, KR, <sup>2</sup>National Cancer Center, Goyang-si, KR, <sup>3</sup>College of Medicine, Inha University, Incheon, KR
- 10:15 - 10:35 **146P - Breast cancer screening in Libya: Results of the first pilot study**  
A. Attia<sup>1</sup>, F. Bilgasim<sup>2</sup>, K. Salem<sup>2</sup>, I. Siala<sup>3</sup>, S. Algaod<sup>4</sup>, <sup>1</sup>Benghazi Medical Center, Benghazi, LY, <sup>2</sup>University of Sirte, Sirte, LY, <sup>3</sup>Tripoli Central Hospital, Tripoli, LY, <sup>4</sup>Sirte Oncology Center, Sirte, LY
- 10:35 - 10:55 **147P - Breast cancer in women with germline pathogenic variants: frequency, clinical behavior, and outcomes of a consecutive series of patients from Spain**  
A. Rodriguez Hernandez<sup>1</sup>, F. Braso Maristany<sup>2</sup>, B. Pastor<sup>3</sup>, M. Potrony<sup>4</sup>, L. Moreno<sup>3</sup>, E. Grau<sup>3</sup>, J. Puig-Butille<sup>1</sup>, O. Martinez Saez<sup>3</sup>, B. Conte<sup>1</sup>, N. Chic<sup>1</sup>, M.J. Vidal Losada<sup>3</sup>, M. Munoz<sup>3</sup>, F. Balaguer<sup>3</sup>, A. Prat<sup>1</sup>, B. Adamo<sup>1</sup>, <sup>1</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>2</sup>Institut D'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, ES, <sup>3</sup>Hospital Clinic of Barcelona, Barcelona, ES, <sup>4</sup>IDIBAPS, Barcelona, ES
- 10:55 - 11:15 **148P - Descriptive study of mutation status and clinical phenotype in breast cancer patients of South Catalonia**  
A. Cochs, M. Rodriguez Balada, B. Roig Bourgine, S. Fernández Castillejo, C.R. Albacar Miro, L. Delamo Palomares, M. Querol Garcia, M. Salvat Casas, J. Repkova, M. Masvidal Hernandez, S. Serrano Solares, K. Amillano Parraga, M. Mele Olive, J. Gumà, Hospital Universitari Sant Joan de Reus, Reus, ES
- 11:15 - 11:35 **149P - Associations between the 313-SNP Polygenic Risk Score and Breast Cancer Risk in women from Crete.**  
K. Yiangou<sup>1</sup>, A. Hadjisavvas<sup>1</sup>, S. Agelaki<sup>2</sup>, D. Aggouraki<sup>3</sup>, N. Androulakis<sup>4</sup>, V. Bozionelou<sup>2</sup>, I. Drositis<sup>4</sup>, K. Kalmpakis<sup>2</sup>, A. Kalykaki<sup>2</sup>, E. Kontopodis<sup>4</sup>, A. Kotsakis<sup>5</sup>, E. Politaki<sup>3</sup>, G. Saloustrou<sup>3</sup>, L. Vamvakas<sup>2</sup>, N. Vardakis<sup>2</sup>, V. Georgoulis<sup>2</sup>, D. Mavroudis<sup>2</sup>, K. Michailidou<sup>1</sup>, E. Saloustrou<sup>5</sup>, <sup>1</sup>The Cyprus Inst. of Neurology and Genetics, Nicosia, CY, <sup>2</sup>University General Hospital of Heraklion, Heraklion, GR, <sup>3</sup>University of Crete - School of Medicine, Heraklion, GR, <sup>4</sup>General Hospital of Heraklion 'Venizelio', Heraklion, GR, <sup>5</sup>University Hospital of Larissa, Larissa, GR
- 11:35 - 11:55 **150P - Molecular characteristics of breast cancer patients subjected to screening for germline predisposition in a population-based observational study**

J. Staaf, D. Oliveira, J. Vallon-Christersson, H. Ehrencrona, A. Kvist, Å. Borg, Lund University, Lund, SE

- 11:55 - 12:15 **151P - Personalized approach to mammography screening during the COVID pandemic: how to make up for lost time without losing effectiveness.**  
F. Giovanardi, G. Bisagni, E. Gasparini, A. Bologna, R. Di Cicilia, G. Moretti, C. Pinto, IRCCS- AUSL Reggio Emilia, Reggio Emilia, IT
- 12:15 - 12:35 **152P - Prognostic Impact of Serum Vascular Endothelial Growth Factor and VEGF Gene Polymorphism (rs2010963) in Breast Cancer patients**  
A. Al Hanafy, S. El-Hefnawy, S. El Naidany, N. Badr, M. Ellaithy, MFM - Menoufia University - Faculty of Medicine, Shebeen El-Kom, EG
- 12:35 - 12:55 **153P - The Role of Screening in the Timely Diagnosis of Breast Cancer in the COVID-19 Pandemic Context**  
D. Kaidarova<sup>1</sup>, A. Zhylkaidarova<sup>2</sup>, M. Saktaganov<sup>3</sup>, Z. Dushimova<sup>1</sup>, O. Shatkovskaya<sup>4</sup>,  
<sup>1</sup>Kazakh Research Institute of Oncology & Radiology, Almaty, KZ, <sup>2</sup>Kazakh Institute of Oncology & Radiology, Almaty, KZ, <sup>3</sup>Kazakhstan School of Public Health, Almaty, KZ, <sup>4</sup>Kazakh Institute of Oncology&Radiology, Almaty, KZ
- 12:55 - 13:15 **154P - Screening of breast cancer: Clinical and biological profile of Tunisian women**  
S. Zouari<sup>1</sup>, M. Frikha<sup>1</sup>, N. Fourati<sup>1</sup>, M. Kallel<sup>1</sup>, M. Frikha<sup>2</sup>, W. Mnejja<sup>1</sup>, J. Daoud<sup>1</sup>,  
<sup>1</sup>University of Sfax - Hopital Habib Bourguiba, Sfax, TN, <sup>2</sup>Universite de Tunis El Manar, Tunis, TN
- 13:15 - 13:35 **155P - A retrospective analysis of women at high risk of breast cancer : a single Centre surveillance experience**  
G. Mammone<sup>1</sup>, L. Roazzi<sup>2</sup>, L. Merlino<sup>1</sup>, M. Specchia<sup>3</sup>, F. Galati<sup>1</sup>, M.G. Piccioni<sup>1</sup>, L. Ballesio<sup>1</sup>, F. Pediconi<sup>1</sup>, L. De Marchis<sup>1</sup>, <sup>1</sup>Umberto I University hospital, Rome, IT, <sup>2</sup>ASST Grande Ospedale Metropolitano Niguarda, Milan, IT, <sup>3</sup>Sapienza - Università di Roma, Rome, IT
- 13:35 - 13:55 **156TiP - BRCA-DIRECT: A randomised UK study evaluating a digital pathway for germline genetic testing and non-inferiority of digitally-delivered information in women with breast cancer.**  
B. Torr<sup>1</sup>, S. Choi<sup>2</sup>, C. Jones<sup>3</sup>, S. Allen<sup>2</sup>, G. Kavanaugh<sup>2</sup>, M. Hamill<sup>2</sup>, K. Monson<sup>4</sup>, S. Machmahon<sup>2</sup>, M. Valgon Petrizan<sup>2</sup>, L. Fallowfield<sup>4</sup>, V. Jenkins<sup>4</sup>, A. George<sup>5</sup>, D. Evans<sup>6</sup>, A. Gandhi<sup>7</sup>, Z. Kemp<sup>5</sup>, M. Hubank<sup>2</sup>, C. Turnbull<sup>2</sup>, <sup>1</sup>ICR - The Institute of Cancer Research - North Site, Sutton, GB, <sup>2</sup>Institute of Cancer Research, London, GB, <sup>3</sup>University of Sussex, Brighton, GB, <sup>4</sup>Brighton and Sussex Medical School - University of Sussex, Brighton, GB, <sup>5</sup>Royal Marsden NHS Foundation Trust, London, GB, <sup>6</sup>The University of Manchester, Manchester, GB, <sup>7</sup>Manchester University NHS Foundation Trust, Manchester, GB
- 13:55 - 14:15 **Immunotherapy**

- 14:15 - 14:35 **157P - Adoptive cell therapy with Cytokine-Induced Killer cells retargeted with immunotools against HER-2 expressing breast cancer**  
 S. Perpinello, E. Cappuzzello, R. Sommaggio, A. Ventura, P. Palmerini, E. Vigolo, A. Dalla Pietà, A. Rosato, IOV - Istituto Oncologico Veneto IRCCS, Padova, IT
- 14:35 - 14:55 **158P - Predictors of Response to Neoadjuvant Checkpoint Inhibition with chemotherapy in Triple-Negative Breast Cancer (TNBC): A Meta-analysis of Randomized Control Trials (RCTs)**  
 A.M. Roy, K. Attwood, S. Gandhi, Roswell Park Comprehensive Cancer Center, Buffalo, US
- 14:55 - 15:15 **159P - Q-TWiST Analysis of Pembrolizumab Combined with Chemotherapy as First Line Treatment of Metastatic TNBC that Expresses PD-L1**  
 P.A. Fasching<sup>1</sup>, M. Huang<sup>2</sup>, A. Haiderali<sup>3</sup>, W. Pan<sup>4</sup>, P. Hu<sup>2</sup>, M. Chaudhuri<sup>5</sup>, C. Le Bailly De Tillegem<sup>6</sup>, N. Cappoen<sup>6</sup>, J. O'Shaughnessy<sup>7</sup>, <sup>1</sup>University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, DE, <sup>2</sup>Merck & Co. Inc - MRL Labs - Upper Gwynedd Campus, North Wales, US, <sup>3</sup>Merck & Co., Inc. - Corporate Headquarters, Kenilworth, US, <sup>4</sup>Merck & Co, Rahway, US, <sup>5</sup>CHEORS - Complete Health Economics Outcomes and Research Solutions, North Wales, US, <sup>6</sup>MSD, Brussels, BE, <sup>7</sup>Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, US
- 15:15 - 15:35 **160TiP - A randomized controlled phase III study of bevacizumab and paclitaxel in combination with atezolizumab as a treatment for patients with locally advanced or metastatic hormone receptor-positive HER2 negative breast cancer: JCOG1919E/AMBITION study**  
 F. Hara<sup>1</sup>, M. Ono<sup>1</sup>, S. Kitano<sup>2</sup>, T. Nakayama<sup>3</sup>, H. Kawabata<sup>4</sup>, K. Watanabe<sup>5</sup>, K. Sasaki<sup>6</sup>, T. Kataoka<sup>7</sup>, S. Saji<sup>8</sup>, K. Yonemori<sup>6</sup>, T. Shien<sup>9</sup>, H. Iwata<sup>10</sup>, <sup>1</sup>Cancer Institute Hospital of JFCR, Koto-ku, JP, <sup>2</sup>Cancer Institute Hospital of JFCR, Tokyo, JP, <sup>3</sup>Osaka International Cancer Institute, Osaka, JP, <sup>4</sup>Toranomon Hospital, Minato-ku, JP, <sup>5</sup>Hokkaido Cancer Center, Sapporo, JP, <sup>6</sup>National Cancer Center Hospital, Chuo-ku, JP, <sup>7</sup>National Cancer Center Hospital, Chuo-ku, JP, <sup>8</sup>Fukushima Medical University, Fukushima, JP, <sup>9</sup>Okayama University Hospital, Okayama, JP, <sup>10</sup>Aichi Cancer Center Hospital, Nagoya, JP
- 15:35 - 15:55 **Metastatic breast cancer**
- 15:55 - 16:15 **168P - Sacituzumab govitecan (SG) efficacy in patients with metastatic triple-negative breast cancer (mTNBC) by HER2 immunohistochemistry (IHC) status: Findings from the Phase 3 ASCENT study**  
 S. Hurvitz<sup>1</sup>, A. Bardia<sup>2</sup>, K. Punie<sup>3</sup>, K. Kalinsky<sup>4</sup>, J. Cortés<sup>5</sup>, J. O'Shaughnessy<sup>6</sup>, L. Carey<sup>7</sup>, H. Rugo<sup>8</sup>, O.K. Yoon<sup>9</sup>, Y. Pan<sup>9</sup>, R. Delaney<sup>9</sup>, S. Hofsess<sup>9</sup>, P. Hodgkins<sup>9</sup>, S.-C. Phan<sup>9</sup>, V. Dieras<sup>10</sup>, <sup>1</sup>David Geffen School of Medicine, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, US, <sup>2</sup>Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, US, <sup>3</sup>University Hospitals Leuven, Leuven, BE, <sup>4</sup>Winship Cancer Institute, Emory University, Atlanta, US, <sup>5</sup>International Breast Cancer Center (IBCC), Quiron Group, Madrid & Barcelona, ES, <sup>6</sup>Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, US, <sup>7</sup>University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, US, <sup>8</sup>University

of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, US, <sup>9</sup>Gilead Sciences, Inc, Foster City, US, <sup>10</sup>Centre Eugène Marquis, Rennes, FR

16:15 - 16:35 **169P - Overall survival with first-line palbociclib plus an aromatase inhibitor (AI) vs AI in metastatic breast cancer: A large real-world database analysis**

H. Rugo<sup>1</sup>, A. Brufsky<sup>2</sup>, X. Liu<sup>3</sup>, B. Li<sup>3</sup>, L. Mcroy<sup>3</sup>, C. Chen<sup>3</sup>, R. Layman<sup>4</sup>, M. Cristofanilli<sup>5</sup>, M. Torres<sup>6</sup>, G. Curigliano<sup>7</sup>, R. Finn<sup>8</sup>, A. Demichele<sup>9</sup>, <sup>1</sup>UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, <sup>2</sup>UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, US, <sup>3</sup>Pfizer Inc, New York, US, <sup>4</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>5</sup>Weill Cornell Medicine, New York, US, <sup>6</sup>Winship Cancer Institute, Emory University School of Medicine, Atlanta, US, <sup>7</sup>European Institute of Oncology, IRCCS and University of Milano, Milan, Italy, Milano, IT, <sup>8</sup>David Geffen School of Medicine at University of California Los Angeles, Santa Monica, US, <sup>9</sup>Abramson Cancer Center, University of Pennsylvania, Philadelphia, US

16:35 - 16:55 **170P - Long-term survival of breast cancer patients with brain metastases: Subanalysis of the BMBC Registry**

K. Riecke<sup>1</sup>, E. Laakmann<sup>1</sup>, T. Neunhöffer<sup>2</sup>, T.-W. Park-Simon<sup>3</sup>, R. Weide<sup>4</sup>, M. Schmidt<sup>5</sup>, A. Polasik<sup>6</sup>, J. Puppe<sup>7</sup>, C. Mundhenke<sup>8</sup>, K. Lübke<sup>9</sup>, T. Hesse<sup>10</sup>, M. Thill<sup>11</sup>, D.-M. Zahm<sup>12</sup>, C. Denkert<sup>13</sup>, T. Fehm<sup>14</sup>, V. Nekljudova<sup>15</sup>, J. Rey<sup>15</sup>, S. Loibl<sup>16</sup>, V. Müller<sup>1</sup>, I. Witzel<sup>1</sup>, <sup>1</sup>UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, <sup>2</sup>Helios Dr. Horst Schmidt Kliniken Wiesbaden, Wiesbaden, DE, <sup>3</sup>MHH - Medizinische Hochschule Hannover, Hannover, DE, <sup>4</sup>Praxis für Hämatologie und Onkologie Koblenz, Koblenz, DE, <sup>5</sup>Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, DE, <sup>6</sup>Universitätsfrauenklinik Ulm, Ulm, DE, <sup>7</sup>Gynecology and Obstetrics University Hospital of Cologne, Köln, DE, <sup>8</sup>Klinikum Bayreuth, Bayreuth, DE, <sup>9</sup>DIAKOVERE gGmbH, Hanover, DE, <sup>10</sup>Agaplesion Diakonieklinikum Rotenburg GmbH, Rotenburg an der Wümme, DE, <sup>11</sup>Kliniken Markus-Krankenhaus, Agaplesion, Frankfurt am Main, DE, <sup>12</sup>SRH Waldklinikum Gera, Gera, DE, <sup>13</sup>Uniklinikum Giessen und Marburg, Marburg, DE, <sup>14</sup>Universitätsklinikum Düsseldorf, Düsseldorf, DE, <sup>15</sup>GBG Forschungs GmbH, Neu-Isenburg, DE, <sup>16</sup>German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE

16:55 - 17:15 **171P - Biomarker and multivariate analyses results from AIPAC: A phase IIb study comparing eftilagimod alpha (a soluble LAG-3 protein) vs. placebo in combination with weekly paclitaxel in HR+ HER2- metastatic breast cancer**

F. Marmé<sup>1</sup>, H. Wildiers<sup>2</sup>, L. Dirix<sup>3</sup>, A. Armstrong<sup>4</sup>, E. De Cuyper<sup>5</sup>, F. Dalenc<sup>6</sup>, C. Pia Schröder<sup>7</sup>, P. Vuylsteke<sup>8</sup>, E. Brain<sup>9</sup>, S. Kuemmel<sup>10</sup>, Z. Pápai<sup>11</sup>, C. Mueller<sup>12</sup>, C. Brignone<sup>13</sup>, F. Triebel<sup>13</sup>, <sup>1</sup>Heidelberg University, Mannheim, DE, <sup>2</sup>Department of General Medical Oncology and Multidisciplinary Breast Centre, Leuven, BE, <sup>3</sup>GZA Ziekenhuizen, campus Sint-Augustinus, Antwerp, BE, <sup>4</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>5</sup>AZ Sint-Jan Brugge-Oostende AV, Brugge, BE, <sup>6</sup>Institut Claudius Regaud, Toulouse, FR, <sup>7</sup>University Medical Center Groningen, GRONINGEN, NL, <sup>8</sup>Clinique Sainte-Elisabeth, Namur, BE, <sup>9</sup>12. Institut Curie -Hôpital René Huguenin, Saint-Cloud, FR, <sup>10</sup>Kliniken Essen Mitte Evang. Huysens-Stiftung, Essen, DE, <sup>11</sup>13. KEM | Evang. Kliniken Essen-Mitte, Budapest, HU, <sup>12</sup>Immutep GmbH, Berlin, DE, <sup>13</sup>Immutep S.A.S., Orsay, FR



- 17:15 - 17:35 **172P - Long-term follow-up of randomized controlled trial (RCT) of locoregional treatment versus not of the primary tumour in de-novo metastatic breast cancer**  
N. Nair<sup>1</sup>, R. Hawaldar<sup>1</sup>, V. Parmar<sup>1</sup>, S. Siddique<sup>1</sup>, I. Mitra<sup>2</sup>, V. Vanmali<sup>1</sup>, S. Joshi<sup>1</sup>, S. Gupta<sup>1</sup>, R. Badwe<sup>1</sup>, <sup>1</sup>Tata Memorial Hospital - Tata Memorial Centre, Mumbai, IN, <sup>2</sup>ACTREC Tata Memorial Centre, Mumbai, IN
- 17:35 - 17:55 **173P - Entrectinib in NTRK fusion-positive (NTRK-fp) breast cancer: updated data from STARTRK-2**  
J. Lu<sup>1</sup>, C.M. Blakely<sup>2</sup>, M. Barve<sup>3</sup>, C. Chung<sup>4</sup>, S.N. Waqar<sup>5</sup>, X. Hu<sup>6</sup>, J.-P. Delord<sup>7</sup>, M. Krzakowski<sup>8</sup>, K. Yonemori<sup>9</sup>, D. Chen<sup>10</sup>, D. Klingbiel<sup>11</sup>, S. Heinzmann<sup>11</sup>, C. Le Tourneau<sup>12</sup>, <sup>1</sup>USC Norris Comprehensive Cancer Center, Los Angeles, US, <sup>2</sup>University of California San Francisco Helen Diller Comprehensive Cancer Center, San Francisco, US, <sup>3</sup>Mary Crowley Cancer Research Center, Dallas, US, <sup>4</sup>Moffitt Cancer Center, Tampa, US, <sup>5</sup>Washington University School of Medicine, St. Louis, US, <sup>6</sup>Shanghai Cancer Center, Fudan University, Shanghai, CN, <sup>7</sup>Institut Universitaire du Cancer, Toulouse, FR, <sup>8</sup>Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL, <sup>9</sup>National Cancer Center Hospital, Tokyo, JP, <sup>10</sup>Genentech Inc., South San Francisco, US, <sup>11</sup>F. Hoffmann-La Roche Ltd, Basel, CH, <sup>12</sup>Paris Saclay University, Institut Curie, Paris, FR
- 17:55 - 18:15 **174P - Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real world setting: Phase 3b LUCY final analysis**  
J. Balmana<sup>1</sup>, P.A. Fasching<sup>2</sup>, S. Delaloge<sup>3</sup>, Y.H. Park<sup>4</sup>, A. Eisen<sup>5</sup>, H. Bourgeois<sup>6</sup>, Z. Kemp<sup>7</sup>, T. Jankowski<sup>8</sup>, J. Sohn<sup>9</sup>, S. Aksoy<sup>10</sup>, C. Timcheva<sup>11</sup>, T.-W. Park-Simon<sup>12</sup>, A. Anton Torres<sup>13</sup>, E. John<sup>14</sup>, K. Baria<sup>15</sup>, G. Walker<sup>16</sup>, K. Gelmon<sup>17</sup>, <sup>1</sup>Hospital Universitari Vall d'Hebron and Vall d'Hebron Institute of Oncology, Barcelona, ES, <sup>2</sup>Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, DE, <sup>3</sup>Gustave Roussy, Villejuif, FR, <sup>4</sup>Sungkyunkwan University School of Medicine, Seoul, KR, <sup>5</sup>Sunnybrook Odette Cancer Centre, Toronto, CA, <sup>6</sup>Victor Hugo Clinic-Jean Bernard Center, Le Mans, FR, <sup>7</sup>Royal Marsden Hospital, NHS Trust, London, GB, <sup>8</sup>Lublin Oncology Center, Lublin, PL, <sup>9</sup>Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, <sup>10</sup>Hacettepe University Cancer Institute, Ankara, TR, <sup>11</sup>Medical Oncology MHAT Nadezhda, Sofia, BG, <sup>12</sup>Hannover Medical School, Hannover, DE, <sup>13</sup>Miguel Servet University Hospital and Aragon Health Research Institute, Zaragoza, ES, <sup>14</sup>AstraZeneca, Cambridge, GB, <sup>15</sup>AstraZeneca, Gaithersburg, US, <sup>16</sup>AstraZeneca, Macclesfield, GB, <sup>17</sup>BC Cancer, University of British Columbia, Vancouver, CA
- 18:15 - 18:35 **175P - Alpelisib (ALP) + Endocrine Therapy (ET) in Patients (pts) With PIK3CA-Mutated, Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Advanced Breast Cancer (ABC): Subgroup Analyses From the BYLieve Study**  
F. Cardoso<sup>1</sup>, D. Juric<sup>2</sup>, F. Lerebours<sup>3</sup>, I. Krop<sup>4</sup>, M. Ruiz Borrego<sup>5</sup>, P. Neven<sup>6</sup>, Y.H. Park<sup>7</sup>, D. Yardley<sup>8</sup>, K. Jhaveri<sup>9</sup>, C. Arce<sup>10</sup>, E. Gu<sup>11</sup>, M. Akdere<sup>12</sup>, H. Rugo<sup>13</sup>, <sup>1</sup>Champalimaud Foundation - Champalimaud Clinical Center, Lisbon, PT, <sup>2</sup>Massachusetts General Hospital Cancer Center, Boston, US, <sup>3</sup>Institut Curie, St. Cloud, FR, <sup>4</sup>Susan F. Smith Center for Women's Cancer, Dana-Farber Cancer Institute, Boston, US, <sup>5</sup>Hospital Virgen del Rocio de Sevilla, Sevilla, ES, <sup>6</sup>University Hospitals, Leuven, BE, <sup>7</sup>Samsung Medical Center,

Sungkyunkwan University, Seoul, KR, <sup>8</sup>Sarah Cannon Research Institute and Tennessee Oncology, Nashville, US, <sup>9</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>10</sup>Novartis Pharmaceuticals Corporation, East Hanover, US, <sup>11</sup>Novartis Institutes for BioMedical Research, Cambridge, US, <sup>12</sup>Novartis Pharma AG, Basel, CH, <sup>13</sup>University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, US

18:35 - 18:55

**176P - Poziotinib for HER2-positive metastatic breast cancer (MBC): Final clinical efficacy and safety results for long-term follow-up of the phase II NOV120101-203 trial**

Y.H. Park<sup>1</sup>, K. Jung<sup>2</sup>, J. Sohn<sup>3</sup>, K.S. Lee<sup>4</sup>, J.H. Kim<sup>5</sup>, Y. Yang<sup>6</sup>, E. Baek<sup>7</sup>, H. Han<sup>7</sup>, S.-A. Im<sup>8</sup>, <sup>1</sup>Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, CA, <sup>2</sup>Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, <sup>3</sup>Yonsei University, Seoul, KR, <sup>4</sup>National Cancer Center, Goyang, KR, <sup>5</sup>Seoul National University Bundang Hospital, Seongnam, KR, <sup>6</sup>Chungbuk National University Hospital, Cheongju, KR, <sup>7</sup>Hanmi Pharmaceutical Co., Ltd, Seoul, KR, <sup>8</sup>Seoul National University College of Medicine, Seoul, KR

18:55 - 19:15

**177P - Low HER2 expression does not influence prognosis in metastatic triple-negative breast cancer: results from an international, multicenter analysis coordinated by the Austrian Group Medical Tumor Therapy (AGMT)**

S.P. Gampenrieder<sup>1</sup>, V. Dezentjé<sup>2</sup>, M. Lambertini<sup>3</sup>, A. De Nonneville<sup>4</sup>, M. Marhold<sup>5</sup>, F. Le Du<sup>6</sup>, C. Saavedra Serrano<sup>7</sup>, D. Alpuim Costa<sup>8</sup>, E. Blondeaux<sup>3</sup>, L. Del Mastro<sup>3</sup>, F. Bertucci<sup>4</sup>, A. Gonçalves<sup>4</sup>, R. Bartsch<sup>5</sup>, A. Deleuze<sup>6</sup>, A. Cortés Salgado<sup>7</sup>, M. Vitorino<sup>9</sup>, C. Tinchon<sup>10</sup>, L. Pecen<sup>11</sup>, G. Rinnerthaler<sup>1</sup>, R. Greil<sup>1</sup>, <sup>1</sup>Paracelsus Medical University Salzburg, Salzburg, AT, <sup>2</sup>The Netherlands Cancer Institute, Amsterdam, NL, <sup>3</sup>U.O.C. Clinica di Oncologia Medica, Policlinico San Martino Hospital - University of Genova, Genova, IT, <sup>4</sup>Institut Paoli-Calmettes, Aix-Marseille Univ, CNRS, INSERM, Marseille, FR, <sup>5</sup>Medical University of Vienna, Vienna, AT, <sup>6</sup>Centre Eugène-Marquis, Rennes, FR, <sup>7</sup>Hospital Universitario Ramón y Cajal, Madrid, ES, <sup>8</sup>CUF Oncologia, Lisbon, PT, <sup>9</sup>Hospital Professor Doutor Fernando Fonseca, Amadora, PT, <sup>10</sup>LKH Hochsteiermark-Leoben, Leoben, AT, <sup>11</sup>Czech Academy of Sciences, Prague, CZ

19:15 - 19:35

**178P - Assessment of side effects (SEs) impacting quality of life (QoL) in patients (pts) undergoing treatment (tx) for advanced breast cancer (ABC) in clinical practice: a real-world (RW) multi-country survey**

F. Cardoso<sup>1</sup>, J. Rihani<sup>2</sup>, D. Aubel<sup>3</sup>, J. De Courcy<sup>4</sup>, V. Harmer<sup>5</sup>, N. Harbeck<sup>6</sup>, A. Casas<sup>7</sup>, H. Rugo<sup>8</sup>, P.A. Fasching<sup>9</sup>, S. Haftchenary<sup>10</sup>, P. Pathak<sup>11</sup>, E. Schumacher-Wulf<sup>12</sup>, <sup>1</sup>Champalimaud Foundation - Champalimaud Clinical Center, Lisbon, PT, <sup>2</sup>KHCC - King Hussein Cancer Center, Amman, JO, <sup>3</sup>Novartis Pharmaceuticals Corporation, East Hanover, US, <sup>4</sup>Adelphi Real World - Adelphi Group, Bollington, GB, <sup>5</sup>Imperial College Healthcare NHS Trust - Charing Cross Hospital, London, GB, <sup>6</sup>Ludwig Maximilians University - Grosshadern, Munich, DE, <sup>7</sup>Hospital Universitario Virgen del Rocío, Seville, ES, <sup>8</sup>UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, <sup>9</sup>Universitätsklinikum Erlangen, Erlangen, DE, <sup>10</sup>Novartis Pharma Canada, Dorval, CA, <sup>11</sup>Novartis Ireland Ltd, Dublin, IE, <sup>12</sup>Mamma MIA - The Breast Cancer Magazine, Köln, DE

19:35 - 19:55

**179P - Time trends in overall survival and systemic therapy in patients with HR+/HER2- advanced breast cancer: a study of the SONABRE Registry**

M. Meegdes<sup>1</sup>, S. Geurts<sup>1</sup>, F. Erdkamp<sup>2</sup>, W. Dercksen<sup>3</sup>, B. Vriens<sup>4</sup>, K. Aaldering<sup>5</sup>, M. Pepels<sup>6</sup>, L. Winkel<sup>7</sup>, J. Tol<sup>8</sup>, J. Heijns<sup>9</sup>, A. Van De Wouw<sup>10</sup>, N. Peters<sup>11</sup>, A. Fallois<sup>1</sup>, M. Van Kats<sup>1</sup>, V. Tjan-Heijnen<sup>1</sup>, <sup>1</sup>Maastricht University Medical Center (MUMC), Maastricht, NL, <sup>2</sup>Zuyderland Medical Center - Sittard-Geleen, Sittard-Geleen, NL, <sup>3</sup>Maxima Medisch Centrum -Veldhoven, Veldhoven, NL, <sup>4</sup>Catharina Hospital Eindhoven, Eindhoven, NL, <sup>5</sup>Laurentius Ziekenhuis, Roermond, NL, <sup>6</sup>Elkerliekziekenhuis, Helmond, NL, <sup>7</sup>St. Anna Hospital, Geldrop, NL, <sup>8</sup>Jeroen Bosch Hospital, 's-Hertogenbosch, NL, <sup>9</sup>Amphia Ziekenhuis-location Molengracht, Breda, NL, <sup>10</sup>VieCuri Medical Center, Venlo, NL, <sup>11</sup>St Jans Gasthuis, Weert, NL

19:55 - 20:15 **180P - A doubling in overall survival of patients with de novo HER2+ advanced breast cancer in the Netherlands**

S. Geurts<sup>1</sup>, K. Ibragimova<sup>1</sup>, M. Meegdes<sup>1</sup>, F. Erdkamp<sup>2</sup>, J. Heijns<sup>3</sup>, J. Tol<sup>4</sup>, B. Vriens<sup>5</sup>, W. Dercksen<sup>6</sup>, K. Aaldering<sup>7</sup>, M. Pepels<sup>8</sup>, L. Winkel<sup>9</sup>, N. Peters<sup>10</sup>, A. Van De Wouw<sup>11</sup>, A. Hochstenbach<sup>1</sup>, M. De Boer<sup>1</sup>, V. Tjan-Heijnen<sup>1</sup>, <sup>1</sup>Maastricht University Medical Center (MUMC), Maastricht, NL, <sup>2</sup>Zuyderland Medical Center, Sittard-Geleen, NL, <sup>3</sup>Amphia, Breda, NL, <sup>4</sup>Jeroen Bosch Hospital, 's-Hertogenbosch, NL, <sup>5</sup>Catharina Hospital, Eindhoven, NL, <sup>6</sup>Máxima Medical Center, Veldhoven, NL, <sup>7</sup>Laurentius hospital, Roermond, NL, <sup>8</sup>Elkerliek hospital, Helmond, NL, <sup>9</sup>St Anna Hospital, Geldrop, NL, <sup>10</sup>Sint Jans Gasthuis Hospital, Weert, NL, <sup>11</sup>VieCuri Medical Centre, Venlo, NL

20:15 - 20:35 **181P - Efficacy of eribulin mesylate in HER2-low metastatic breast cancer (MBC): Results from a pooled analysis of two phase 3 studies**

C. Twelves<sup>1</sup>, J. Cortés<sup>2</sup>, P. Kaufman<sup>3</sup>, A. Awada<sup>4</sup>, S.-A. Im<sup>5</sup>, W. Hauck<sup>6</sup>, I. Greenfield<sup>7</sup>, R. Xie<sup>6</sup>, L. Vahdat<sup>8</sup>, <sup>1</sup>University of Leeds, Leeds, GB, <sup>2</sup>International Breast Cancer Center (IBCC), Madrid & Barcelona, ES, <sup>3</sup>University of Vermont Cancer Center, Burlington, US, <sup>4</sup>Institut Jules Bordet, Brussels, BE, <sup>5</sup>Cancer Research Institute, Seoul National University College of Medicine, Seoul, KR, <sup>6</sup>Eisai Inc., Nutley, US, <sup>7</sup>Eisai Europe Ltd, Hatfield, GB, <sup>8</sup>Dartmouth Cancer Center, Lebanon, US

20:35 - 20:55 **182P - Radium-223 (223Ra) in Combination with Exemestane and Everolimus (EXE-EVE) in Patients (pts) with Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative (HR+/HER2-) Metastatic Breast Cancer (MBC) with Bone Metastases: A Phase 2 Study**

H. Rugo<sup>1</sup>, K. Drumea<sup>2</sup>, S.C. Lee<sup>3</sup>, M. Campone<sup>4</sup>, C. Van Poznak<sup>5</sup>, P. Neven<sup>6</sup>, E. Vega Alonso<sup>7</sup>, B. Naume<sup>8</sup>, J. Siegel<sup>9</sup>, R. Li<sup>9</sup>, D. Uema<sup>9</sup>, V. Wagner<sup>10</sup>, R. Coleman<sup>11</sup>, <sup>1</sup>University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, US, <sup>2</sup>Rambam Medical Center, Haifa, IL, <sup>3</sup>National University Hospital (S) Pte Ltd, Singapore, SG, <sup>4</sup>ICO Institut de Cancerologie de l'Ouest, Saint-Herblain, FR, <sup>5</sup>University of Michigan, Ann Arbor, US, <sup>6</sup>Universitair Ziekenhuis Leuven, Leuven, BE, <sup>7</sup>Centro Integral Oncológico Clara Campal (CIOCC), MADRID, ES, <sup>8</sup>Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO, <sup>9</sup>Bayer HealthCare Pharmaceuticals, Whippany, US, <sup>10</sup>Bayer Consumer Care AG, Basel, CH, <sup>11</sup>Weston Park Hospital - Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, GB

20:55 - 21:15 **183P - Efficacy and Safety of Tenalisib, a PI3K  $\delta/\gamma$  and SIK3 inhibitor in Patients with Locally Advanced or Metastatic Breast Cancer: Initial results from a Phase II study**



T. Makharadze<sup>1</sup>, I. Kiladze<sup>2</sup>, G. Dzagnidze<sup>3</sup>, N. Semionova- Peskova<sup>4</sup>, L. Katselashvili<sup>2</sup>, N. Vekua<sup>5</sup>, K. Routhu<sup>6</sup>, P. Barde<sup>6</sup>, A. Nair<sup>6</sup>, <sup>1</sup>High Technology Hospital Medcenter, Batumi, GE, <sup>2</sup>CMC - Caucasus Medical Centre, Tbilisi, GE, <sup>3</sup>Simon Khechinashvili University Hospital, Tbilisi, GE, <sup>4</sup>LTD High Technology Hospital Medcenter, Batumi, GE, <sup>5</sup>S.Khechinashvili Hospital, Tbilisi, GE, <sup>6</sup>Rhizen Pharmaceuticals AG, Basel, CH

21:15 - 21:35 **184P - Efficacy of adding an immune checkpoint inhibitor to chemotherapy in the first-line treatment of metastatic triple-negative breast cancer: A meta-analysis of randomized controlled trials**

Y. Ergün<sup>1</sup>, Z. Kalkan<sup>2</sup>, S. Ileri<sup>2</sup>, S. Tunc<sup>2</sup>, Z. Urakci<sup>2</sup>, <sup>1</sup>Batman Training and Research Hospital, Batman, TR, <sup>2</sup>Dicle University, Diyarbakir, TR

21:35 - 21:55 **185P - Long Term Efficacy of Trastuzumab Biosimilar CT-P6 in Patients with HER2 Positive Early Breast Cancer: 6-year Survival Analysis of Phase III Study Results**

J. Stebbing<sup>1</sup>, Y. Baranau<sup>2</sup>, V. Baryash<sup>2</sup>, V. Moiseyenko<sup>3</sup>, D. Boliukh<sup>4</sup>, N. Antone<sup>5</sup>, A. Manikhas<sup>6</sup>, A. Chornobai<sup>7</sup>, S.H. Kim<sup>8</sup>, K. Ahn<sup>8</sup>, T. Park<sup>8</sup>, E. Baek<sup>8</sup>, S. Park<sup>8</sup>, S.J. Lee<sup>8</sup>, I.S. Chang<sup>8</sup>, S.H. Kim<sup>8</sup>, J.Y. Lee<sup>8</sup>, J.I. Choi<sup>9</sup>, <sup>1</sup>Editor of Oncogene, London, GB, <sup>2</sup>Minsk City Clinical Cancer Center, Minsk, BY, <sup>3</sup>St. Petersburg Clinical Scientific and Practical Centre of specialized kinds of medical care, Saint-Petersburg, RU, <sup>4</sup>Vinnytsya Regional Clinical Oncology Dispensary, Vinnytsya, UA, <sup>5</sup>IOCN - The Oncology Institute Prof. Dr. Ion Chiricuta, Cluj-Napoca, RO, <sup>6</sup>City Clinical Oncological Dispensary, Saint-Petersburg, RU, <sup>7</sup>Poltava Regional Clinical Oncology Center, Poltava, UA, <sup>8</sup>Celltrion Inc., Incheon, KR, <sup>9</sup>Celltrion Inc, Incheon, KR

21:55 - 22:15 **186P - A Real-World Study on Prevalence of and Outcomes Related to Brain Metastases among Patients with HER2-Positive Metastatic Breast Cancer (mBC)**

J. Collins<sup>1</sup>, D. Varghese<sup>2</sup>, M. Miranda<sup>3</sup>, B. Nordstrom<sup>1</sup>, B. Murphy<sup>1</sup>, D. Harland<sup>3</sup>, <sup>1</sup>Evidera - Waltham, Waltham, US, <sup>2</sup>AstraZeneca Pharmaceuticals, Gaithersburg, US, <sup>3</sup>AstraZeneca Pharmaceuticals, Cambridge, GB

22:15 - 22:35 **187P - Development of a patient-centered core outcome set for metastatic breast cancer**

K. De Ligt<sup>1</sup>, B. De Rooij<sup>2</sup>, E. Hedayati<sup>3</sup>, M. Karsten<sup>4</sup>, V. Smaardijk<sup>2</sup>, M. Velting<sup>5</sup>, C. Saunders<sup>6</sup>, L. Travado<sup>7</sup>, F. Cardoso<sup>7</sup>, E. López Ramírez<sup>8</sup>, N. Carney<sup>9</sup>, Y. Wengstrom<sup>10</sup>, A. Ives<sup>6</sup>, G. Velikova<sup>11</sup>, M.D.L. Sousa Fialho<sup>12</sup>, L. Koppert<sup>13</sup>, L. Van De Poll-Franse<sup>1</sup>, <sup>1</sup>NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, <sup>2</sup>Netherlands Comprehensive Cancer Organization, Utrecht, NL, <sup>3</sup>Karolinska University Hospital and Karolinska Comprehensive Cancer Centre, Solna, SE, <sup>4</sup>Charité - Universitätsmedizin Berlin, Berlin, DE, <sup>5</sup>The Dutch Breast Cancer Association for patients, Utrecht, NL, <sup>6</sup>University of Western Australia, Perth, AU, <sup>7</sup>Champalimaud Foundation - Champalimaud Clinical Center, Lisbon, PT, <sup>8</sup>GenesisCare, Madrid, ES, <sup>9</sup>F.Hoffmann-La Roche Ltd, Basel, CH, <sup>10</sup>Karolinska Institutet, Solna, SE, <sup>11</sup>St. James's University Hospital Leeds, Leeds, GB, <sup>12</sup>International Consortium for Health Outcomes Measurement, Boston, US, <sup>13</sup>Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam, NL

22:35 - 22:55 **188P - Pooled analysis of two phase II randomised studies (NorBreast-231 &**



**TEMPO Breast) evaluating weekly oral vinorelbine (VNR) as first-line chemotherapy in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC)**

L. Collet<sup>1</sup>, G. Freyer<sup>2</sup>, R. Raymond<sup>3</sup>, C. Ta Thanh Minh<sup>3</sup>, M. Aapro<sup>4</sup>, <sup>1</sup>Hospices civils de Lyon, Centre Hospitalier Lyon Sud, Lyon, FR, <sup>2</sup>Lyon Sud Hospital Center - HCL, Pierre Benite, FR, <sup>3</sup>Pierre Fabre Medicament, Boulogne, FR, <sup>4</sup>Clinique de Genolier, Genolier, CH

22:55 - 23:15 **189P - Pharmacokinetics (PK) of Sacituzumab Govitecan (SG) in Patients (Pts) With Metastatic Triple-Negative Breast Cancer (mTNBC) and Other Solid Tumors**

A.G. Sathe<sup>1</sup>, I. Singh<sup>1</sup>, P. Singh<sup>1</sup>, P. Diderichsen<sup>2</sup>, X. Wang<sup>2</sup>, P. Chang<sup>2</sup>, S.-C. Phan<sup>1</sup>, S. Girish<sup>1</sup>, A.A. Othman<sup>1</sup>, <sup>1</sup>Gilead Sciences, Inc, Foster City, US, <sup>2</sup>Certara USA, Inc, Princeton, US

23:15 - 23:35 **190P - Palbociclib treatment in pre/perimenopausal women with advanced/metastatic breast cancer (ABC/mBC): real-world patient characteristics, treatment patterns, and outcomes data from POLARIS**

M. Karuturi<sup>1</sup>, J. Blum<sup>2</sup>, D. Anderson<sup>3</sup>, S. Kurian<sup>4</sup>, S. Wilks<sup>5</sup>, G. Wang<sup>6</sup>, E. Gauthier<sup>7</sup>, Z. Zhang<sup>8</sup>, Y. Wang<sup>9</sup>, D. Tripathy<sup>1</sup>, G. Rocque<sup>10</sup>, <sup>1</sup>The University of Texas MD Anderson Cancer Center, Houston, US, <sup>2</sup>Texas A&M College of Medicine, Dallas, US, <sup>3</sup>Health Partners Institute, Saint Paul, US, <sup>4</sup>West Virginia University, Morgantown, US, <sup>5</sup>Texas Oncology, San Antonio, US, <sup>6</sup>Miami Cancer Institute, Miami, US, <sup>7</sup>Pfizer Inc, San Francisco, US, <sup>8</sup>Pfizer Inc, San Diego, US, <sup>9</sup>Pfizer Inc, New York, US, <sup>10</sup>The University of Alabama at Birmingham, Birmingham, US

23:35 - 23:55 **191P - Radiotherapy (RT) in oligoprogressive metastatic breast cancer (mBC): A retrospective analysis.**

F. Marazzi<sup>1</sup>, A. Orlandi<sup>1</sup>, V. Masiello<sup>1</sup>, T. Zinicola<sup>1</sup>, F. Moschella<sup>2</sup>, A. Palazzo<sup>1</sup>, S. Chiesa<sup>1</sup>, G. Garufi<sup>1</sup>, V. Frascino<sup>1</sup>, L. Tagliaferri<sup>1</sup>, G. Franceschini<sup>2</sup>, A. Fabi<sup>2</sup>, M.A. Gambacorta<sup>1</sup>, E. Bria<sup>1</sup>, R. Masetti<sup>2</sup>, G. Tortora<sup>1</sup>, V. Valentini<sup>1</sup>, <sup>1</sup>Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, <sup>2</sup>Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT

23:55 - 00:15 **192P - Treatment patterns and outcomes of metastatic breast cancer (mBC) patients with HER2 IHC2+/ISH- status in the US**

J. Macewan<sup>1</sup>, E. Scherrer<sup>2</sup>, A. Surinach<sup>1</sup>, Z. Wang<sup>3</sup>, <sup>1</sup>Genesis Research, Hoboken, US, <sup>2</sup>Seagen Inc., Bothell, US, <sup>3</sup>Seattle Genetics Inc, Bothell, US

00:15 - 00:35 **193P - A national retrospective multicentre audit of long term trastuzumab use in metastatic breast cancer: Breast Cancer Trainees Collaborative Group**

T. McCartney<sup>1</sup>, P. Closier<sup>2</sup>, N. Chopra<sup>3</sup>, P. Gallagher<sup>4</sup>, A. Jenner<sup>5</sup>, F. Mark<sup>6</sup>, T. Robinson<sup>7</sup>, E. Copson<sup>8</sup>, <sup>1</sup>Belfast City Hospital - Belfast Health & Social Care Trust, Belfast, GB, <sup>2</sup>University Hospitals Bristol NHS Foundation Trust, Bristol, GB, <sup>3</sup>Royal Free Hospital School of Medicine, London, GB, <sup>4</sup>Northern Ireland Cancer Centre - Belfast Health & Social Care Trust, Belfast, GB, <sup>5</sup>Royal United Hospital Bath, Bath, GB, <sup>6</sup>University Hospital Plymouth NHS Trust, Plymouth, GB, <sup>7</sup>Bristol Haematology and Oncology Centre - NHS Foundation Trust, Bristol, GB, <sup>8</sup>Southampton General Hospital, Southampton, GB

- 00:35 - 00:55 **194P - Increased Blood Creatinine Level Due to CDK 4/6 Inhibitor Treatments; Single Center Experience**  
M. Keskin<sup>1</sup>, H. Semiz<sup>2</sup>, T. Yavuzsen<sup>2</sup>, A. Karaoglu<sup>3</sup>, <sup>1</sup>Dokuz Eylul University Faculty of Medicine, Izmir, TR, <sup>2</sup>Dokuz Eylul University School of Medicine - Institute of Oncology, Izmir, TR, <sup>3</sup>Dokuz Eylul University - Faculty of Medicine, Izmir, TR
- 00:55 - 01:15 **195P - REACH AUT: Efficacy and safety of first line (1L) ribociclib (RIB) + endocrine therapy (ET) in HR+, HER2- metastatic breast cancer (MBC) from a real-world (RW) study - 3rd interim analysis**  
C. Singer<sup>1</sup>, D. Egle<sup>2</sup>, R. Greil<sup>3</sup>, E. Petru<sup>4</sup>, L. Ohler<sup>5</sup>, M. Balic<sup>4</sup>, C. Tinchon<sup>6</sup>, G. Pfeiler<sup>1</sup>, M. Marhold<sup>1</sup>, C. Brunner<sup>2</sup>, K. Haider<sup>7</sup>, A. Galid<sup>8</sup>, U. Pluschnig<sup>9</sup>, F. Haslbauer<sup>10</sup>, M. Hubalek<sup>11</sup>, A. Redl<sup>12</sup>, J. Flatschacher<sup>13</sup>, S. Uthman<sup>13</sup>, B. Mraz<sup>13</sup>, R. Bartsch<sup>1</sup>, <sup>1</sup>Medical University of Vienna, Vienna, AT, <sup>2</sup>Medical University of Innsbruck, Innsbruck, AT, <sup>3</sup>Oncologic Center, Paracelsus Medical University, Salzburg, Center for Clinical Cancer and Immunology Trials, Salzburg Cancer Research Institute, Cancer Cluster Salzburg, Salzburg, AT, <sup>4</sup>Medical University of Graz, Graz, AT, <sup>5</sup>St Joseph Hospital, Vienna, AT, <sup>6</sup>Leoben State Hospital, Leoben, AT, <sup>7</sup>State Hospital Wiener Neustadt, Wiener Neustadt, AT, <sup>8</sup>Breast Center Hanusch KH, Vienna, AT, <sup>9</sup>Klinikum Klagenfurt, Klagenfurt, AT, <sup>10</sup>Salzkammergut Klinikum Vöcklabruck, Vöcklabruck, AT, <sup>11</sup>Brustzentrum Schwaz, Schwaz, AT, <sup>12</sup>Datamedrix GmbH, Vienna, AT, <sup>13</sup>Novartis Pharma GmbH, Vienna, AT
- 01:15 - 01:35 **196P - Final analysis of PUFFIN: A Phase III, randomised double-blind, placebo (Pla)-controlled study of pertuzumab, trastuzumab and docetaxel (PHD) for Chinese patients (pts) with previously untreated HER2-positive locally recurrent or metastatic breast cancer (LR/MBC)**  
B. Xu<sup>1</sup>, W. Li<sup>2</sup>, Q. Zhang<sup>3</sup>, Q. Li<sup>1</sup>, X. Wang<sup>4</sup>, H. Li<sup>5</sup>, T. Sun<sup>6</sup>, Y. Yin<sup>7</sup>, H. Zheng<sup>8</sup>, J. Feng<sup>9</sup>, H. Zhu<sup>10</sup>, A. Siddiqui<sup>11</sup>, H. Macharia<sup>12</sup>, A. Knott<sup>11</sup>, <sup>1</sup>Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN, <sup>2</sup>The First Hospital of Jilin University, Changchun, CN, <sup>3</sup>Harbin Medical University Cancer Hospital, Harbin, CN, <sup>4</sup>Zhejiang Cancer Hospital - Cancer Research Institute, Hangzhou, CN, <sup>5</sup>Peking University Cancer Hospital and Institute, Beijing, CN, <sup>6</sup>Liaoning Cancer Hospital & Institute, Shenyang, CN, <sup>7</sup>Jiangsu Province Hospital - The First Affiliated Hospital with Nanjing Medical University, Nanjing, CN, <sup>8</sup>West China Medical Center of Sichuan University, Chengdu, CN, <sup>9</sup>Jiangsu Cancer Hospital, Nanjing, CN, <sup>10</sup>Shanghai Roche Pharmaceuticals Ltd, Shanghai, CN, <sup>11</sup>Roche Products Limited, Welwyn Garden City, GB, <sup>12</sup>F. Hoffmann-La Roche AG, Basel, CH
- 01:35 - 01:55 **197P - Current treatment landscape of HR+/HER2- advanced breast cancer in the Nordics: A modified Delphi study**  
P. Karihtala<sup>1</sup>, A. Valachis<sup>2</sup>, M. Tuxen<sup>3</sup>, J. Geisler<sup>4</sup>, <sup>1</sup>Helsinki University Central Hospital, Helsinki, FI, <sup>2</sup>Örebro University Hospital, Örebro, SE, <sup>3</sup>Herlev and Gentofte Hospital, Herlev, DK, <sup>4</sup>Akershus universitetssykehus HF, Lorenskog, NO
- 01:55 - 02:15 **198P - Cerebrospinal fluid immune cell profiling in patients with metastatic breast cancer and leptomeningeal disease**  
L. Huppert<sup>1</sup>, K. (Chris) Im<sup>2</sup>, A. Combes<sup>2</sup>, H. Rugo<sup>1</sup>, M. Krummel<sup>2</sup>, M. Melisko<sup>1</sup>, <sup>1</sup>UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, <sup>2</sup>UCSF -

University of California San Francisco, San Francisco, US

- 02:15 - 02:35 **199P - Advanced breast cancer patient involvement in the evaluation of an available on-line exercise program for use in a future clinical trial.**  
C. Harper-Wynne<sup>1</sup>, J. Glendenning<sup>2</sup>, G. Davison<sup>3</sup>, <sup>1</sup>Kent Oncology Centre- Maidstone & Tunbridge NHS Trust, Maidstone, GB, <sup>2</sup>Kent Oncology Centre- East Kent Hospitals University Trust, Canterbury, GB, <sup>3</sup>University of Kent, Canterbury, GB
- 02:35 - 02:55 **200P - Increased of vertebral fractures in patients with metastatic breast cancer treated with endocrine therapy combined with CDK 4/6 inhibitor.**  
L. Lorini<sup>1</sup>, E. Conforti<sup>1</sup>, M. Frigerio<sup>2</sup>, L. Laini<sup>1</sup>, V. Amoroso<sup>1</sup>, A. Alberti<sup>1</sup>, G. Schivardi<sup>1</sup>, P. Di Mauro<sup>1</sup>, D. Cosentini<sup>1</sup>, L. Vassalli<sup>1</sup>, V. Cremaschi<sup>1</sup>, A. Esposito<sup>1</sup>, E. Simoncini<sup>3</sup>, R. Gasparotti<sup>2</sup>, A. Berruti<sup>1</sup>, R. Pedersini<sup>1</sup>, <sup>1</sup>ASST Spedali Civili / University of Brescia, Brescia, IT, <sup>2</sup>ASST Spedali Civili di Brescia, Brescia, IT, <sup>3</sup>ASST Spedali Civili of Brescia, Brescia, IT
- 02:55 - 03:15 **201P - Metastatic and survival characteristics of de novo versus replaced breast cancer in female aged>35-year-old: A nationwide multicenter study based on hospital population.**  
J. Zhang<sup>1</sup>, J. Wang<sup>2</sup>, J. Fan<sup>1</sup>, B. Xu<sup>1</sup>, Y. Qiao<sup>1</sup>, <sup>1</sup>Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN, <sup>2</sup>Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CAMS), Beijing, CN
- 03:15 - 03:35 **202P - Abemaciclib in HR+/Her2- metastatic breast cancer patients after previous progression on palbociclib or ribociclib: clinical experience in a tertiary hospital in Madrid, Spain.**  
A. De Luna Aguilar, F. Moreno Anton, J.D. Benitez Fuentes, J. Ortega Anselmi, J. Olalla Inoa, P. Flores Navarro, J.Á. García Saenz, Hospital Clinico Universitario San Carlos, Madrid, ES
- 03:35 - 03:55 **203P - Curative treatment outcomes in metaplastic breast cancer**  
L.F.N. Yit<sup>1</sup>, S.Z.H. Quek<sup>1</sup>, F.Y. Wong<sup>1</sup>, P.H. Tan<sup>2</sup>, B. Tan<sup>3</sup>, Y. Sim<sup>1</sup>, B.F. Tan<sup>1</sup>, R.X. Wong<sup>1</sup>, T. Tan<sup>1</sup>, <sup>1</sup>NCCS - National Cancer Centre Singapore, Singapore, SG, <sup>2</sup>SGH - Singapore General Hospital, Singapore, SG, <sup>3</sup>SGH-Singapore General Hospital/Singhealth-Academia, Singapore, SG
- 03:55 - 04:15 **204TiP - A Phase II Study of HER3-DXD in Patients (pts) with Metastatic Breast Cancer (MBC)**  
E. Hamilton<sup>1</sup>, N. Bagegni<sup>2</sup>, J. Beck<sup>3</sup>, J. Cultrera<sup>4</sup>, O. Dosunmu<sup>5</sup>, W. Gwin<sup>6</sup>, A. Heeke<sup>7</sup>, K. Khoury<sup>8</sup>, D. Sellami<sup>9</sup>, M. Shastry<sup>5</sup>, D. Sternberg<sup>9</sup>, D. Toppmeyer<sup>10</sup>, V. Wright-Browne<sup>11</sup>, Y. Yuan<sup>12</sup>, <sup>1</sup>Sarah Cannon Research Institute-Cancer Centre, Nashville, US, <sup>2</sup>Center for Advanced Medicine, St. Louis, US, <sup>3</sup>Highlands Oncology, Springdale, US, <sup>4</sup>Florida Cancer Specialists North, The Villages, US, <sup>5</sup>Sarah Cannon Research Institute, Nashville, US, <sup>6</sup>Cancer Vaccine Institute University of Washington, Seattle, US, <sup>7</sup>Levine Cancer Institute Morehead, Charlotte, US, <sup>8</sup>O'Neal Comprehensive Cancer Center at the University of Alabama, Birmingham, US, <sup>9</sup>Daiichi Sankyo Inc., Basking Ridge, US, <sup>10</sup>Rutgers Cancer Institute of New Jersey, New Brunswick, US, <sup>11</sup>Florida Cancer Specialists, Port Charlotte,



US, <sup>12</sup>City of Hope, Duarte, US

04:15 - 04:35

**205TiP - ATRACTIB: A Phase 2 Trial of First-Line (1L) Atezolizumab (A) in Combination with Paclitaxel (P) and Bevacizumab (B) in Metastatic Triple-Negative Breast Cancer (mTNBC)**

A. Cortés Salgado<sup>1</sup>, J.M. Perez Garcia<sup>2</sup>, S.P. Cortez Castedo<sup>3</sup>, M. Gion Cortes<sup>4</sup>, S. Morales Murillo<sup>5</sup>, I. Blancas López-Barajas<sup>6</sup>, S. Blanch<sup>7</sup>, I. Calvo Plaza<sup>8</sup>, N. Diaz Fernandez<sup>9</sup>, F. Marmé<sup>10</sup>, A. Martinez Bueno<sup>11</sup>, M.T. Taberner Bonastre<sup>12</sup>, M. De Laurentiis<sup>13</sup>, M. Ruiz Borrego<sup>14</sup>, P. Schmid<sup>15</sup>, V. Guarneri<sup>16</sup>, J. Gligorov<sup>17</sup>, M. Sampayo-Cordero<sup>18</sup>, A. Llombart Cussac<sup>19</sup>, J. Cortés<sup>20</sup>, <sup>1</sup>Hospital Universitario Ramón y Cajal, Madrid, ES, <sup>2</sup>International Breast Cancer Center (IBCC), Quiron Group, Barcelona, ES, <sup>3</sup>Complejo Hospitalario Ruber Juan Bravo, Madrid, ES, <sup>4</sup>Hospital Universitario Ramon y Cajal, Madrid, ES, <sup>5</sup>Hospital Arnau de Vilanova - Lleida, Alpicat, ES, <sup>6</sup>Hospital Clinico San Cecilio, Granada, ES, <sup>7</sup>IVO - Fundación Instituto Valenciano de Oncología, Valencia, ES, <sup>8</sup>MD Anderson Cancer Center, Madrid, ES, <sup>9</sup>Hospital General Universitario de Alicante, Alicante, ES, <sup>10</sup>UMM - Universitaetsklinikum Mannheim - Medizinische Fakultät, Mannheim, DE, <sup>11</sup>11. Hospital Quirón-Deixeus, Barcelona, ES, <sup>12</sup>12. La Ribera de Alzira University Hospital, Valencia, ES, <sup>13</sup>Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, <sup>14</sup>Hospital Universitario Virgen del Rocío, Seville, ES, <sup>15</sup>Barts Cancer Institute-Queen Mary University of London, London, GB, <sup>16</sup>University of Padua, Padova, IT, <sup>17</sup>Institut Universitaire de Cancérologie AP-HP. Sorbonne Université, Hôpital Tenon, Paris, FR, <sup>18</sup>Medica Scientia Innovation Research (MEDSIR), Barcelona, ES, <sup>19</sup>Hospital Arnau de Vilanova, Valencia, ES, <sup>20</sup>International Breast Cancer Center (IBCC), Quiron Group, Barcelona, Spain; Medica Scientia Innovation Research (MEDSIR), Barcelona, ES

04:35 - 04:55

**206TiP - Randomized, Multicenter, International Phase 3 ARTEST Study to Evaluate Enobosarm Versus Active Control for the Treatment of AR+ ER+ HER2-Metastatic Breast Cancer in Patients Who Previously Received an Estrogen Blocking Agent and a CDK 4/6 inhibitor**

A. Brufsky<sup>1</sup>, H. Linden<sup>2</sup>, H. Rugo<sup>3</sup>, C. Vogel<sup>4</sup>, J. O'Shaughnessy<sup>5</sup>, R. Getzenberg<sup>6</sup>, K.G. Barnette<sup>6</sup>, D. Rodriguez<sup>6</sup>, M. Steiner<sup>6</sup>, E. Mayer<sup>7</sup>, <sup>1</sup>UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, US, <sup>2</sup>University of Washington Seattle Cancer Care Alliance, Seattle, US, <sup>3</sup>UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, <sup>4</sup>Miami Cancer Institute - Baptist Health South Florida, Miami, US, <sup>5</sup>Texas Oncology - Baylor Sammons Cancer Center, Dallas, US, <sup>6</sup>Veru Inc., Miami, US, <sup>7</sup>Dana Farber Cancer Institute, Boston, US

04:55 - 05:15

**207TiP - Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress)**

V. Dieras<sup>1</sup>, M. Martin Jimenez<sup>2</sup>, C. O'Sullivan<sup>3</sup>, J. Sohn<sup>4</sup>, K. Tryfonidis<sup>5</sup>, L. Santarpia<sup>6</sup>, S. Yang<sup>6</sup>, E. Hamilton<sup>7</sup>, <sup>1</sup>Eugene Marquis Centre, Rennes, FR, <sup>2</sup>Hospital General Universitario Gregorio Marañón, Madrid, ES, <sup>3</sup>Mayo Clinic, Rochester, US, <sup>4</sup>Yonsei Cancer Center, Seoul, KR, <sup>5</sup>Merck, North Wales, US, <sup>6</sup>Seagen Inc., Bothell, US, <sup>7</sup>Sarah Cannon Research Institute at Tennessee Oncology, Nashville, US

05:15 - 05:35

**208TiP - SOLTI-1303 PATRICIA: Cohort C. Combination of palbociclib with trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in pretreated HER2-positive and hormone receptor-positive (HER2+/HR+) / PAM50 luminal metastatic breast cancer (BC): A randomized phase II trial**



E. Ciruelos<sup>1</sup>, J. Ponce<sup>2</sup>, S. Pernas Simon<sup>3</sup>, J. Cortés<sup>4</sup>, B. Cantos<sup>5</sup>, E. Garate<sup>6</sup>, E. Vega Alonso<sup>7</sup>, M. Mele Olive<sup>8</sup>, E. Martinez De Dueñas<sup>9</sup>, A. Montaña Perianez<sup>10</sup>, N. Martinez<sup>11</sup>, A. Perello Martorell<sup>12</sup>, B. Bermejo De Las Heras<sup>13</sup>, C. Arqueros Nunez<sup>14</sup>, I. Fernández<sup>15</sup>, J. De La Haba Rodriguez<sup>16</sup>, M. Oliveira<sup>17</sup>, X. González<sup>18</sup>, P. Villagrasa Gonzalez<sup>19</sup>, A. Prat<sup>20</sup>, <sup>1</sup>Hospital Universitario 12 de Octubre / SOLTI Cancer Research Group, Madrid / Barcelona, ES, <sup>2</sup>Hospital General Universitario de Alicante, Alicante, ES, <sup>3</sup>ICO - Institut Català d'Oncologia / SOLTI Cancer Research Group, L'Hospitalet de Llobregat / Barcelona, ES, <sup>4</sup>International Breast Cancer Center (IBCC), Quiron Group, Madrid & Barcelona, ES, <sup>5</sup>University Hospital Puerta de Hierro, Majadahonda (Madrid), ES, <sup>6</sup>Hospital Universitario de Basurto, Bilbao, ES, <sup>7</sup>Centro Integral Oncológico Clara Campal (CIOCC), MADRID, ES, <sup>8</sup>Hospital Universitari Sant Joan de Reus, Reus, ES, <sup>9</sup>Hospital Provincial Castellon, Castellon de la Plana, ES, <sup>10</sup>Hospital Universitario Virgen del Rocío, Seville, ES, <sup>11</sup>Hospital Universitario Ramon y Cajal, Madrid, ES, <sup>12</sup>Hospital Universitario Son Espases, Palma de Mallorca, ES, <sup>13</sup>Hospital Clinico Universitario de Valencia, Valencia, ES, <sup>14</sup>Hospital de la Santa Creu i Sant Pau, Barcelona, ES, <sup>15</sup>Hospital Alvaro Cunqueiro, Vigo, ES, <sup>16</sup>Hospital Universitario Reina Sofía, Cordoba, ES, <sup>17</sup>Vall d'Hebron Institute of Oncology / Vall d' Hebron University Hospital / SOLTI Cancer Research Group, Barcelona / Barcelona / Barcelona, ES, <sup>18</sup>IOR - Instituto Oncologico Dr. Rosell / Hospital General de Catalunya / SOLTI Cancer Research Group Hospital General de Catalunya, Barcelona / Sant Cugat del Vallés / Barcelona, ES, <sup>19</sup>Reveal Genomics / SOLTI Cancer Research Group, Barcelona / Barcelona, ES, <sup>20</sup>Hospital Clínic de Barcelona / SOLTI Cancer Research Group, Barcelona / Barcelona, ES

05:35 - 05:55

**250TiP - HER2-positive and HER2-low Breast Cancer Patients in the ACE-Pan tumor-01 study: Phase 1 Study evaluating ARX788 as Monotherapy in Advanced Solid Tumors with HER2-expression or mutation**

J. Lu<sup>1</sup>, G.T. Budd<sup>2</sup>, S. Frentzas<sup>3</sup>, H. Park<sup>4</sup>, C. Shannon<sup>5</sup>, H. Rugo<sup>6</sup>, J. O'Shaughnessy<sup>7</sup>, A. Demichele<sup>8</sup>, S. Tolaney<sup>9</sup>, R. Eek<sup>10</sup>, A. McCartney<sup>11</sup>, K. Cuff<sup>12</sup>, L. Esserman<sup>6</sup>, A. Aliko<sup>13</sup>, D. Xu<sup>13</sup>, M. Li<sup>13</sup>, T. Le<sup>13</sup>, D. L'Heureux<sup>13</sup>, J. Yan<sup>13</sup>, S. Hurvitz<sup>14</sup>, <sup>1</sup>USC - University of Southern California - Norris Comprehensive Cancer Center, Los Angeles, US, <sup>2</sup>Case Western Reserve University / University Hospitals, Cleveland, US, <sup>3</sup>Monash Health - Monash Cancer Centre, Bentleigh East, AU, <sup>4</sup>Washington University School of Medicine, St. Louis, US, <sup>5</sup>Mater Adult Hospital, Brisbane, AU, <sup>6</sup>UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, <sup>7</sup>Texas Oncology - Baylor Sammons Cancer Center, Dallas, US, <sup>8</sup>Abramson Cancer Center, University of Pennsylvania, Philadelphia, US, <sup>9</sup>Dana Farber Cancer Institute, Boston, US, <sup>10</sup>Border Medical Oncology Murray Valley Private Hospital, Wodonga, AU, <sup>11</sup>Monash Health - Monash Medical Centre, Clayton, AU, <sup>12</sup>Princess Alexandra Hospital, Brisbane, AU, <sup>13</sup>Ambrx, Inc., La Jolla, US, <sup>14</sup>UCLA Hematology/Oncology Santa Monica, Santa Monica, US

05:55 - 06:15

**Supportive care and survivorship**

06:15 - 06:35

**209P - Clinically Relevant Impact of Persistent Peripheral Neuropathy on Health-Related Quality of Life among Early-Stage Breast Cancer Survivors: A Population-Based Study**

K. Engvall<sup>1</sup>, H. Green<sup>2</sup>, M. Lagerlund<sup>3</sup>, F. Lewin<sup>1</sup>, M. Fredriksson<sup>2</sup>, E. Avall-Lundqvist<sup>2</sup>, <sup>1</sup>Linköping University, Jönköping, SE, <sup>2</sup>Linköping University, Linköping, SE, <sup>3</sup>Kalmar County Hospital, Kalmar, SE

- 06:35 - 06:55 **210P - Worsening of breast cancer patients' condition: what happened during Covid-19?, A meta-analysis.**  
M. Nagy, S. Abdel Mawgoud, Ain Shams University - Faculty of Medicine, Cairo, EG
- 06:55 - 07:15 **211P - Assessment of the financial toxicity after oncological treatment in patients with breast cancer in private oncological reference institutions in Brazil.**  
A. Vieira<sup>1</sup>, M. Costa E Silva<sup>2</sup>, F. Bittencourt<sup>1</sup>, R. Dienstmann<sup>2</sup>, C. Souza<sup>3</sup>, L. Landeiro<sup>4</sup>, M. Mano<sup>2</sup>, <sup>1</sup>Oncoclinicas Curitiba, Curitiba, BR, <sup>2</sup>Grupo Oncoclinicas, Sao Paulo, BR, <sup>3</sup>Hospital de Amor (Hospital De Cancer De Barretos) - Fundacao Pio XII, Barretos, BR, <sup>4</sup>Nucleo de Oncologia da Bahia-nob, Salvador, BR
- 07:15 - 07:35 **212P - A Cohort study on the Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Breast Cancer; Does Trastuzumab Interfere with the Outcome?**  
S.A. Javadinia<sup>1</sup>, M. Dehghani<sup>2</sup>, M. Ariamanesh<sup>2</sup>, Z. Roudsarabi<sup>1</sup>, <sup>1</sup>Vasei Hospital, Sabzevar University of Medical Sciences, Sabzevar, IR, <sup>2</sup>Hakim Hospital, Neyshabur University of Medical Sciences, Neyshabur, IR
- 07:35 - 07:55 **213P - Photobiomodulation therapy for the management of chemotherapy-induced alopecia: preliminary results of a randomized, controlled trial**  
J. Lodewijckx<sup>1</sup>, J. Robijns<sup>1</sup>, M. Claes<sup>1</sup>, J. Mebis<sup>2</sup>, <sup>1</sup>Hasselt University, Hasselt, BE, <sup>2</sup>Jesse Ziekenhuis - Campus Virga Jesse, Hasselt, BE
- 07:55 - 08:15 **214P - Obstetric complications at time of delivery amongst breast cancer survivors: a population-based cohort study**  
O. Kaidar-Person<sup>1</sup>, R. Yoeli-Ullman<sup>2</sup>, N. Pillar<sup>3</sup>, S. Paluch-Shimon<sup>3</sup>, P. Poortmans<sup>4</sup>, Y. Lawrence<sup>2</sup>, <sup>1</sup>Sheba Medical Center, TEL HASHOMER, IL, <sup>2</sup>Sheba Medical Center, Ramat Gan, IL, <sup>3</sup>Hadassa, Jerusalem, IL, <sup>4</sup>AZ Sint-Augustinus - Oncologisch Centrum GZA - Iridium Kankernetwerk, Antwerpen, BE
- 08:15 - 08:35 **215P - Analysis of factors impacting the outcome in Young Breast Cancers in Low middle-income countries**  
P. Iyer, Cancer Institute Adyar Chennai, CHENNAI, IN
- 08:35 - 08:55 **216P - Socio-economic burden of disease: survivorship costs for breast cancer**  
J. Michaeli<sup>1</sup>, T. Michaeli<sup>2</sup>, T. Boch<sup>2</sup>, S. Albers<sup>2</sup>, D. Michaeli<sup>2</sup>, <sup>1</sup>Asklepios-Clinic Hamburg-Altona, Asklepios Hospital Group, Hamburg, DE, <sup>2</sup>Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, DE
- 08:55 - 09:15 **217P - Maintenance of physical activity after exercise interventions: A systematic review and meta-analysis**  
S. Goldschmidt<sup>1</sup>, M. Schmidt<sup>2</sup>, K. Steindorf<sup>2</sup>, <sup>1</sup>DKFZ - German Cancer Research Center and Medical Faculty of the University of Heidelberg, Heidelberg, DE, <sup>2</sup>German Cancer Research Center - National Center for Tumor Diseases (NCT), Heidelberg, DE

- 09:15 - 09:35 **218P - Fear of cancer recurrence in long-term post-menopausal breast cancer survivors**  
A.-D. Bouhnik<sup>1</sup>, C. Magnani<sup>2</sup>, A. Smith<sup>3</sup>, D. Rey<sup>4</sup>, A. Sarradon-Eck<sup>1</sup>, M. Bendiane<sup>5</sup>, J. Mancini<sup>5</sup>, <sup>1</sup>SESSTIM Sciences Economiques et Sociales de la Sante & Traitement de l'Information Medicale, Marseille, FR, <sup>2</sup>Aix-Marseille University - Faculté de Médecine - Timone, Marseille, FR, <sup>3</sup>Ingham Institute for Applied Medical Research - Western Sydney University, Liverpool, AU, <sup>4</sup>SESSTIM-INSERM UMR1252- IRD - AMU, Marseille, FR, <sup>5</sup>UMR 1252 SESSTIM AMU, INSERM, IRD, Marseille, FR
- 09:35 - 09:55 **219P - Bone Mineral Density screening and monitoring in Early Breast Cancer patients treated with Aromatase Inhibitors.**  
S. Gilani, N. Ikram, Royal Stoke University Hospital, Stoke-on-Trent, GB
- 09:55 - 10:15 **220P - Distant disease free survival according to different subtypes in young breast cancer patients (YBCP)**  
B. Cantos, M. Mendez Garcia, J.C. Sanchez Gonzalez, B. Nuñez Garcia, M. Blanco Clemente, C. Traseira Puchol, R. Aguado, A. Royuela, S. Gonzalez Gonzalez, M. Provencio Pulla, University Hospital Puerta de Hierro Majadahonda, Majadahonda, ES
- 10:15 - 10:35 **221P - Primary and Secondary Breast Sarcoma: Clinical and Pathological Characteristics, Prognostic Factors and Nomograms for Predicting Survival**  
S. Fala, Suez Canal University - Faculty of Medicine, Ismailia, EG
- 10:35 - 10:55 **222P - Is quality of life (QoL) during chemotherapy affected by body composition?**  
M. Pavlovic Mavic, R. Separovic, L. Vazdar, A. Tecic Vuger, P. Lepetic, P. Linaric, University Hospital for Tumors, University Hospital Center Sestre Milosrdnice, Zagreb, HR
- 10:55 - 11:15 **223P - Implementing an Exercise Oncology Program for Breast Cancer Patients in Brazil: the Maple Tree Cancer Alliance Experience**  
A. Francisco, J. Brito, O. Machado, J.L. Moura, K. Wonders, Maple Tree Cancer Alliance, Sorocaba, BR
- 11:15 - 11:35 **224P - Adherence to adjuvant hormonal therapy in patients with localized breast cancer**  
I. Voutsadakis<sup>1</sup>, S. Davies<sup>2</sup>, <sup>1</sup>Sault Area Hospital, Sault Sainte Ma, CA, <sup>2</sup>NOSM - Northern Ontario School of Medicine, Thunder Bay, CA
- 11:35 - 11:55 **225P - Impact of potential drug-drug interactions (PDDI) on adherence to endocrine therapy (ET) among patients with breast cancer (BC) in the Health Improvement Network (THIN)**  
E. Rassy<sup>1</sup>, A. Bardet<sup>1</sup>, O. Bougacha<sup>2</sup>, L. Gantzer<sup>2</sup>, B. Lekens<sup>2</sup>, I. Luis<sup>1</sup>, S. Delalogue<sup>1</sup>, F. André<sup>1</sup>, S. Michiels<sup>1</sup>, B. Pistilli<sup>1</sup>, <sup>1</sup>Institut Gustave Roussy, Villejuif, FR, <sup>2</sup>CEGEDIM R&D, Paris, FR
- 11:55 - 12:15 **226P - Cancer Supportive care model in a developing country -An online delivery program**

P.P. Bapsy<sup>1</sup>, S. Ravi<sup>2</sup>, A. Sadanandan<sup>1</sup>, <sup>1</sup>Apollo Hospitals Bannerghatta, Bangalore, IN, <sup>2</sup>Prameya Health Pvt Ltd, BANGALORE, IN

- 12:15 - 12:35 **227P - Development of a novel free-to-use software for upper limb volume assessment in breast cancer related lymphedema: integrating an augmented reality tool in the complex management of breast cancer survivors**  
L. Lippi<sup>1</sup>, M. Nascinben<sup>1</sup>, A. De Sire<sup>2</sup>, A. Folli<sup>1</sup>, N. Fusco<sup>3</sup>, L. Rimondini<sup>1</sup>, M. Invernizzi<sup>1</sup>, <sup>1</sup>University of Eastern Piedmont "A. Avogadro", Novara, IT, <sup>2</sup>University of Catanzaro "Magna Graecia", Catanzaro, IT, <sup>3</sup>IEO - Istituto Europeo di Oncologia, Milan, IT
- 12:35 - 12:55 **228P - Association between chemotherapy toxicities and financial problems in the first three cycles of chemotherapy breast cancer patients.**  
A. Kurniawan<sup>1</sup>, N. Sutandyo<sup>2</sup>, S.S. Panigoro<sup>3</sup>, <sup>1</sup>Faculty of Medicine, Pelita Harapan University, Tangerang, ID, <sup>2</sup>Dharmais Hospital National Cancer Center, Jakarta, ID, <sup>3</sup>RS Umum Pusat Nasional Dr Cipto Mangunkusumo, Jakarta, ID
- 12:55 - 13:15 **229P - Efficiency of SARS-CoV-2 vaccines in breast cancer patients - single institutional experience from Institute for Oncology and Radiology of Serbia (IORS)**  
O. Djurmez, M. Calamac, M. Dimitrijevic, J. Vukosavljevic, K. Serovic, J. Oblakovic-Babic, N. Stanic, I. Minic, Z. Tomasevic, I. Bozovic Spasojevic, Institute for Oncology and Radiology of Serbia, Belgrade, RS
- 13:15 - 13:35 **230P - A digital therapeutic intervention for breast cancer patients during active treatment: a feasibility study.**  
G.E. Thorvardardottir<sup>1</sup>, H. Gudmundsson<sup>2</sup>, J. Mészáros<sup>3</sup>, A.E. Bjornsdottir<sup>2</sup>, M.L. Amundadottir<sup>2</sup>, O. Bjarnadottir<sup>4</sup>, E. Magnusdottir<sup>1</sup>, H. Helgadottir<sup>2</sup>, S. Oddsson<sup>2</sup>, <sup>1</sup>Ljósið - Cancer Rehabilitation Centre, Reykjavik, IS, <sup>2</sup>Sidekick Health, Kópavogur, IS, <sup>3</sup>Sidekick Health, Berlin, DE, <sup>4</sup>The National University Hospital of Iceland - Landspítali, Reykjavik, IS
- 13:35 - 13:55 **231P - Body Image dissatisfaction among tunisian young women in post treatment of breast cancer**  
R. Zanzouri, S. Tbessi, H. Haj Abdallah, S. Kanoun Belajouza, N. Bouzid, S. Tebra, CHU Farhat Hached, Sousse, TN
- 13:55 - 14:15 **232TiP - Early acupuncture treatment of vasomotor symptoms and sleep disorders in Breast Cancer LHRHa induced menopause: AcuFLASH Study**  
A. Fabi<sup>1</sup>, C. Maggiore<sup>1</sup>, A. Di Micco<sup>1</sup>, M.M. Rossi<sup>1</sup>, A. Filippone<sup>1</sup>, C. Rossi<sup>1</sup>, L. Forcina<sup>1</sup>, D. Giannarelli<sup>2</sup>, R. Masetti<sup>1</sup>, S. Magno<sup>1</sup>, <sup>1</sup>Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT, <sup>2</sup>Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, IT
- 14:15 - 14:35 **General interest**
- 14:35 - 14:55 **233P - Breast Cancer Organoids Mimic Disease Heterogeneity, Allow High-**



**Throughput Drug Screening and Show Correlation with Clinical Outcomes**

Z. Dantes<sup>1</sup>, A. Manjunath<sup>1</sup>, L. Ferreira<sup>1</sup>, J. Slawska<sup>1</sup>, K. Steiger<sup>2</sup>, N. Pfarr<sup>2</sup>, K. Bernlochner<sup>1</sup>, B. Hefel<sup>1</sup>, L. Huang<sup>3</sup>, M. Jesinghaus<sup>2</sup>, R. Rosell<sup>4</sup>, M. Kiechle<sup>2</sup>, M. Dantes<sup>5</sup>, K. Lindner<sup>1</sup>, C. Peschel<sup>6</sup>, W. Weichert<sup>2</sup>, S. Paepke<sup>2</sup>, <sup>1</sup>Invitrocue Europe AG, Munich, DE, <sup>2</sup>Technical University of Munich, Munich, DE, <sup>3</sup>Invitrocue Hong Kong Ltd, Hong Kong, CN, <sup>4</sup>HUGTP - Hospital Universitario Germans Trias i Pujol, Badalona, ES, <sup>5</sup>University Hospital LMU Munich, Munich, DE, <sup>6</sup>TUM, Munich, DE

14:55 - 15:15

**234P - Equivalence of NGS-based MammaPrint 70-gene signature risk of recurrence and Blueprint 80-gene signature of molecular subtyping tests to the centralized microarray tests**

E. Schuler<sup>1</sup>, S. Uygun<sup>2</sup>, L. Mittempergher<sup>3</sup>, S. Mee<sup>2</sup>, A. Witteveen<sup>3</sup>, A. Glas<sup>3</sup>, <sup>1</sup>ZOTZ | KLIMAS MVZ Düsseldorf-Centrum GbR, Düsseldorf, DE, <sup>2</sup>Agendia Inc., Irvine, US, <sup>3</sup>Agendia N.V, Amsterdam, NL

15:15 - 15:35

**235P - Resumption of menses (ROM), Fertility status perception and pregnancy desire in young breast cancer survivors: A real-world data survey**

K. Salas Espinoza<sup>1</sup>, K.M. Roque Perez<sup>2</sup>, Z. Morante Cruz<sup>2</sup>, G. Valencia Mesias<sup>2</sup>, P. Rioja Viera<sup>2</sup>, H. Fuentes<sup>2</sup>, S. Neciosup Delgado<sup>2</sup>, J.M.M. Cotrina Concha<sup>2</sup>, H. Gomez Moreno<sup>2</sup>, <sup>1</sup>Universidad Peruana Cayetano Heredia-North Campus, Lima, PE, <sup>2</sup>INEN - Instituto Nacional de Enfermedades Neoplásicas, Lima, PE

15:35 - 15:55

**236P - Predicting Oncotype DX recurrence scores using clinicopathologic features: Tennessee University Nomogram: an external validation.**

F. Pikabea Díaz<sup>1</sup>, E. Galve Calvo<sup>2</sup>, A. Zumarraga<sup>2</sup>, C. Figaredo Bejarano<sup>2</sup>, M.A. Sala Gonzalez<sup>2</sup>, M. Lopez Santillan<sup>1</sup>, B. Lopez De San Vicente<sup>2</sup>, P. Casado<sup>3</sup>, M. Martinez Del Prado<sup>2</sup>, <sup>1</sup>Hospital de Basurto, Bilbao, ES, <sup>2</sup>Hospital Universitario de Basurto, Bilbao, ES, <sup>3</sup>Hospital Universitario Basurto, Bilbao, ES

15:55 - 16:15

**237P - Are YouTube videos a reliable information source for young women with metastatic breast cancer?**

N. Morena<sup>1</sup>, Y. Ahisar<sup>1</sup>, X. Wang<sup>1</sup>, D. Nguyen<sup>2</sup>, C. Rentschler<sup>1</sup>, A. Meguerditchian<sup>3</sup>, <sup>1</sup>McGill University, Montreal, CA, <sup>2</sup>Research Institute - McGill University Health Centre, Montreal, CA, <sup>3</sup>McGill University Health Centre - Glen Site - Royal Victoria Hospital, Montreal, CA

16:15 - 16:35

**238P - Budget impact analysis for the Health Care Package by using MammaPrint in Belgium**

K. De Lameillieure<sup>1</sup>, C. Van Der Meijden<sup>1</sup>, J. Klinkhamer<sup>1</sup>, P. Cusumano<sup>2</sup>, <sup>1</sup>Agendia NV., Amsterdam, NL, <sup>2</sup>Centre Hospitalier Chrétien, Liège, BE

16:35 - 16:55

**239P - Real World Evidence of comorbidities related to prognostic factors in European breast cancer patients**

P. Kosmidis, E. Deligianni, T. Kosmidis, Care Across Ltd, London, GB

16:55 - 17:15

**240P - Covid-19 pandemic impact on diagnosis and management of breast cancer in northern Portugal**

R. Teixeira-Pinto<sup>1</sup>, J. Rodrigues<sup>2</sup>, P. Redondo<sup>3</sup>, M. José-Bento<sup>2</sup>, J. Savva-Bordalo<sup>1</sup>,  
<sup>1</sup>Portuguese Institute of Oncology, Porto, PT, <sup>2</sup>Instituto Portugues de Oncologia do Porto  
 Francisco Gentil, EPE (IPO-Porto), Porto, PT, <sup>3</sup>Portuguese Oncology Institute of Porto  
 (IPO Porto), Porto, PT

- 17:15 - 17:35 **241P - Factors associated with delayed presentation of breast cancer among south asian women(Nepal)**  
A. Shahi, PAHS - Patan Academy of Health Sciences, Lalitpur, NP
- 17:35 - 17:55 **242P - Patterns of management of positive sentinel lymph nodes in breast cancer patients after the American College of Surgeons Oncology Group Z0011 trial: a retrospective cohort.**  
M.H. El Charif, American University of Beirut Medical Center, Beirut, LB
- 17:55 - 18:15 **243P - The landscape of RUNX1 mutations in breast cancer and its therapeutic potential**  
N.S. Ariffin, Faculty of Pharmacy, Universiti Teknologi MARA, Bandar Puncak Alam, MY
- 18:15 - 18:35 **244P - The incidence of infusion related reactions with trastuzumab-emtansine**  
P. Begum, K. Ajauskaite, A. Ring, Royal Marsden Hospital Institute of Cancer Research, Sutton, GB
- 18:35 - 18:55 **245P - A multidisciplinary virtual intervention to addresses information needs of Mexican patients with breast cancer**  
R.L. López-Bejarano<sup>1</sup>, I. Rivera Olvera<sup>1</sup>, A. Mohar<sup>2</sup>, P.A. Cabrera-Galeana<sup>2</sup>, M. Bermúdez Pavón<sup>1</sup>, C.L. Gálvez-Hernández<sup>2</sup>, <sup>1</sup>UNAM - Universidad Nacional Autonoma de Mexico, Ciudad de Mexico, MX, <sup>2</sup>INCAN - Instituto Nacional de Cancerologia, Ciudad de Mexico, MX
- 18:55 - 19:15 **246P - DNA repair protein RAD51 homolog 1 (RAD51), a potential prognostic biomarker and target for breast cancer**  
Y.-Q. Tang, W.H. Yap, A.Y.Y. Chia, Taylor's University - Lakeside Campus, Subang Jaya, MY
- 19:15 - 19:35 **247P - Usage and side effects of each common Aromatase Inhibitor in 5 large European countries: real world data analysis**  
P. Kosmidis, E. Deligianni, T. Kosmidis, Care Across Ltd, London, GB
- 19:35 - 19:55 **248P - Axillary nodal involvement (ANI) predictive model by primary histopathological features in invasive breast cancer (IBC): a real-world analysis of 1,400 cases**  
B. Cutuli<sup>1</sup>, C. Charles<sup>2</sup>, <sup>1</sup>Institut du Cancer Courlancy, Reims, FR, <sup>2</sup>Scilink, BIARRITZ, FR
- 19:55 - 20:15 **249P - Significance of intraoperative frozen assessment of cavity shave margins in patients undergoing breast conservation surgery: a tertiary care centre experience**  
P. Jain, E. Rebba, D. Muduly, M. Sultania, P. Mishra, M. Sable, S. Mohakud, M. Kar, AIIMS - All India Institute of Medical Sciences - Bhubaneswar, Bhubaneswar, IN

<b>13:00 - 14:00</b>	<b>Type: Industry Satellite Symposium</b> <b>Title: Pfizer Oncology - Broadening horizons in HER2- advanced breast cancer</b> Chair(s): M.P.L., DE	<b>Hamburg Hall</b>
13:00 - 13:05	<b>Welcome and introductions</b> <u>M.P. Lux</u> , Frauenklinik St. Louise, Paderborn; St. Josefs-Krankenhaus, Salzkotten; Frauen- und Kinderklinik St. Louise, Paderborn, DE	
13:05 - 13:20	<b>Expanding perspectives: Progress in treatment choice in HER2- aBC</b> <u>V. Dieras</u> , Centre Eugene - Marquis, Rennes, FR	
13:20 - 13:35	<b>Managing individual needs: Real-world evidence in HER2- aBC</b> <u>M.P. Lux</u> , Frauenklinik St. Louise, Paderborn; St. Josefs-Krankenhaus, Salzkotten; Frauen- und Kinderklinik St. Louise, Paderborn, DE	
13:35 - 13:50	<b>Q&amp;A, discussion and close</b> <u>M.P. Lux</u> , Frauenklinik St. Louise, Paderborn; St. Josefs-Krankenhaus, Salzkotten; Frauen- und Kinderklinik St. Louise, Paderborn, DE	

<b>13:00 - 14:00</b>	<b>Type: Industry Satellite Symposium</b> <b>Title: Seagen - Treatment sequencing in HER2-positive metastatic breast cancer: from guidelines to clinical practice</b> Chair(s): V.M., DE	<b>Munich Hall</b>
13:00 - 13:05	<b>Introduction</b> <u>V. Müller</u> , UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE	
13:05 - 13:20	<b>Patient case study: how does treatment sequencing vary in local clinical practice across Europe for HER2-positive MBC?</b> <u>V. Müller</u> <sup>1</sup> , <u>F. Penault-Llorca</u> <sup>2</sup> , <u>M. Martin Jimenez</u> <sup>3</sup> , <u>A. Okines</u> <sup>4</sup> , <sup>1</sup> UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, <sup>2</sup> Jean Perrin Center, Clermont-Ferrand, FR, <sup>3</sup> Hospital General Universitario Gregorio Marañón, Madrid, ES, <sup>4</sup> The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB	
13:20 - 13:35	<b>Patient case study: how does local clinical practice vary for patients with brain metastases?</b> <u>V. Müller</u> <sup>1</sup> , <u>F. Penault-Llorca</u> <sup>2</sup> , <u>M. Martin Jimenez</u> <sup>3</sup> , <u>A. Okines</u> <sup>4</sup> , <sup>1</sup> UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, <sup>2</sup> Jean Perrin Center, Clermont-Ferrand, FR, <sup>3</sup> Hospital General Universitario Gregorio Marañón, Madrid, ES, <sup>4</sup> The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB	
13:35 - 13:40	<b>Live Q&amp;A</b>	
13:40 - 13:45	<b>Which local factors influence treatment sequencing for HER2-positive MBC?</b> <u>V. Müller</u> <sup>1</sup> , <u>F. Penault-Llorca</u> <sup>2</sup> , <u>M. Martin Jimenez</u> <sup>3</sup> , <u>A. Okines</u> <sup>4</sup> , <sup>1</sup> UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, <sup>2</sup> Jean Perrin Center, Clermont-Ferrand, FR, <sup>3</sup> Hospital General Universitario Gregorio Marañón, Madrid, ES, <sup>4</sup> The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB	
13:45 - 13:50	<b>Consistency of approach: how can we personalise and adapt treatment sequencing for patients with HER2-positive MBC?</b> <u>V. Müller</u> <sup>1</sup> , <u>F. Penault-Llorca</u> <sup>2</sup> , <u>M. Martin Jimenez</u> <sup>3</sup> , <u>A. Okines</u> <sup>4</sup> , <sup>1</sup> UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, <sup>2</sup> Jean Perrin Center, Clermont-Ferrand, FR, <sup>3</sup> Hospital General Universitario Gregorio Marañón, Madrid, ES, <sup>4</sup> The Royal Marsden Hospital (Chelsea) - NHS Foundation Trust, London, GB	
13:50 - 13:55	<b>Live Q&amp;A</b>	
13:55 - 14:00	<b>Summary and session close</b> <u>V. Müller</u> , UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE	



<b>13:00 - 14:00</b>	<b>Type: Young Oncologists session Title: Young Oncologists session 3</b>	<b>Frankfurt Hall</b>
<b>13:00 - 14:00</b>	<b>Type: Industry Satellite Symposium Title: Pierre Fabre - What about HER journey? Let's focus on HER2+ early breast cancer</b>	<b>Cologne Hall</b>
13:00 - 13:05	<b>Welcome and introduction</b> <u>D. Lüftner</u> , University Hospital Charité, Berlin, DE	
13:05 - 13:17	<b>We need to talk about risk   Refining our approach towards risk of recurrence discussions with patients</b> <u>J. Crown</u> , St. Vincent's University Hospital, Dublin, IE	
13:17 - 13:29	<b>Know your options   Improving clinical outcomes in patients with high risk HER2+ early breast cancer</b> <u>N. Harbeck</u> , Ludwig Maximilians University - Grosshadern, Munich, DE	
13:29 - 13:41	<b>Stay the course   Working on treatment adherence in HER2+ early breast cancer</b> <u>D. Lüftner</u> , University Hospital Charité, Berlin, DE	
13:41 - 13:55	<b>What is HER future?   Experts in conversation about the future perspectives for HER2+ early breast cancer</b>	
13:55 - 14:00	<b>Summary and close</b> <u>D. Lüftner</u> , University Hospital Charité, Berlin, DE	
<b>14:10 - 14:40</b>	<b>Type: Keynote lecture Title: Keynote lecture: How shall our knowledge of cancer evolution transform breast oncology?</b> Chair(s): S.D., FR; S.-B.K., KR	<b>Berlin Hall</b>
14:10 - 14:15	<b>Introduction by the Chairs</b>	
14:15 - 14:40	<b>How shall our knowledge of cancer evolution transform breast oncology?</b> <u>C. Swanton</u> , Francis Crick Institute, London, GB	

**14:45 - 16:15**    **Type: Multidisciplinary Tumour Board**    **Hamburg Hall**  
**Title: Tailoring treatment for early HER2 breast cancer**  
 Chair(s): V.G., IT

14:45 - 15:05    **Refining prognosis in HER2+ early breast cancer (eBC): Insight from biology**  
A. Prat, Hospital Clinic y Provincial de Barcelona, Barcelona, ES

15:05 - 15:25    **Neoadjuvant platform as a “risk adapted” strategy**  
V. Guarneri, University of Padua, Padova, IT

15:25 - 15:45    **Early prediction of pathologic response: Where do we stand?**  
H.J. Lee, Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR

15:45 - 16:05    **Is it time to reconsider the locoregional approach?**  
P. Poortmans, AZ Sint-Augustinus - Oncologisch Centrum GZA - Iridium Kankernetwerk, Antwerpen, BE

16:05 - 16:15    **Q&A**

**14:45 - 16:15**    **Type: Educational session**    **Munich Hall**  
**Title: Antibody drug conjugates (ADCs) to treat breast cancer**  
 Chair(s): S.C., US

14:45 - 15:05    **TROP2-targeted ADCs in breast cancer**  
A. Bardia, Massachusetts General Hospital Cancer Center, Boston, US

15:05 - 15:25    **HER2-targeted ADCs in breast cancer**  
C. Saura Manich, Vall d'Hebron University Hospital, Barcelona, ES

15:25 - 15:45    **ADC biomarkers**  
P. Tarantino, Dana Farber Cancer Institute, Boston, US

15:45 - 16:05    **ADC combinations**  
S. Chandralapaty, MSKCC - Memorial Sloan Kettering Cancer Center, New York, US

16:05 - 16:15    **Q&A**

**14:45 - 16:15**    **Type: Special Symposium**    **Frankfurt Hall**  
**Title: Challenges and landscape of emerging approaches in metastatic triple negative breast cancer (mTNBC)**  
 Chair(s): S.L., AU

14:45 - 15:05    **Updates in metastatic TNBC: Immunotherapy**  
S. Loi, Peter MacCallum Cancer Centre, Melbourne, AU

15:05 - 15:25    **Updates in metastatic TNBC: Precision medicine**  
F. André, Gustave Roussy - Cancer Campus, Villejuif, FR

15:25 - 15:45    **Immune biomarkers in mTNBC: Current and emerging**  
R. Salgado, GZA Ziekenhuizen Campus Sint-Augustinus, Wilrijk, BE

15:45 - 16:05    **New therapies on the horizon for mTNBC**  
S. Loibl, German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE

16:05 - 16:15    **Q&A**

**14:45 - 16:15**    **Type: Special session**    **Cologne Hall**  
**Title: EONS - Supportive care issues in breast cancer**

14:45 - 15:05    **Supportive care needs of women with ABC undergoing chemotherapy**

15:05 - 15:25    **Physical activity for patients with breast cancer during radiotherapy**  
N. Dodlek, KBC Osijek - Clinical Medical Center Osijek, Osijek, HR

15:25 - 15:45    **Cachexia syndrome in breast cancer patients**

15:45 - 16:05    **Health education and healthy lifestyles in breast cancer patients**

16:05 - 16:15    **Q&A and discussion**

**16:45 - 18:15**    **Type: Proffered Paper session**    **Berlin Hall**  
**Title: Proffered Paper session 2**

16:45 - 17:00    **1610 - VIOLETTE: Randomised Phase 2 Study of Olaparib (ola) + Ceralasertib (cer) or Adavosertib (ada) vs Ola Alone in Patients (pts) With Metastatic Triple-**

**Negative Breast Cancer (mTNBC)**

A. Tutt<sup>1</sup>, Z. Nowecki<sup>2</sup>, R. Szoszkiewicz<sup>3</sup>, S.-A. Im<sup>4</sup>, H.-T. Arkenau<sup>5</sup>, A. Armstrong<sup>6</sup>, W. Jacot<sup>7</sup>, J.H. Kim<sup>8</sup>, M. Webster<sup>9</sup>, J. Balmana<sup>10</sup>, S. Delaloge<sup>11</sup>, N. Lukashchuk<sup>12</sup>, R. Odegbami<sup>12</sup>, E. Casson<sup>12</sup>, A. Loembe<sup>13</sup>, M. Drachsler<sup>12</sup>, E. Dean<sup>12</sup>, K. Punie<sup>14</sup>, <sup>1</sup>Institute of Cancer Research and Kings College London, London, GB, <sup>2</sup>Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL, <sup>3</sup>Centrum Medyczne Pratia Poznan, Skorzewo, PL, <sup>4</sup>Seoul National University Hospital, Seoul, KR, <sup>5</sup>Sarah Cannon Research Institute, London, GB, <sup>6</sup>The Christie NHS Foundation Trust, Manchester, GB, <sup>7</sup>Institut du Cancer de Montpellier, Montpellier, FR, <sup>8</sup>Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, KR, <sup>9</sup>Tom Baker Cancer Centre, Calgary, CA, <sup>10</sup>Hospital Vall D'Hebron, Barcelona, ES, <sup>11</sup>Institut Gustave Roussy, Villejuif, FR, <sup>12</sup>AstraZeneca, Cambridge, GB, <sup>13</sup>AstraZeneca, Oss, NL, <sup>14</sup>Leuven Cancer Institute, University Hospitals Leuven, Leuven, BE

17:00 - 17:15

**580 - Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment.**

F. Marmé<sup>1</sup>, C. Hanusch<sup>2</sup>, J. Furlanetto<sup>3</sup>, P. Morris<sup>4</sup>, T. Link<sup>5</sup>, C. Denkert<sup>6</sup>, P.A. Fasching<sup>7</sup>, C. Jackisch<sup>8</sup>, S. Antolín<sup>9</sup>, C. Solbach<sup>10</sup>, P. Aftimos<sup>11</sup>, J. Huober<sup>12</sup>, M. Untch<sup>13</sup>, M. Balic<sup>14</sup>, M. Reinisch<sup>15</sup>, J.-U. Blohmer<sup>16</sup>, A. Gonçalves<sup>17</sup>, J. Rey<sup>3</sup>, T. Büchele<sup>3</sup>, S. Loibl<sup>3</sup>, <sup>1</sup>Heidelberg University, University Hospital Mannheim, Mannheim, DE, <sup>2</sup>Breast Center, Red Cross Hospital München, München, DE, <sup>3</sup>German Breast Group (GBG), Neu-Isenburg, DE, <sup>4</sup>Beaumont Hospital, Dublin, IE, <sup>5</sup>Technische Universität Dresden, Dresden, DE, <sup>6</sup>Philipps University Marburg and Marburg University Hospital (UKGM), Marburg, DE, <sup>7</sup>University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Erlangen, DE, <sup>8</sup>Sana Klinikum Offenbach, Offenbach am Main, DE, <sup>9</sup>Complejo Hospitalario Universitario A Coruña-Hospital Teresa Herrera (CHUAC), A Coruña, ES, <sup>10</sup>Universitätsklinikum Frankfurt, Frankfurt am Main, DE, <sup>11</sup>Clinical Trials Conduct Unit, Institut Jules Bordet-Université Libre de Bruxelles, Brussels, BE, <sup>12</sup>Kantonsspital St.Gallen, Brustzentrum, St.Gallen, CH, <sup>13</sup>Helios Klinikum Berlin-Buch, Berlin, DE, <sup>14</sup>Medical University of Graz, Graz, AT, <sup>15</sup>Kliniken Essen Mitte, Essen, DE, <sup>16</sup>Charité - Universitätsmedizin Berlin, Berlin, DE, <sup>17</sup>Institut Paoli-Calmettes, Marseille, FR

17:15 - 17:25

**Invited Discussant 1610 and 580**

17:25 - 17:40

**One LBA TBC**

17:40 - 17:55

**One LBA TBC**

17:55 - 18:05

**Invited Discussant two LBAs TBC**

18:05 - 18:15

**Q&A and discussion**



<b>18:30 - 19:30</b>	<b>Type: Industry Satellite Symposium</b> <b>Title: Novartis - HR+/HER2– Breast Cancer: How the Latest Data Help Inform Treatment Decisions</b> Chair(s): M.T., DE	<b>Hamburg Hall</b>
18:30 - 18:35	<b>Welcome and Introduction</b> <u>M. Thill</u> , Agaplesion Markus Krankenhaus, Frankfurt am Main, DE	
18:35 - 18:43	<b>Reaching New Frontiers in the Treatment of Patients with HR+/HER2– Advanced Breast Cancer</b> <u>M. Thill</u> , Agaplesion Markus Krankenhaus, Frankfurt am Main, DE	
18:43 - 18:51	<b>Panel Discussion</b>	
18:51 - 18:59	<b>Thinking Beyond HR and HER2 Status in HR+/HER2– Breast Cancer</b> <u>D. Cameron</u> , Edinburgh Cancer Centre Western General Hospital, Edinburgh, GB	
18:59 - 19:07	<b>Panel Discussion</b>	
19:07 - 19:15	<b>Striving for Better Outcomes in the Adjuvant Treatment for HR+/HER2– Breast Cancer</b> <u>K. Jerzak</u> , Sunnybrook Health Sciences Centre - Odette Cancer Centre, Toronto, CA	
19:15 - 19:23	<b>Panel Discussion</b>	
19:23 - 19:30	<b>Live Q&amp;A</b>	

<b>18:30 - 19:30</b>	<b>Type: Industry Satellite Symposium Title: MSD - Advancements in immune-oncology for triple negative breast cancer</b>	<b>Munich Hall</b>
18:30 - 18:35	<b>Introductions and Objectives</b>	
18:35 - 18:50	<b>Review of Recent IO+Chemotherapy Data in Early TNBC</b>	
18:50 - 19:05	<b>Review of Recent IO + Chemotherapy Data in mTNBC</b>	
19:05 - 19:15	<b>PD-L1 testing in mTNBC</b>	
19:15 - 19:25	<b>Q&amp;A / discussion and Close</b>	
<b>18:30 - 19:30</b>	<b>Type: Industry Satellite Symposium Title: Daiichi Sankyo / AstraZeneca - A new horizon for HER2 expressing breast cancer</b>	<b>Frankfurt Hall</b>
18:30 - 18:35	<b>Housekeeping and introduction</b> <u>V. Müller</u> , UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE	
18:35 - 18:50	<b>Will new definitions for HER2 status make a difference for my patients? - An Oncologist's perspective</b> <u>V. Dieras</u> , Centre Eugene - Marquis, Rennes, FR	
18:50 - 19:05	<b>Key milestones and stumbling points in defining HER2 status - A Pathologist's perspective</b> <u>F. Penault-Llorca</u> , Jean Perrin Center, Clermont-Ferrand, FR	
19:05 - 19:25	<b>Round-table discussion</b> <u>V. Müller</u> <sup>1</sup> , <u>V. Dieras</u> <sup>2</sup> , <u>F. Penault-Llorca</u> <sup>3</sup> , <sup>1</sup> UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, <sup>2</sup> Centre Eugene - Marquis, Rennes, FR, <sup>3</sup> Jean Perrin Center, Clermont-Ferrand, FR	
19:25 - 19:30	<b>Q&amp;A and closing remarks</b> <u>V. Müller</u> , UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE	

**05.05.2022**

**08:45 - 10:15**    **Type: Educational session**    **Hamburg Hall**  
**Title: Treating HER2 low metastatic breast cancer**  
 Chair(s): H.I., JP

08:45 - 09:05    **Is HER2 low breast cancer a real entity?**  
F. Penault-Llorca, Jean Perrin Center, Clermont-Ferrand, FR

09:05 - 09:25    **Will ADC transform the treatment of HER2 low?**  
H. Iwata, Aichi Cancer Center Hospital, Nagoya, JP

09:25 - 09:45    **New horizons for HER2 low breast cancer treatments (incl. combination therapy, vaccine therapy)**  
E. Mittendorf, Brigham and Women's Hospital, Boston, US

09:45 - 10:05    **How to treat HER2 low breast cancer on Monday?**  
J. Sohn, Yonsei University, Seoul, KR

10:05 - 10:15    **Q&A**

**08:45 - 10:15**    **Type: Special Symposium**    **Frankfurt Hall**  
**Title: Emerging new drugs and strategies for breast cancer**  
 Chair(s): R.D., SG

08:45 - 09:05    **Oral SERDs: Coming soon but to what end?**  
M. Oliveira, Vall d'Hebron University Hospital, Barcelona, ES

09:05 - 09:25    **Targeting the PIK/AKT/mTOR pathway: Making sense of the relationships**  
R. Dent, NCCS - National Cancer Centre Singapore, Singapore, SG

09:25 - 09:45    **Epigenetic modulation: Revealing the hidden layers?**  
Z. Jiang, 307th Hospital of PLA (AMMS China), Beijing, CN

09:45 - 10:05    **Targeting metabolism: Changing breast cancer's diet**  
V. Longo, USC - Institute for Global Health, Los Angeles, US

10:05 - 10:15    **Q&A**

<b>09:00 - 10:00</b>	<b>Type: Controversy session</b> <b>Title: Is molecular profiling useful for metastatic luminal breast cancer?</b> Chair(s): M.P., BE	<b>Munich Hall</b>
09:00 - 09:10	<b>Introduction and first vote</b> <u>M. Piccart</u> , Institute Jules Bordet, Brussels, BE	
09:10 - 09:30	<b>Yes</b> <u>B. Lim</u> , The University of Texas MD Anderson Cancer Center - Breast Medical Oncology, Houston, US	
09:30 - 09:50	<b>No</b> <u>T. Bachelot</u> , Centre Léon Bérard, Lyon, FR	
09:50 - 10:00	<b>Second vote and conclusions</b> <u>M. Piccart</u> , Institute Jules Bordet, Brussels, BE	
<b>10:45 - 12:15</b>	<b>Type: Educational session</b> <b>Title: Adjuvant treatment luminal in breast cancer</b> Chair(s): L.D.M., IT	<b>Hamburg Hall</b>
10:45 - 11:05	<b>Gene-expression signature for treatment decision-making: Who to test? Which signature?</b> <u>M. Martin Jimenez</u> , Hospital General Universitario Gregorio Marañón, Madrid, ES	
11:05 - 11:25	<b>Neoadjuvant therapy: Endocrine therapy or chemotherapy?</b> <u>S.-B. Kim</u> , Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR	
11:25 - 11:45	<b>Endocrine therapy beyond 5 years: Who to treat and for what duration</b> <u>L. Del Mastro</u> , IRCCS Ospedale Policlinico San Martino, Genova, IT	
11:45 - 12:05	<b>Optimal management of endocrine therapy toxicity</b> <u>H. Rugo</u> , UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US	
12:05 - 12:15	<b>Q&amp;A</b>	



<b>10:45 - 12:15</b>	<b>Type: Educational session</b> <b>Title: Lessons from real world data</b> Chair(s): P.A.F., DE	<b>Munich Hall</b>
10:45 - 11:05	<b>Implementation of new systemic therapies for advanced breast cancer in the Netherlands: Lessons learned from the SONABRE register</b> <u>S. Geurts</u> , Maastricht University Medical Center (MUMC), Maastricht, NL	
11:05 - 11:25	<b>Patient attrition across lines of treatment for metastatic disease in the real world</b> <u>F. Montemurro</u> , IRCCS - Istituto di Candiolo - FPO, Candiolo, IT	
11:25 - 11:45	<b>Therapy landscapes and molecular markers, the German PRAEGNANT registry</b> <u>A. Hartkopf</u> , Klinik für Frauenheilkunde und Geburtshilfe (Frauenklinik) - Universitätsklinikum Ulm, Ulm, DE	
11:45 - 12:05	<b>Enabling large scale analysis: The ESME Project</b> <u>T. Grinda</u> , Institut Gustave Roussy, Villejuif, Cedex, FR	
12:05 - 12:15	<b>Q&amp;A</b>	

10:45 - 11:45	Type: Mini Oral session Title: Mini Oral session 3	Frankfurt Hall
10:45 - 10:52	<b>One LBA TBC</b>	
10:52 - 10:59	<b>1MO - Prognostic and biologic significance of HER2-low expression in early breast cancer</b>	
	<p><u>P. Tarantino</u><sup>1</sup>, Q. Jin<sup>2</sup>, N. Tayob<sup>2</sup>, R. Jeselsohn<sup>1</sup>, S. Schnitt<sup>3</sup>, J. Vincuilla<sup>2</sup>, T. Parker<sup>2</sup>, S. Tyekucheva<sup>2</sup>, N. Lin<sup>1</sup>, M. Hughes<sup>1</sup>, A.C. Weiss<sup>2</sup>, T. King<sup>3</sup>, E. Mittendorf<sup>3</sup>, G. Curigliano<sup>4</sup>, S. Tolaney<sup>2</sup>, <sup>1</sup>Dana Farber Cancer Institute, Boston, US, <sup>2</sup>Dana-Farber Cancer Institute, Boston, US, <sup>3</sup>Brigham and Women's Hospital, Boston, US, <sup>4</sup>IEO - Istituto Europeo di Oncologia, Milan, IT</p>	
10:59 - 11:06	<b>2MO - Development of a prognostic gene-expression signature for early stage HER2-positive breast cancer patients</b>	
	<p><u>S. Di Cosimo</u><sup>1</sup>, C.M. Ciniselli<sup>1</sup>, C. Sotiriou<sup>2</sup>, K. Pogue-Geile<sup>3</sup>, D. Fumagalli<sup>4</sup>, E. De Azambuja<sup>2</sup>, D. Venet<sup>5</sup>, L. De Cecco<sup>1</sup>, N. Pong<sup>3</sup>, V. Cappelletti<sup>1</sup>, E. Tagliabue<sup>1</sup>, Y. Wang<sup>6</sup>, C. Saura Manich<sup>7</sup>, P. Nuciforo<sup>8</sup>, S. Kuemmel<sup>9</sup>, L. Pusztai<sup>10</sup>, M.G. Daidone<sup>1</sup>, S. Pizzamiglio<sup>1</sup>, G. Pruneri<sup>1</sup>, P. Verderio<sup>1</sup>, <sup>1</sup>Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, <sup>2</sup>Institute Jules Bordet, Brussels, BE, <sup>3</sup>NSABP Foundation, Pittsburgh, US, <sup>4</sup>Breast International Group (BIG) - AISBL, Brussels, BE, <sup>5</sup>Institut Jules Bordet, Brussels, BE, <sup>6</sup>Novartis Pharmaceuticals Corp, Florham Park, US, <sup>7</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>8</sup>Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES, <sup>9</sup>Kliniken Essen Mitte Evang. Huysens-Stiftung, Essen, DE, <sup>10</sup>Yale University School of Medicine, New Heaven, US</p>	
11:06 - 11:13	<b>3MO - Association of the research-based HER2DX signatures with survival in early-stage triple-negative breast cancer (eTNBC)</b>	
	<p><u>B. Conte</u><sup>1</sup>, F. Brasó-Maristany<sup>1</sup>, T. Pascual<sup>2</sup>, F. Schettini<sup>1</sup>, J. Staaf<sup>3</sup>, L. Paré<sup>4</sup>, M. Marín-Aguilera<sup>4</sup>, O. Martínez-Sáez<sup>2</sup>, A. Rodriguez Hernandez<sup>2</sup>, M.J. Vidal Losada<sup>2</sup>, P.F. Conte<sup>5</sup>, A. Vivancos<sup>6</sup>, P. Villagrasa Gonzalez<sup>4</sup>, J. Parker<sup>7</sup>, C. Perou<sup>8</sup>, A. Prat<sup>1</sup>, <sup>1</sup>August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, ES, <sup>2</sup>Hospital Clinic of Barcelona, Barcelona, ES, <sup>3</sup>Lund University, Medicon Village, Lund, SE, <sup>4</sup>Reveal Genomics, Barcelona, ES, <sup>5</sup>IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, <sup>6</sup>Vall d'Hebron University Hospital, Barcelona, ES, <sup>7</sup>UNC - Lineberger Cancer Center, Chapel Hill, US, <sup>8</sup>UNC - Lineberger Comprehensive Cancer Center, Chapel Hill, US</p>	
11:13 - 11:23	<b>Invited Discussant one LBA TBC, 1MO, 2MO and 3MO</b> <u>C. Criscitiello</u> , IEO - Istituto Europeo di Oncologia, Milan, IT	
11:23 - 11:35	<b>Q&amp;A and discussion</b>	

<b>12:30 - 13:30</b>	<b>Type: Industry Satellite Symposium</b> <b>Title: Lilly - Aiming to Minimize the Risk of Recurrence in Early Breast Cancer: Integrating Risk Assessment and Adjuvant Therapies into Practice</b>  Chair(s): H.R., US; J.C., ES	<b>Hamburg Hall</b>
12:30 - 12:35	<b>Welcome and Introduction</b>	
12:35 - 12:45	<b>Predicting Risk of Recurrence in HR-positive, HER2-negative Early Breast Cancer: A Focus on Clinicopathological Factors</b>	
12:45 - 12:55	<b>Tools to Guide Risk Assessment and Adjuvant Treatment Decisions in HR-positive, HER2-negative Early Breast Cancer: A Focus on Best Practices</b>	
12:55 - 13:05	<b>Impact of CDK4/6 Inhibitors as Adjuvant Therapy in HR-positive, HER2-negative Early Breast Cancer: A Focus on Recent Evidence</b>	
13:05 - 13:15	<b>Optimizing the Use of CDK4/6 Inhibitors as Adjuvant Therapy in HR-positive, HER2-negative Early Breast Cancer: A Focus on Patient Management</b>	
13:15 - 13:30	<b>Questions and Take-Home Learnings</b>	
<b>12:30 - 13:30</b>	<b>Type: Industry Satellite Symposium</b> <b>Title: Daiichi Sankyo - Special Delivery: ADC Targets for Breast Cancer (BC)</b>  Chair(s): E.C., ES	<b>Munich Hall</b>
12:30 - 12:45	<b>Introduction</b> <u>S.-A. Im</u> , Seoul National University College of Medicine, Seoul, KR	
12:45 - 13:00	<b>Clinical Data for ADCs in Advanced HER2-expressing BC</b> <u>E. Ciruelos</u> , Hospital Universitario 12 de Octubre, Madrid, ES	
13:00 - 13:15	<b>Clinical Data for ADCs in Advanced HR+/HER2- BC and TNBC</b> <u>S. Loibl</u> , German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE	
13:15 - 13:30	<b>Q&amp;A / Discussion</b>	

**12:30 - 13:30**

**Type: Industry Satellite Symposium**

**Frankfurt Hall**

**Title: Industry Satellite Symposium - Eisai EMEA**